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Abstract 
 
This thesis presents a comparative analysis of the type I Interferon (IFN) subtypes and an 
evaluation of their potential as DNA vaccines in a model of murine cytomegalovirus 
(MCMV) infection and disease.  MCMV induces acute and chronic phases of myocarditis, a 
heart disease characterised by an inflammatory cell infiltrate, in susceptible BALB/c mice.  
The type I IFNs comprise 14 IFNα genes in the human and >10 IFNα genes in the mouse 
with a single IFNβ gene in both species, however, the purpose of their multiplicity has 
remained unclear to date.  An extensive panel of murine type I IFN subtype genes, including 
IFNA1, A2, A4, A5, A6, A9 and B, were sub-cloned into the mammalian expression vector 
pkCMVint (Vical, Inc.) for expression in BALB/c mice.  These DNA constructs express 
biologically active IFN both in vitro and in vivo with systemic, low level expression 
persisting in the mouse for up to 4 weeks.  The individual type I IFN subtypes differentially 
affect the immune response to MCMV challenge.  IFNA6 proved most efficacious, reducing 
viral replication and inflammation in the acute and chronic phase of disease.  Data suggests 
this occurs via induction of a Th1-like cytokine and antibody response.  Furthermore, IFNA6 
inoculation after the acute phase was shown to protect mice from the onset of chronic 
myocarditis.  Characterisation of the immune cell response in IFN-treated, MCMV-infected 
mice demonstrated that type I IFN subtypes modulate the type of immune cells infiltrating 
the myocardium during myocarditis.  Notably, reduced CD8+ and CD4+ T cells and B cell 
numbers in the heart was associated with reduced chronic myocarditis.  Finally, co-
administration of type I IFNs, in particular, IFNA6 and IFNB, synergistically improved 
immunotherapy against MCMV infection and myocarditis.  The findings detailed here 
highlight the potential for the type I IFNs as DNA vaccines and most importantly, 
demonstrate that the type I IFNs have differential antiviral and immunomodulatory efficacies 
in the MCMV model of infection and myocarditis. 
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1.1 Interferon 
Interferon (IFN) was originally discovered as a virus interference factor in rabbits in 1954 
(Nagano and Kojima, 1954) however the name, IFN, was coined by Isaacs and Lindenman in 
1957 when they observed a protein produced by virus-infected cells rendering resistance to 
many viruses (Isaacs and Lindenman, 1957).  ‘IFN’ now applies to a group of proteins with a 
broad range of biological activities including antiviral, antiproliferative and 
immunoregulatory activities.  The biological properties of the IFNs make them useful 
therapeutic tools.  In 1980, TIME Magazine ran a cover story, ‘Interferons: the If Drug for 
Cancer’.  In fact, annual global sales of IFN are valued at more than US$4 billion and they 
are being prescribed in more than 80 countries. These proteins are now ranked among the top 
50 drugs in dollar sales in the world.   
 
Currently, the IFNs have been approved for therapeutic use in malignancies such as hairy 
cell leukemia, chronic myeloid leukemia and renal cell carcinoma and in diseases such as 
multiple sclerosis, hepatitis B virus (HBV), hepatitis C virus (HCV) and human 
immunodeficiency virus (HIV).  The continuing discovery of novel subtypes and the 
development of recombinant technology enabling large quantities of a number of IFN 
species to be manufactured have enabled the expansion of IFN research.  Furthermore, the 
evolution of gene transfer technology has introduced new and exciting challenges which can 
be applied to the IFN system as a tool in viral and disease pathogenesis and in determining 
the functions and mechanisms of action of members of the IFN family. 
 
1.1.1 Classification of IFN 
IFN is the term given to a family of inducible glycoproteins that are produced by cells in 
response to biologic stimuli (virus, bacteria, mycoplasma, protozoa, cytokines, mitogen, 
natural and synthetic double-stranded RNA (ds-RNA) and other substances).  The IFNs were 
originally classified according to the cell types from which they were derived, their chemical Chapter One  
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properties and their antigenicity.  Thus, three types of IFN were recognised: leukocyte 
(alpha), fibroblast (beta) and immune (gamma) (Pestka et al., 1987; Samuel, 1991).   
However, the IFNs can also be characterised by their stability at pH 2.0 and importantly, 
their sequence homology.  The currently accepted classification divides the IFNs into two 
groups, type I and II.  
 
1.1.1.1 Type I IFN 
The type I IFNs are a diverse group of polypeptides which share a high degree of sequence 
homology.  They are divided into 5 families on the basis of divergence in nucleotide 
sequence and antigenic distinctions, these comprise the major subtypes, alpha (α) and beta 
(β) in addition to omega (ω), tau (τ) delta (δ) and kappa (κ).  These proteins are encoded by 
a  set of clustered intronless genes (rare for eukaryotic nuclear genes) which have been 
localised to the short arm of chromosome 9 in the human and chromosome 4 in the mouse 
(Kelley et al., 1983; Weissman and Werber, 1986).  All have an identical three-dimensional 
structure, a monomeric functional unit, stability at pH 2.0, are inducible by viral stimulation 
and recognise the same distinct multicomponent cell-surface receptor, the type I IFN 
receptor (IFNAR).  The biological actions of IFN are mediated by their interaction with 
specific cell-surface receptors.  The human IFNAR has been localised to the long arm of 
chromosome 21 (21q), corresponding to chromosome 16 in the mouse (Platanias and 
Colamonici, 1992). 
 
The type I IFNs exhibit a high degree of sequence homology (Table 1.1).  The human IFNα 
(HuIFNα) genes encode proteins of 166 amino acids (aa) with 80-95% homology in aa 
sequence.  The murine IFNα (MuIFNα) family protein structure is comparable to that of 
HuIFNα (Zwarthoff et al., 1985; Seif and DeMaeyer-Guignard, 1986).  The MuIFNα genes 
encode for proteins of 166aa with the exception of α2 (165aa), α4 (161aa - 5aa deletion at 
bases 103-107) and αA which has an additional C-terminus.  A 28kb region within the IFN  Chapter One  
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Table 1.1.  Comparison of human and murine IFNα and IFNβ. 
  IFNα IFNβ 
  Human Mouse Human Mouse 
Classification  Type I  Type I  Type I  Type I 
Receptor  Type  IFNAR IFNAR IFNAR IFNAR 
1
o Source  Leukocytes  Leukocytes  Fibroblasts  Fibroblasts 
Chromosome Localisation  9  4  9  4 
No Genes  >14  >10  1  1 
No. amino acids (aa)  166  161-167  166  161 
Homology (aa)  80-95%
a >70%
b 30%
b 63%
c 
aSequence homology within IFNα family at the aa level. 
bSequence homology in comparison to HuIFNα at the aa level. 
cSequence homology to HuIFNβ at the aa level. Chapter One  
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encoding chromosomal murine DNA has been shown to contain a cluster of 4 of the 
MuIFNα subtypes (IFNα1, α4, α5 and α6).  Three of these genes (IFNα1, α5 and α6) are 
93-95% homologous at the nucleotide level, with IFNα4 exhibiting 88% homology (Kelley 
and Pitha, 1985).  The majority of HuIFNα are non-glycosylated, whereas, the MuIFNα 
species have been shown to have one potential N-glycosylation site (Kawade, 1987).  The 
sugar moiety is dispensable for biological activity, though it is thought that it may affect 
cross-species activity.  Comparison of the IFNβ gene sequence to IFNα reveals 
approximately 45% homology of nucleotides and 30% homology of amino acids, which is 
reflected in both the human and murine system (Foster and Finter, 1998).  In addition, 
MuIFNβ displays 63% homology at the level of coding sequence to HuIFNβ. 
IFN alpha (α) 
The IFNα family is a multigenic group of related polypeptides.  There are at least 14 human 
IFNα genes identified to date (Foster and Finter, 1998; Walter et al., 1998).  Of these, one is 
a pseudogene and of the remaining genes, two encode identical proteins, IFNα1 and 
IFNα13.  Thus there are 12 unique IFNα subtypes, some of which exist in variant forms (eg. 
IFNα2a, IFNα2b and IFNα2c, each of which differs from the other two by a single amino 
acid (aa)) (Foster and Finter, 1998).  The human and murine IFN systems are highly 
analogous, there are at least 10 IFNα genes in the mouse, in fact, multigene IFNα families 
have been detected in all mammalian genomes studied to date (Kelley and Pitha, 1985).  
IFNα is most commonly produced following viral stimulation by lymphoid cells including 
plasmacytoid monocytes (Cella et al., 1999) and activated precursors of dendritic cells (DCs) 
(Siegal et al., 1999).  
IFN beta (β) 
Human IFNβ was the first IFN to be purified (Knight, 1976), and IFNβ exists as a single 
gene in most species including the human and mouse.  However, in species such as cattle, Chapter One  
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sheep and pigs IFNβ exists as a multigene family.  IFNβ is produced by fibroblasts in 
response to virus or ds-RNA. 
IFN omega(ω), tau(τ), delta(δ) and kappa (κ) 
Additional type I IFN subtypes, IFNω,  τ,  δ, and κ  weren’t discovered until relatively 
recently (Roberts et al., 1997; LaFleur et al., 2001).  IFNω was observed by two groups 
independently of each other in 1985, and exists as a multigene family in cattle, horses and 
humans (Capon et al., 1985; Haupton and Swetly, 1985).  The protein encoding for the 
functional IFNω is 172 aa in length, slightly longer than the IFNα and β polypeptides (166 
aa).  Similar to IFNα, IFNω is secreted by peripheral blood leucocytes and haematopoietic 
cell lines.   
 
IFNτ was originally known as ovine trophoblast protein until its relation to the type I IFNs 
was proven (Imakakawa et al., 1987).  This 172aa protein shares greatest homology with 
IFNω.  It is not readily inducible by virus and is produced by the trophoblast of the 
conceptus during a short period close to implantation.  IFNτ is expressed from a multigene 
family restricted to the ruminant ungulate species (cattle, ovine and goat).  
 
IFNδ was discovered in pigs by Lefevre and Boulay (Lefevre and Boulay, 1993).  This IFN 
is produced by the trophoblast during the period of implantation in the uterus.  The mature 
polypeptide is only 149aa in length, the smallest of the type I IFNs. A multigene family, of 
which only one gene is functional, encodes IFNδ.  IFNδ has not yet been discovered in other 
species. 
 
IFNκ was recently identified by high throughput cDNA sequencing and is selectively 
expressed in human epidermal keratinocytes (LaFleur et al., 2001).  Expression of IFNκ is 
upregulated following virus infection, exposure to ds-RNA or treatment with either IFNγ or Chapter One  
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IFNβ.  The protein consists of 207aa and displays 30% homology to other members of the 
type I IFN family. 
 
1.1.1.2 Type II IFN 
The type II IFN family comprises the single IFNγ subtype (Baron et al., 1991).  The human 
IFNγ maps to the long arm of chromosome 12, whereas the murine IFNγ is localised to 
chromosome 10. IFNγ is induced in T-lymphocytes by mitogen or foreign antigen 
presentation to activated T cells.  Under some conditions, natural killer (NK) cells may also 
produce IFNγ.  IFNγ exerts its highly species-specific biological activity via a distinct type II 
IFN cellular receptor. Type II IFNs are characterised by several features including the 
existence of 3 introns in their gene sequence and their acid-labile nature - IFNγ can be 
inactivated by treatment at pH 2.0. 
 
1.1.2 Type I IFN Subtypes 
The purpose of the multiplicity of the type I IFN subtypes is not yet completely understood. 
Several hypotheses have been proposed to explain the existence of the multiple type I IFN 
subtypes.  Firstly, the subtypes may simply be a result of a series of evolutionary accidents 
of neutral biological significance indicating that they are essentially interchangeable, being 
so important to the host that enormous redundancy is required.  Secondly, each subtype may 
be a separate cytokine with a specific function (some of which may overlap).  Thirdly, there 
are modulatory interactions, synergies and antagonisms between IFNs and other cytokines 
formed in the body under various circumstances and the different IFN subtypes interact to 
restore homeostasis.  Although the controversial debate as to whether the different IFNs have 
essentially similar properties is continuing, recent studies indicate that differences in the 
biological activity of the IFN subtypes do exist. 
 Chapter One  
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1.1.2.1 Evolution of the Subtypes 
The homology between type I IFN genes indicates that they possibly evolved from a 
common primordial progenitor gene.  A phylogenetic analysis of mammalian type I IFN 
genes showed: (1) IFNα, IFNβ and IFNω diverged after the divergence of birds and 
mammals but before radiation of the eutherian orders and (2) IFNβ diverged first (Hughes, 
1995).  It is estimated that IFNα/β split about 310-400 million years ago.  This ancestral 
IFNβ arose due to gene duplication about the time of divergence of mammals, reptiles and 
birds from amphibia and fish.  Since many mammalian species contain multiple IFNα loci, it 
appears that this was established before the mammalian radiation (~85 million years ago).  It 
is thought that IFNδ diverged from IFNα about 180 million years ago, while IFNω diverged 
about 120 million years ago.  The most recent divergence is that of IFNτ from IFNω within 
the last 30-65 million years, this could explain why this class of IFN is limited to the 
ruminants (Konstek and Konstekova, review 1997). 
 
What remains to be resolved is whether the various IFNα genes duplicated independently 
from their progenitor gene after the major eutherian orders diverged or whether there were 
already multiple IFNα genes in the earliest eutherian mammals.  A recent opinion based on 
comparison of all available human and rodent sequences available in 1995 favours the 
former hypothesis, ie. duplication occuring early rather than late (Roberts, Liu and 
Alexenko, 1997). 
 
1.1.2.3 Functional Variation 
The potential for functional variation amongst the type I IFN subtypes was first 
demonstrated by studies investigating the antiviral activity of the IFNα subtypes in various 
cell lines (reviewed in Pestka, 2000).  Antiviral activity between subtypes varied 50-fold 
(Pestka, 2000).  In another study, human IFNα8 proved most efficacious against Chapter One  
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Encephalomyocarditis virus (EMCV) with IFNα1 exhibiting least antiviral activity (Foster et 
al., 1996).  In addition, murine IFN systems have been studied for differential antiviral 
efficacies between subtypes.  A study evaluating the antiviral efficacy of type I IFNs against 
Herpes Simplex virus-1 (HSV-1) in L929 cells demonstrated superior antiviral efficacy for 
IFNβ which reduced virus by 30-fold in comparison to IFNα5, the least effective subtype, 
which reduced viral titre by 3-fold (Harle et al., 2002a).  Similarly, this group demonstrated 
superior antiviral activity for IFNβ in HSV-1 and HSV-2 infected L929 and 3T12.3 cells 
(Harle et al., 2002b).  Furthermore, studies in our laboratory have demonstrated differential 
in vivo antiviral activity in a murine cytomegalovirus (MCMV) model following inoculation 
of IFN-expressing DNA constructs (Yeow et al., 1998). 
 
Early investigations of the antiproliferative activity of type I IFN subtypes also demonstrated 
variation between subtypes.  For example, human carcinomas growing in nude mice were 
treated with IFN, IFNα was shown to be more effective than IFNβ (Balkwill et al., 1985).  
In addition, in vitro studies in erythroid cells showed that murine IFNα1 exhibited less than 
8% of the antiproliferative activity of IFNα4 (Swaminathan et al., 1992).  More recently, 
differences in antiproliferative activity have been demonstrated in vivo in a murine model of 
erythroleukemia.  Type I IFN subtypes were demonstrated to differentially regulate the 
development of erythroleukemia in nu/nu mice, IFNA6 and IFNA9 transgene inoculation 
resulted in survival rates of 60% and 40% respectively compared to 0% survival in control 
groups (Cull et al., 2003). 
 
Type I IFNs are immunomodulatory cytokines and recent studies have reported differential 
immunological responses following individual IFN subtype administration.  The effect of 
type I IFN on humoral responses has been examined and it has been reported that some IFN 
subtypes (IFNα8 and IFNβ) are capable of activating B cell proliferation while others do not 
(Hibbert et al., 1996).  It has also been reported that some type I IFN subtypes (IFNα1) can Chapter One  
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increase expression of human leukocyte antigen (HLA) Class II on the surface of antigen 
presenting cells (APCs) (Rhodes et al., 1986).  Furthermore, evidence suggests that type I 
IFN subtypes can exert differential functions on lymphoid and epithelial cells (Overall et al., 
1992).  Indeed, type I HuIFN subtypes act differentially to stimulate NK cell cytotoxicity 
with IFNα2 being more effective than IFNα4 and IFNα1 (Verhagen et al., 1990; Losinno et 
al., 1992). 
 
In addition to the direct biological activity of the type I IFN subtypes, evidence is 
accumulating to suggest that the type I IFNs vary at the level of gene regulation and 
induction, receptor activation and signalling pathways.  A recent in vitro study proposed a 
signal pathway involving an ‘immediate-early’ and a ‘delayed-induction’ set of IFN genes in 
mouse embryo fibroblast cells (Marié et al., 1998).  This model demonstrates that the 
synthesis of the early IFN genes (IFNα4 and IFNβ) is required, along with IFN regulatory 
factor-7 (IRF-7), for the activation of the delayed set of IFN genes (IFNα2, α5, α6 and α8) 
(Marié  et al., 1998).  Authors hypothesise that the early genes evolved to provide an 
immediate response to viral infection while the induction of delayed genes allows a 
prolonged protective response.  
 
The effect of viral infection on induction of IFN subtype expression has also been examined.  
A differential pattern of IFN expression following MCMV infection in the spleen and livers 
of C57BL/6, B6.C-H-28
c and BALB/c mice was demonstrated (Yeow et al., 1997).  This 
suggests that mouse genotype and tissue-type are the major determinants of the IFN subtype 
response pattern in vivo. In addition, the expression of IFN subtypes, MuIFNα1, α4, α5, α6, 
α9 and β, in the spleens and livers of mice correlated with susceptibility to MCMV.   
Interestingly, the absence of IFNα6 in the spleens and IFNα6 and α9 (with or without IFNβ) 
in the livers of C57BL/6 and B6.C-H-28
c mice correlated with resistance to viral infection Chapter One  
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(Yeow  et al., 1997).  Thus, the pattern of type I IFN subtype expression may be a 
determinant of susceptibility or resistance to viral infection. 
 
Current studies of the type I IFN receptor components suggest that there are differences in 
the way in which some subtypes bind the receptor and that this may lead to subtype-specific 
responses.  This was initially proposed by Weber and colleagues who introduced a series of 
selected amino acid substitutions into the D helix of the poorly cross-reactive HuIFNα2, 
which substantially increased its activity in mouse cells (Weber et al., 1987).  These 
substitutions were selected from the sequence of MuIFNα1 and consequently gave a cross-
reactivity comparable to that of MuIFNα1, however, the changes corresponded better to 
MuIFNβ.  More recently, studies have shown that IFN signalling specificities are achieved 
by the presence of cytokine-specific receptor components.  More specifically, IFNα2 and 
IFNβ utilise different regions of the βL subunit for signalling and induction of an antiviral 
response (Domanski et al., 1998) resulting in differential activation of the Janus kinase- 
signal transducers and activators of transcription (JAK-STAT) signal pathway as well as 
induction of transcription of β-R1 genes (Rani et al., 1996).  
 
Studies comparing the differential effects of the type I IFN subtypes on the activation of the 
JAK-STAT signal pathway have been relatively limited, however, evidence to suggest that 
the subtypes induce a differential signal cascade following binding to their receptor is 
accumulating.  One study involving a mutant cell line lacking tyrosine kinase 2 (Tyk2) 
protein kinase showed the cell line responded to IFNβ but not to IFNα (with the exception of 
IFNα8) (Pellegrini et al., 1989; Foster et al., 1996).  In a different study it was shown that 
only IFNβ was capable of inducing the gene β-R1, however, this could not be achieved in 
cells lacking Tyk2 (Rani et al., 1996).  Thus, it appears that there may be distinct signalling 
pathways for IFNβ.  Furthermore, data from our laboratory demonstrates differential Chapter One  
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activation of the STAT and mitogen activated protein kinase (MAPK) signalling molecules 
following type I IFN subtype stimulation of J2E erythroid cells (Cull et al., 2003). 
 
Therefore, evidence indicates that type I IFN subtypes exhibit functional diversity.  Studies 
demonstrate that type I IFN subtypes differ in antiviral, antiproliferative and 
immunomodulatory activity.  In addition, some variation in IFN gene induction, receptor 
binding and signal pathways has been demonstrated. 
 
1.1.3 Signal Transduction 
1.1.3.1 IFN Genes and Regulation 
The production of IFN is one of the earliest host responses to viral infection and foreign 
invasion in mammalian cells.  Control of IFN production occurs at the level of gene 
transcription and induction is transient even in the sustained presence of inducers.  This may 
be due to destabilising sequences giving the IFNs short half-lives (Caput et al., 1986).  The 
induction of IFNs is regulated by the interaction of trans-acting factors (eg IRF-1 and IRF-2) 
with negative (NRD) and positive (PRD) regulatory domains in the 5’ flanking region of the 
IFNα/β genes (Taniguchi, 1988). 
 
Regulation of the IFNβ gene is best understood.  A 200bp virus-inducible enhancer sequence 
upstream of the site of transcriptional initiation is important in regulating gene induction.  
This sequence contains two NRDs – NRDI and NRDII, which are responsible for the 
constitutive repression of this gene prior to the addition of inducers (Tanaka and Taniguchi, 
1992; Goodbourn and Maniatis, 1988).  Located between the NRDs are four PRD (PRDI-
PRDIV), these sites are involved in the post-inductive inhibition of transcription of IFNβ.  
The PRDI element is induced by ds-RNA, IFNα and IFNγ (Fujita et al., 1987).  Trans-acting 
factors that bind to PRDI and PRDIII include transcriptional regulators such as members of Chapter One  
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the IRF family.  Originally, IRF-1 and IRF-2 were identified as transcriptional activators and 
repressors respectively for IFNβ (Fujita et al., 1989; Harada et al., 1989).  However, 
disruption of the IRF-1 gene in mice did not impair the induction of IFN gene expression 
(Matsuyama et al., 1993).  Recent evidence suggests the involvement of IRF-3 and possibly 
IRF-7 in the transcriptional induction of IFNβ (Lin et al., 1998; Sato et al., 1998; Schafer et 
al., 1998; Wathelet et al., 1998; Yoneyama et al., 1998).  PRDII also contains a site that is 
equivalent to the nuclear factor-κB (NF-κB) binding site of Ig genes (Lenardo et al., 1989; 
Viswanathan and Goodbourn, 1989).  Activation of NF-κB occurs in the cytoplasm.  Both 
NF-κB and inhibitory-κB (I-κB) are present in the cytoplasm as a complex.  Treatment with 
cytokines or peroxide radical generation leads to dissociation of this complex, presumably 
via phosphorylation of I-κB and its subsequent degradation.  NF-κB then translocates to the 
nucleus and binds to the cognate DNA element as a dimer thus activating gene transcription 
(Baeuerle, 1991; Beg, 1993).  PRDIV binds a heterodimer of ATF-2 and c-jun. 
 
Regulation of the IFNα genes is less well characterised though, like IFNβ, IFNα expression 
is regulated at the transcriptional level.  The virus-responsive element (VRE) in the IFNα 
promoter contains PRDI-like sequences suggesting inducibility by various agents such as 
viral infection or IRF proteins (Au et al., 1993).  The VRE contains no NF-κB binding sites.  
Studies have suggested that IRF-7 may have an important role in regulation of IFNα (Au et 
al., 1998).  Interestingly, the expression of IRF-7, similar to the expression of IFNα genes, is 
limited to cells of lymphoid origin and is also activated by viral infection, lipopolysaccharide 
and IFNα.  In addition to this, overexpression of IRF-7 exhibits the same specificity in the 
transcriptional induction of IFNα4 and IFNα6 as viral infection.  Also, IRF-7 specifically 
binds the IFN-stimulated response element (ISRE) of the IFNα4 promoter in vitro (Au et al., 
1998).  As previously described (section 1.1.2.3), Marié and colleagues proposed that IFNα4 
is induced rapidly and directly following viral infection while other IFNα subtypes are 
expressed in a delayed manner that is dependent on IRF-7 accumulation (Marié et al., 1998). Chapter One  
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1.1.3.2 Type I IFN Receptor 
IFNAR is composed of at least two subunits: IFNAR1 (also known as the α chain) 
(Colamonici  et al., 1990; Uze et al., 1990) and IFNAR2 (also known as the β chain) 
(Colamonici et al., 1992). The IFNAR2 gene encodes multiple mRNA transcripts, which are 
translated into several isoforms (Owczarek et al., 1997).  These have been designated 
IFNAR2a, a soluble form, IFNA2b, a ‘short transmembrane form, and IFNAR2c, a ‘long’ 
transmembrane form (Domanski et al., 1995; Lutfalla et al., 1995).  IFNARs are present on 
the surface of cells in all tissues at an abundance of 2x10
2 to 6x10
3 receptors per cell.  The 
IFNAR1 subunit associates with the IFNAR2 forms to produce high affinity receptors and 
both forms of the β subunit are able to bind IFNα and IFNβ.  However, studies have shown 
that co-expression of the IFNAR1 and IFNAR2b subunits does not allow activation of the 
JAK-STAT pathway since the IFNAR2b form of the subunit does not bind JAK1 (Domanski 
et al., 1995; Lutfalla et al., 1995).  The IFNAR1 subunit alone will not bind IFN, however, it 
is required in conjunction with IFNAR2 for high affinity binding and associates with Tyk2 
kinase.  
 
One mechanism of regulating cytokine activity is by soluble receptors.  Studies investigating 
the role of the soluble IFNAR2a isoform of the receptor in mice have demonstrated that 
IFNAR2a mRNA transcripts are generally more abundant than the full-length 
transmembrane component, IFNAR2c, mRNA transcripts and the ratio of these transcripts 
varied markedly in different organs and cell-types (Hardy et al., 2001).  In addition, 
recombinant muIFNAR2a was able to inhibit type I IFN activity and transmit type I IFN 
signals.  These results suggest that the soluble receptor component, IFNAR2a, has an 
important role in regulating both endogenous and systemically administered type I IFN 
activity. 
 Chapter One  
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1.1.3.3 JAK-STAT Signal Pathway 
Type I IFNs signal via the JAK-STAT pathway (Fig. 1.1).  Following the binding of an IFN 
molecule to its cognate receptor the receptor will undergo dimerisation and subsequently 
induce activation and tyrosine phosphorylation of its associated tyrosine kinases, namely 
Tyk2 and JAK1 (Taga and Kishimoto, 1992; Stahl and Yancopoulos, 1993; Kishimoto et al., 
1994; Schindler and Darnell, 1995; Nadeau et al., 1999).  Tyk2 is associated with IFNAR1 
and JAK1 is associated with IFNAR2 both before and after binding (Uze et al.,1996).  The 
activated kinases then phosphorylate the receptor chains at the tyrosine residues.  A receptor 
complex with phosphorylated JAK1 and Tyk2 allows recognition and phosphorylation of the 
STAT proteins, STAT1 and STAT2.  These proteins contain src homology 2 (SH2) domains, 
protein modules capable of specifically recognising phosphorylated tyrosine residues.   
Activated STAT1 and STAT2 proteins then dimerise through their SH2 domains (Shuai et 
al., 1994) and associate with ISGF3γ (p48), a DNA-binding protein belonging to the IRF 
family, to form the transcription factor IFN-stimulated gene factor 3 (ISGF3) which then 
translocates to the nucleus.  These proteins are located in the cytoplasm of untreated cells 
and become rapidly activated and translocate to the nucleus upon treatment with IFNα.  The 
ISGF3 complex is able to recognise the ISRE of a group of genes termed IFN-stimulated 
genes (ISGs).  It is important to note that although over 30 cytokine systems can activate the 
JAK-STAT pathway, only type I IFNs require STAT2, and only the IFNAR induces the 
formation of STAT1-STAT2 heterodimers and the formation of ISGF3 (reviewed, Prejean 
and Colamonici, 2000).  Sequence-specific recognition of DNA by ISGF3 involves both the 
STAT proteins and p48.  p48 is a member of the IRF DNA binding family that recognise the 
PRDI of IFNβ genes and the ISRE of ISGs.  However, it is distinct from other members of 
the family since it has a higher affinity for the ISRE than the PRDI and it complexes 
specifically with STAT1 and STAT2 heterodimers, adding to its specificity for the ISRE.  
Binding of ISGF3 to the ISRE is both necessary and sufficient for the transcriptional 
activation of ISGs and subsequent mediation of the response to IFN.  Chapter One  
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Figure 1.1.  Type I IFNs exert their biological effects via the JAK-STAT signalling 
pathway.  Binding of IFNα/β to the type I IFN receptor, IFNAR initiates a cascade of 
events which ultimately leads to the formation of the transcription factor ISGF3 which 
binds to the ISRE of ISGs, activating transcription. 
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It is becoming increasingly evident that IFNs are able to activate a number of pathways in 
addition to the ‘classical’ JAK-STAT pathway.  These include: i) type I IFN induction of the 
tyrosine phosphorylation of insulin receptor substrate (IRS) proteins IRS1 and IRS2 which 
are significant components of the insulin receptor and are involved in insulin-stimulated 
growth (Platanias et al., 1996; Uddin et al., 1995).  ii) The alpha subunit of the type I IFN 
receptor has been reported to interact with members of the MAPK family of intracellular 
signalling molecules and IFNβ can induce tyrosine phosphorylation and activation of 
extracellular signal regulated kinase 2 (ERK2) MAPK (David et al., 1995).  iii) Binding of 
IFNα to human T cells results in the activation, by phosphorylation, of T-cell receptor-
associated proteins such as Lck, Zap70 and CD45 (Petricoin et al., 1997).  iv) Activation of 
an alternative STAT1 and phosphatidylinositol 3-kinase (PI3-K) independent pathway 
demonstrates that STAT1 is not essential for IFN inhibition of B cell lymphopoiesis.  The 
mechanisms involved are unclear, however, it is proposed that a functional ISGF-3 complex 
lacking STAT1 may be activated (Gongora et al., 2000).  Some evidence is therefore 
accumulating to support the idea that activation of different pathways may be required for 
the activation of specific cellular functions. 
 
1.1.4 Mechanisms of Interferon Action 
1.1.4.1 Antiviral 
Viral infection is known to elicit a number of protective immune responses, foremost among 
these is the early production of IFNα/β.  Though there are alternative pathways of IFN 
induction, ds-RNA, known to result from many viral replication cycles, is a potent inducer of 
IFNα/β during viral infection (Vilcek and Sen, 1996).  Thus, high levels of IFNα/β are 
characteristic of early cytokine responses to viral as opposed to non-viral infection.  In 
addition, IL-12, which is expressed in some but not all viral infections, can be blocked by 
IFNα/β production (Cousens et al., 1997).  Reductions in IL-12 are accompanied by a Chapter One  
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decrease in the IFNγ response.  These effects suggest it may be important to limit IL-12 
during certain viral infections.  This is consistent with studies demonstrating a detrimental 
effect of normally tolerated IL-12 doses administered during lymphocytic choriomeningitis 
virus (LCMV) infection which is normally associated with high CD8+ T cell responses 
during infection (Orange et al., 1994; Orange et al., 1995).  In addition, other cytokines such 
as TNFα, which also have direct antiviral functions, can activate pathways, which may 
overlap with those induced by IFNα/β.  For example, TNF can synergise with IFNα/β to 
activate, inducible nitric oxide synthase (iNOS) and iNOS-dependent pathways of antiviral 
defense mediated by macrophage-lineated cells (MacMicking et al., 1997).  
 
The best characterised IFNα/β-induced antiviral pathways result from production of two ds-
RNA activated enzymes, (2’-5’)-oligoadenylate synthetase (2’5’OAS) and ds-RNA-
dependent protein kinase (PKR).  These enzymes are the products of ISGs and expression is 
induced via activation of the JAK-STAT pathway by binding of IFNα/β to its cell-surface 
receptor.  2’5’OAS uses ATP to synthesise short oligomers of up to 12 adenylate residues 
linked by 2’-5’ phosphodiester bonds.  The resulting oligoadenylate molecules allosterically 
activate a latent ribonuclease, RNase L that is able to degrade viral and cellular mRNA 
(reviewed in Jaramillo et al., 1995).  This pathway originally appeared to be exclusively 
related to picornaviruses (Gribaudo et al., 1991), however, recent studies have established 
that this pathway extends resistance to other viruses including flaviviruses (Mashimo et al., 
2002; Perelygin et al., 2002).  The IFN-induced protein Mx also shows selective antiviral 
action for influenza virus (Staeheli et al., 1986).  In contrast, PKR is able to induce an 
effective anti-viral state in a number of viral infections (Samuel, 1988).  Expression of wild-
type PKR mediates phosphorylation of eukaryotic initiation factor 2 (eIF-2).  PKR is 
activated by binding to ds-RNA resulting in autophosphorylation followed by 
phosphorylation of Ser51 of the α-subunit of eIF-2.  Phosphorylation of eIF-2α blocks the 
eIF-2β utilisation of eIF-2.  eIF-2 is required to bind initiator Met-tRNA to the ribosomal Chapter One  
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subunit in protein synthesis initiation.  Such translational inhibition in infected cells may be 
effective in preventing the spread of infection (reviewed in Jaramillo et al., 1995; Williams, 
2001). 
 
1.1.4.2 Antiproliferative 
In addition to antiviral activity, the IFNs also have a profound effect on cell growth.   
Oncogenes such as c-myc, c-fos and c-Ha-ras may be down-regulated during IFN treatment.  
The proto-oncogene c-myc encodes a nuclear binding protein, which functions as a positive 
regulator of DNA replication.  Endogenous IFNβ may function as an autocrine growth 
inhibitor during differentiation of hematopoietic cells.  Insufficient IFNβ expression can 
result in overexpression of c-myc and subsequent malignant transformation (Resnitzky et al., 
1993).  The proto-oncogene c-fos, which forms heterodimers with c-jun to induce 
transcription of several cellular genes containing activator protein-1 (AP-1) sites is normally 
up-regulated in response to colony stimulating factor 1 (CSF-1), macrophage colony 
stimulating factor (M-CSF) and platelet-derived growth factor (PDGF).  However, IFNα/β 
treatment is sufficient to inhibit the PDGF-induced expression of c-fos (Einat et al., 1985).  
The expression of the oncogene c-Ha-ras, along with the src oncogene has been shown to be 
reduced by IFNβ treatment in human bladder carcinoma (Souslau et al., 1984).  Expression 
of c-Ha-ras also induces transformation of RS485, a NIH3T3 mouse cell line (Samid et al., 
1984).  However, c-ras mRNA expression is reduced following chronic IFN treatment, 
which correlates with reductions in p21 protein levels, encoded by c-Ha-ras, and phenotypic 
reversion to normal cell morphology (Souslau et al., 1984).  Treatment of other malignant 
cell lines with IFN may also result in reversion to nonmalignant phenotype. 
 
These antiproliferative effects include other mechanisms known to slow the growth of tumor 
cells by increasing the length of their cell multiplication cycle.  This may include the 
modulation of ISGs which contribute to the antiviral effects of IFN such as members of the Chapter One  
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IRF family, PKR and 2’5’OAS, all of which may contribute to tumor suppression following 
IFN treatment.  The role of these proteins as tumor suppressors has been further supported 
by observations that some of the tumorigenic DNA viruses target the function of the ISGs.  
For example, the human papilloma virus-encoded E6 oncogene binds the transcription factor, 
IRF-3 which is responsible for the induction of type I IFN genes, affecting formation of the 
transcription complex enhanceosome and consequently induction of IFNβ genes (Ronco et 
al., 1998).  Adenoviruses employ a similar mechanism where the E1A oncogene inhibits 
IRF-3 and IRF-7-mediated activation of type I IFN genes (Kalvakolanu et al., 1991).  In 
addition to this mechanism, IFNs are able to deplete certain essential metabolites, which may 
contribute to an antiproliferative state in the cell.  Both type I and type II IFNs can inhibit 
ornithine decarboxylase induction which leads to a reduction in the biosynthesis of 
putrescine and other polyamines (Sekar  et al., 1983). 
 
1.1.4.3 Immunoregulatory  
IFNs are involved in modulating both innate and adaptive immunity (Fig. 1.2).  More 
specifically, they are known to regulate antigen processing and presentation via MHC gene 
expression, activate NK cells to mediate antibody-dependent cytotoxicity via other cytokines 
and induce bystander T cell proliferation and potentiate the clonal expansion and survival of 
antigen-specific CD8+ T cells (Tough et al., 1996).  In addition, the type I IFNs promote 
Th1-type responses by inhibiting the secretion of Th2-type cytokines (IL-4 and IL-5) while 
promoting Th1-type cytokine production (IFNγ) in CD4+ T cells (Demeure et al., 1994; 
Brinkmann  et al., 1993) and enhancing IgM, IgG2a and IgA, but not IgG1 antibody 
production in B cells (Estes et al., 1998).  
 
All IFNs have the capacity to upregulate MHC Class I protein expression, thereby promoting 
the development of CD8+ T cell responses (Boehm et al., 1997).  MHC molecules function 
in the presentation of antigen to T lymphocytes and their subsequent activation.  This  Chapter One  
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Figure 1.2.  Immunoregulatory effects of type I IFNs.  This diagrammatic 
representation demonstrates the extensive immunological actions that IFNs exert on T 
cells, B cells, NK cells and macrophages.  
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upregulation by IFNs is driven by the transcription factor IRF-1 (Reis et al., 1992; Chang et 
al., 1992).  Studies have shown that murine cells with targeted mutations in either IFNα/β or 
IFNγ receptors, STAT1, PKR or IRF-1 fail to demonstrate any upregulation of MHC Class I 
protein expression in response to IFN stimulation. 
 
The immunoregulatory effect of type I IFN on T cell responses has been well characterised.  
IFN plays a role in inducing proliferation in memory phenotype subsets and in prolonging 
survival of activated T cell populations.  Tough and colleagues demonstrated that during 
viral infection T cell proliferation is affected, in particular, the CD44
hi subset of CD8+ T 
cells (Tough et al., 1996), an effect mimicked by poly (I:C), an inducer of type I IFN, and 
also purified type I IFN.  Type I IFN stimulated CD8+ T cells survived for prolonged periods 
in vivo and displayed the phenotype of antigen-specific CD8+ T cells.  Type I IFNs also 
potentiated the clonal expansion and survival of CD8+ T cells responding to specific antigen  
indicating that the survival of memory cells requires minimal T-cell receptor (TCR) contact 
or may be TCR-independent in that local IFN production, during viral infection, is able to 
augment the response and survival of early memory T cells (Tough et al., 1996).  The latter 
response may be due to the ability of type I IFN to induce IL-15 production by macrophages 
(Zhang et al., 1998).  Type I IFN activity is also known to interfere with the rapid death of 
activated T cells following antigen stimulation as demonstrated by Marrack and colleagues 
(Marrack et al., 1999).  T cells were activated in vivo, then cultured with various cytokines to 
test their effect on T cell survival.  Two groups of cytokines were active, members of the IL-
2 family and type I IFN.  The authors state that “the fact that type I IFN prevents activated T 
cell death may contribute to the large numbers of antigen-specific and non-specific T cells 
that appear during viral infection”.  The hypothesis that this phenomenon may also account 
for the long suspected association between viral infection and autoimmune disease is also 
suggested (Marrack et al., 1999). 
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In addition to the effect on T cell response, type I IFNs also mediate activation of NK cell 
cytotoxicity and proliferation in vivo.  However, recent studies have shown that during viral 
infection, type I IFN mediated activation of both NK cell and T cell responses is selective 
and does not extend to IFNγ expression by these subsets (Nguyen et al., 2000).  Type I IFNs 
negatively regulate IFNγ expression through interactions with their receptor and activation of 
STAT1.  This is achieved by induction of NK and T cell refractoriness to IFNγ production 
following stimulation by IL-12 and/ or through the TCR.  In the absence of STAT1, viral 
infections induce high levels of IFNγ in serum as well as NK and T cell IFNγ expression.  
This research suggested that during viral infection, two pathways are activated by type I IFN 
to mediate immunoregulatory effects on lymphocytes.  Early, STAT1 mediated pathways are 
predominant with inhibition of IFNγ expression by NK and T cells.  Later, STAT1 activation 
is down-regulated, presumably by suppressor of cytokine signalling-1 (SOCS1), to allow 
type I IFN stimulated IFNγ production.  This work demonstrates that type I IFN can act to 
both promote and inhibit IFNγ expression (Nguyen et al., 2000). 
 
Type I IFNs have an indirect role in various aspects of adaptive antiviral immunity, 
including the maturation and survival of dendritic cells (DCs).  The majority of adaptive 
immune responses are initiated by the cells in the innate immune system inducing the 
maturation of DCs with proinflammatory cytokines such as IL-1 and TNFα.  Mature DCs 
then initiate the adaptive immune response via activation of antigen-specific naïve T cells 
and determine the T helper (Th) response to be either Th1 or Th2.  It has recently been 
established that type 2 DC precursors (pre-DC2s), present in human blood, are the equivalent 
to natural IFNα/β producing cells (IPCs).  Viral stimuli induces production of large amounts 
of type I IFN in these cells and subsequent differentiation into mature DCs.  Type I IFN and 
TNFα act as autocrine survival factors and differentiation factors respectively (Kadowaki, 
2000). 
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Type I IFNs modulate the humoral immune response.  More specifically they regulate B cell 
functions including development and proliferation, immunoglobulin (Ig) secretion, and Ig 
heavy-chain switching (Stark et al., 1998).  The phenomenon of Ig class switching is 
significant since the Ig isotypes promote different effector functions in the host and the 
production and/or inhibition of certain isotypes can facilitate interactions between the host 
humoral and cellular immune response.  Evidence suggesting that type I IFN affected the 
isotypes of antibodies secreted during an immune response was first observed by Finkelman 
and colleagues who observed that administration of IFNα enhanced IgG2a isotype switching 
in anti-IgD injected mice (Finkelman et al., 1991).  More recently, DCs have been identified 
as a target cell through which type I IFN can induce isotype switching.  Here IFNα/β 
enhanced the production not only of IgG2a, but also of IgG1, IgG2b and IgG3 antibodies (Le 
Bon et al., 2001).  Indeed, a role for DCs in enhancing the proliferation of B cells in the 
germinal centre, in addition to isotype switching of naive B cells towards IgG1, has been 
previously proposed (Dubois et al., 1999).  The ability of type I IFN to enhance the Th1 
response is also linked to isotype switching, the increased production of IFNγ subsequently 
promotes switching of B cells to the IgG2a isotype (Sinigaglia et al., 1999). 
 
A recently discovered immunomodulatory mechanism of the type I IFNs is their ability to 
induce cellular apotosis (Tanaka et al., 1998).  This mechanism extends to their antiviral and 
antiproliferative activities (Lokshin et al., 1995; Rodriguez-Villanueva and McDonnell, 
1995).  IFNs promote apoptosis in infected cells via an autocrine mechanism (Tanaka et al., 
1998).  However, studies have also implicated ISGs such as PKR and 2’5’OAS in some 
forms of apoptosis (Der et al., 1997; Zhou et al., 1997).  In addition, IFN-inducible factors 
such as IRF-1 and STAT1 which activate Caspase1 gene expression play a role in the 
regulation of apoptosis (Tamura et al., 1995; Chin et al., 1997).  
 Chapter One  
  25
1.1.5 Current Therapeutic Applications of IFN 
Currently, type I IFN treatment consists of a single recombinant subtype (generally 
recombinant IFNα2) obtained from transfected E. coli, or an IFNα/β mix containing many 
type I IFN subtypes.  This mixture is obtained from Sendai virus stimulated human 
lymphoblastoid cells or primary human blood leukocytes and its specific composition 
depends on the methods used in its manufacture.  However, IFNα1, which is the main 
component of human leukocytes, is often diminished during the purification process and in 
most IFN preparations, IFNα2 is the major component (Foster and Finter, 1998).  IFNα and 
IFNβ are now routinely used in the treatment of conditions such as hepatitis B (IFNα2a or 
IFNα2b) and C (IFNα2b), multiple sclerosis (Avonex, IFNβ-1a, or Betaseron, IFNβ-1b), 
chronic myelogenous leukemia (IFNα2b), Kaposi’s sarcoma, hairy cell leukemia (IFNα2b) 
and condyloma acuminatum (Baron et. al, 1991; Borden et. al, 2000; Brod et. al, 1996; 
Golomb et al., 1988). 
 
IFN therapy is frequently associated with adverse side effects.  This is thought to be related 
to the administration of high doses of IFN, usually in excess of 10
6 international units (IU).  
In some patients these side effects range from mild to moderate systemic effects 
characterised by a flu-like syndrome occurring 2 to 4h following IFN administration and 
consisting of mild fever, chills, headache, lethargy, arthralgias and myalgias and are thought 
to be dose-related.  In patients given higher doses, the side-effects can be more severe and 
may consist of nausea, vomiting, anorexia, hypotension, tachycardia and rashes.  Peripheral 
neuropathy and thrombocytopenia are often observed in patients given more than 10
7 IU IFN 
daily.  Confusion and other psychiatric complications occur rarely.  In addition, some 
patients receiving IFNα/β therapy may develop neutralising antibodies to the IFN 
preparations thus limiting the effectiveness of IFN treatment (Baron et. al, 1991). 
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In the field of IFN therapy much remains to be discovered which may lead to novel clinical 
applications.  One particular area which has not yet been exploited is the diversity of the type 
I IFN family.   Despite the discovery of multiple IFNα subtypes, IFN therapy remains 
limited to IFNα2 and IFNβ.  However, preliminary trials conducted in the US and China 
using IFNα1 have shown some success. IFNα1 was shown to significantly reduce the side 
effects associated with IFNα2 therapy and despite limited trials, appears to have some 
activity in chronic myelogenous leukemia and hairy cell leukemia (Hawkins et. al, 1984; 
Edwards et. al, 1984).  IFNα1 has been more widely assessed in China, where it is being 
used to effectively treat chronic HBV and HCV (Tong, 1997).  These studies underline the 
potential for more efficacious IFN therapy than is currently available. 
 
Naked DNA delivery of type I IFN subtype transgenes may provide a useful tool for 
evaluation of the functional diversity of type I IFN subtypes and their potential clinical 
efficacy. 
 
1.2 Naked DNA Gene Therapy 
The initial observation that foreign genes could be directly transferred into skeletal muscle in 
vivo (Wolff et al., 1990) and furthermore, that intradermal inoculation of DNA constructs 
encoding foreign genes leads to induction of antibody responses (Tang et al., 1992) was 
initially surprising.  However, immunisation using ‘naked’ plasmid DNA (ie. DNA that is 
not associated with any delivery vehicle such as lipid) has been established as an effective 
activator of both the humoral and cellular immune responses (Donnelly et al., 1997).   
Numerous studies have demonstrated the potential for naked DNA therapy in viral models 
such as influenza, HIV, HBV and HCV in addition to autoimmune disease, inhibition of 
allergic responses and cancer (Donnelly et al., 1997).   
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Naked DNA vaccines consist of a protein-encoding gene, such as a viral protein or cytokine, 
incorporated into a self-replicating, closed circular DNA plasmid.  The plasmid contains 
DNA sequences for control of replication in bacteria, for vaccine production, and for control 
of expression of the foreign gene within mammalian cells.  The latter include mammalian 
promoters and enhancers to drive expression of the gene, polyadenylation sequences to 
increase stability of the transcribed mRNA and transcription termination sequences.   
Following manufacture in bacteria, the plasmid is then purified to remove contaminating 
bacterial products prior to administration, hence the term ‘naked DNA’. 
 
The naked DNA method of immunisation has several advantages over conventional 
immunisation strategies, which rely on the delivery of purified or recombinant proteins, or 
live or attenuated viruses.  DNA vaccines are readily deliverable, molecularly defined 
reagents that offer in situ antigen synthesis, which is neither infectious nor replicative.  In 
addition, both humoral and cellular immune responses may be elicited.  The immune 
response may be manipulated by delivery (or co-delivery) of cytokine genes or co-
stimulatory molecules.  The genetic sequence encoded by the plasmid may be modified to 
allow the removal or insertion of residues, which may affect antigen processing.  Site-
directed mutagenesis may also permit modification leading to enhancement of antigenic 
potency of epitopes or the abolishment of specific physiological effects of the wild-type 
protein.  Lastly and importantly, naked DNA vaccines can be constructed economically and 
in large quantities high in purity and stability (reviewed in Tüting et al., 2000).  
 
1.2.1 Routes of Administration 
Gene vaccines have been administered by a variety of routes and while most studies have 
focused on the intradermal and intramuscular (i.m.) routes, studies have also reported 
efficacy following intravenous (i.v.), intranasal (i.n.) and ocular inoculation.  Gene 
vaccination can be accomplished by either injection of a small volume of DNA (25-200µg) Chapter One  
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in saline solution using a hypodermic needle, or by ‘gene gun’, which uses DNA-coated gold 
particles which are bolistically propelled into the cytoplasm of cells in the target tissue by 
means of electrical discharge of helium pulse (Tang et al., 1992).  Gene gun delivery of 
DNA requires approximately 5000 times less DNA than i.m. or intradermal inoculation in 
aqueous solution to initiate an effective immune response (Eisenbraun et al., 1993).  This is 
due to the fact that the gene gun delivers DNA directly to the cytoplasm while inoculation of 
DNA in saline results in cells taking up the DNA from extracellular spaces. 
 
It is important to note that both the site and method of delivery affects the nature of the 
subsequent immune response (Feltquate et al., 1997; Torres et al,. 1997).  There are 
significant differences in immunocompetency of skin compared to muscle.  The skin and 
mucous membranes are the sites where most endogenous antigen is encountered.  These sites 
have a highly developed immune surveillance function and are rich in Langherhan’s cells 
(LCs), or APCs and keratinocytes (Bos and Kapsenberg, 1993).  These cells can secrete 
proinflammatory cytokines (IL-1, TNFα and granulocyte macrophage-colony stimulating 
factor  (GM-CSF)) in response to allergens, infection and injury.  LCs carry antigen from the 
skin to draining lymph nodes where they present antigen to naive T cells.  In contrast, 
muscle is not thought to have a specialised immune system and contains few DCs, 
macrophages and lymphocytes, though some APCs may be recruited to this site by the local 
irritation that occurs following injection (Danko and Wolff, 1994).  However, it is unlikely 
that plasmid uptake is merely the result of muscle fibre injury.  There is evidence to suggest 
that T tubules and caveolae, structures unique to muscle, have a role in DNA uptake.   
Electron-microscopic images of muscle injected with gold-coated DNA show gold 
preferentially localised to these structures, whereas this distribution pattern was not seen 
with other cationic gold conjugates (Danko and Wolff, 1994).  Tubules are common features 
of skeletal and cardiac muscle, both of which are capable of DNA uptake, whereas they do 
not exist in smooth muscle, correlating with lack of DNA uptake capacity. 
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Regenerating muscle is reported to enhance the expression of i.m. inoculated transgenes.  
Bupivacaine, also known as Marcaine, is a local amide anaesthetic that selectively destroys 
myofibres leaving satellite cells, the basement membrane and vessels intact.  Following 
bupivacaine injection, myonecrosis and phagocytosis occurs, however, this is followed by 
regeneration and after 2 weeks the injured muscle is indistinguishable from normal muscle 
(Danko and Wolff, 1994).  Up to 40-fold increases in gene expression have been 
demonstrated following pre-treatment with bupivacaine in comparison to conventional 
inoculation (Danko and Wolff, 1994). 
 
1.2.2 Immunology of DNA Vaccine Strategy 
1.2.2.1 Priming of CD8+ T cell Response 
The classical form of naked DNA vaccination involves inoculation of genes encoding 
antigenic proteins.  This form of gene vaccination is highly effective at inducing a strong 
MHC Class I-restricted cytotoxic T lymphocyte (CTL) response.  Viral CTLs have been 
induced by gene vaccination with plasmid DNA encoding viral proteins from influenza 
virus, LCMV, HIV-1, HBV, HCV and rabies virus (Tighe et al., 1998).  DNA immunisation 
is able to induce activation of both the humoral and cellular immune responses, therefore, the 
DNA-encoded antigen must be able to access both the MHC Class I and Class II antigen 
processing pathways.  However, the predominantly transfected cell type following i.m. DNA 
inoculation is the myocyte and since myocytes express only low levels of MHC Class I and 
co-stimulatory molecules (such as B7.1 and B7.2), presentation of antigen by myocytes 
alone would be expected to cause either immunological ignorance or tolerance (reviewed in 
Tüting et al., 2000). 
 
Priming of an antigen-specific CTL requires two signals, one conferred by recognition of 
peptide bound to a MHC Class I complex and the other by a non-specific co-stimulation Chapter One  
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signal requiring the presence of a professional APC (Schwartz, 1992).  Presentation of 
antigen by non-professional APCs lacking a co-stimulatory capacity results in tolerance 
rather than priming (Anderson and Matzinger, 2000).  It was hypothesised that CTLs receive 
the first signal from peptide-MHC complexes expressed by muscle tissue and the second 
signal from haematopoietic cells recruited by the local inflammatory response at the site of 
DNA inoculation (Tighe et al., 1998).  However, studies have demonstrated that bone 
marrow (BM)-derived cells rather than somatic cells (eg. myocytes) provide both signals in 
response to i.m. gene injection (Corr et al.,1996; Doe et al., 1996).  It is thought that BM-
derived cells may be directly transfected at the site of inoculation, however, the favoured 
hypothesis is that transfected myocytes produce protein, which is then transferred to BM-
derived professional APCs via cross-priming.  This mechanism has been demonstrated in a 
study where transfected myoblasts of the H-2
k haplotype demonstrated induction of a H-2
d 
restricted CTL response when injected intra-peritoneally (i.p.) into (H-2
kxd)F1 mice (Ulmer et 
al., 1996). 
 
1.2.2.2 Plasmid DNA Induces a Th1 Response 
DNA vaccination has the capacity to affect the generation of CD4+ T lymphocyte 
populations.  The MHC Class II restricted CD4+ T cells can be categorised into Th 
subpopulations Th1 and Th2 according to the production of certain cytokines.  Interestingly, 
intradermal and i.m. injection of DNA typically elicits a Th1 biased immune response in 
mice (Raz et al., 1996; Hsu et al., 1996; Manickan et al., 1995).  This response is 
characterised by the production of IFNγ and IL-2, promotion of the delayed-type 
hypersensitivity reaction (DTH) and enhancement of macrophage activation to kill parasites, 
in addition to increasing IgG2a and IgG3 isotype synthesis via IFNγ secretion.  In contrast, 
protein vaccines and DNA delivery by gene gun promote the induction of a Th2 type 
immune response (Feltquate et al., 1997).  This type of immune response is characterised by Chapter One  
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the production of IL-4, IL-5, IL-6 and IL-10 and the activation of B cells to produce IgG1 
and IgE isotypes via IL-4 stimulation and activation of eosinophil production. 
 
While gene vaccination generally leads to an IgG2a biased immune response, the total 
humoral immune response is lower than or equal to that induced by protein alone and lower 
than that produced by protein in conjunction with an adjuvant.  However, it is interesting to 
note that the effect of DNA vaccination is dominant.  Studies have demonstrated evidence of 
the potential for the therapeutic application of plasmid DNA vaccination in allergic disease.  
A plasmid encoding the house dust-mite allergen, Der p5, was shown to prevent IgE 
synthesis, histamine release in bronchioalveolar lavage fluid and airway hyperresponsiveness 
in rats upon challenge with allergen (Hsu et al., 1996).  Similar outcomes have been 
demonstrated in different allergy models, thus gene vaccination has been shown both to 
prevent allergic response and to down-regulate the Th2 response. 
 
1.2.2.3 Immunostimulatory DNA Sequences 
Plasmid DNA as a vaccine can be divided into two units: (i) transcription unit that directs 
protein synthesis and (ii) and adjuvant/ mitogen unit within the plasmid DNA backbone.  
The molecular basis of this adjuvant effect has been recently elucidated and attributed to 
sequences known as immunostimulatory DNA sequences (ISS).  These ISS include 
unmethylated CpG-containing hexamers that follow the formula: 5’-purine-purine-CG-
pyrimidine-pyrimidine-3’ (eg. 5’-GACGTC-3’, 5’-AGCGCT-3’ and 5’-AACGTT-3’) and 
which occur with a frequency of 1 in 16 bases in prokaryotic DNA and only 1 in 50 in 
eukaryotic DNA (Yamamoto et al., 1992).  
 
Sequence analysis of the ampicillin resistance gene (ampR) has shown the presence of two 
repeats of the palindromic CpG hexamer 5’-AACGTT-3’.  No such ISS has been identified 
in the kanamycin resistance gene (kanR).  Indeed, a study comparing the induction of an Chapter One  
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antibody-mediated immune response following intradermal vaccination with expression 
plasmids encoding β-galactosidase (β-gal) and containing either ampR or kanR found that 
the ampR-containing vector produced a stronger antibody response to β-gal than the kanR-
containing vector (Sato et al., 1996).  
 
The ISS in the plasmid backbone is thought to skew intradermal and i.m. vaccination 
towards a Th1 bias.  ISS have been reported to induce production of type I IFN and IFNγ 
from mouse splenocytes and human peripheral lymphocytes and to enhance NK cell activity.  
They also promote IL-12 and IL-18 production by macrophages and play a role in the 
differentiation of naive Th cells to Th1 cells (Sato et al., 1996).  This evidence may explain 
why intradermal and i.m. DNA vaccination generate a Th1 response while gene gun delivery 
elicits a Th2 response since at least 100-fold less DNA is used in gene gun delivery and 
vaccination is followed by rapid systemic dispersal of the plasmid DNA (reviewed in Tighe 
et al., 1998). 
 
1.2.2.4 Cytokine Gene Transfer 
A more recent area of research in DNA vaccination is immuno-gene therapy.  This involves 
the transfer of genes encoding regulatory cytokines or inflammatory cytokines which can be 
delivered i.m. and expressed for weeks to months (Prud’homme et al., 2001).  This type of 
gene transfer has proven effective in several autoimmune diseases, infectious diseases and 
cancers.  Effective cytokine immunotherapy has been demonstrated using DNA constructs 
expressing IL-10 (Nitta et al., 1998; Ko et al., 2001), IL-6 (Carr and Campbell, 1999), IL-2 
(Barouch et al., 1998; Tanaka et al., 2000), IL-4 (Ko et al., 2001), IL-12 (Kusakabe et al., 
2000; Mendiratta et al., 2000; Tanaka et al., 2000; Melero et al., 2001), GM-CSF (Kusakabe 
et al., 2000), IFNγ (Salesse et al., 2000) and type I IFN (Yeow et al., 1998; Noisakran et al., 
1999; Cui and Carr, 2000; Salesse et al., 2000; Mendiratta et al., 2000).  The transfer of 
cytokine genes for i.m. protein expression allows for mediation of the immunological milieu.  Chapter One  
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Thus, by inoculation with cytokines of choice, the immune response can be ‘skewed’ 
towards a protective outcome in viral infection and disease development.  
 
This thesis will investigate the therapeutic efficacy and immunological mechanisms of 
individual type I IFN subtype gene transfer in a model of MCMV infection and the 
subsequent induction of myocarditis.  
 
1.3 Cytomegalovirus 
Cytomegalovirus (CMV) is a member of the family of herpesviruses but is further classified 
under the genus of betaherpesviruses.  The betaherpesviruses are classified by strict host 
specificity, a long replication cycle, characteristic cytopathic effects and large ds-DNA 
genomes of approximately 240kb (150 million daltons) (reviewed in Mocarski, 1996).  CMV 
infection characteristically produces cell enlargement (cytomegalia) with intranuclear 
inclusions and co-survival of the cell and virus is often established.  In addition, primary 
CMV infection is often followed by persistent or recurrent infections, as is characteristic of 
herpesvirus infections.  Recurrent infection is often caused by reactivation of latent virus, 
since the virus can be maintained in a latent form in lymphoreticular cells and possibly in 
secretory glands, kidneys and other tissues (reviewed in Alford and Britt, 1990). 
 
The molecular weight of murine and other animal CMVs is similar to human CMV 
(HCMV).  MCMV possesses remarkable biological similarity to HCMV.  These viruses 
have extensive homology within their genes (Rawlinson et al., 1996) and exhibit similar 
pathology in their respective hosts (Mocarski, 1996).  Comparison of the viral genomes 
revealed extensive sequence homology in more than 75 open reading frames (Rawlinson et 
al., 1996).  In addition, these viruses target common organs and tissues in their hosts and 
infection progresses to persistence, latency and periodic reactivation.  Despite the defined Chapter One  
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host specificity of the betaherpesviruses, MCMV is an excellent model for the study of 
HCMV (Abenes et al., 2001). 
 
1.3.1 Molecular Biology of Human CMV 
1.3.1.1 The Virion 
The virion structure of CMV is typical of the herpes virus family.  The nucleic acid is 
complexed helically to form a core, which is enclosed in a protein capsid of 162 capsomere 
subunits.  The capsid measures 100nm in diameter and is surrounded by the tegument.  This 
is enclosed in a lipid bilayer envelope containing peplomers to give a diameter of 180nm for 
the whole virion.  The envelope is derived from both the internal nuclear membrane and the 
endoplasmic reticulum of the infected cell (Griffiths and Grundy, 1987). 
 
1.3.1.2 Nucleic Acid 
The nucleic acid in the virion is linear ds-DNA.  Viral DNA synthesis occurs within the 
nucleus of an infected cell by “rolling circle” replication using virus-encoded DNA 
polymerase.  The DNA is synthesised as a long concatemeric molecule and is then cleaved 
into individual genomes ready for packaging into daughter capsids.  The CMV genome 
contains sequences of repeated genetic information and unique sequences.  The sequences at 
both ends of the genome are termed terminal repeats (TR).  The sequences between the 
repeat regions are referred to as unique sequences and since the genome can be divided into 
two segments referred to as the long (L) and short (S) components, these are known as the 
unique long (UL) and unique short (US) regions.  The junction between the L and S 
components is composed of internal repeats (IR) which are designated IRL and IRS 
respectively.  In HCMV, UL and US components are capable of isomerisation (they can 
invert during replication) thus there are four isomers of HCMV and it is referred to as an 
isomerising betaherpesvirus (Griffiths and Grundy, 1987).  The animal CMVs studied to date Chapter One  
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do not contain repeat sequences at an internal location, therefore, these virions have only one 
DNA isomer and are referred to as nonisomerising betaherpesviruses (Stinski, 1990).  
 
1.3.1.3 Transcription 
The CMV genome can remain in cells in either a quiescent, persistent or productive state, 
therefore, a number of control features that regulate transcription of the genome are required.  
Following infection of a susceptible cell, the temporal expression of the viral genome is 
closely regulated. Expression of the genome proceeds by cascade synthesis of viral mRNA 
and proteins since the presence of the earlier gene products is required for the expression of 
the late products (Wathen and Stinski, 1982).  The viral genes are categorised into immediate 
early (IE; alpha), early (beta) and late (gamma) genes (Griffiths and Grundy, 1987).  
 
The first genes to be transcribed in the cascade are the IE genes.  The products of the IE 
genes are those that the virus requires to take over control of host cell macromolecular 
synthesis, they are also involved in stimulating subsequent viral and possibly host cell gene 
expression. The early gene products are required to control production of daughter virions. 
The early phase of gene expression extends for 24 hours or more (compared to a rapid IE 
gene expression phase).  The IE and early genes are transcribed by host cell RNA 
polymerase II  (Thomsen et al., 1984; Stinski and Roehr, 1985; Mocarski, 1996).  Their 
expression is controlled by sequences proximal to the promoter which are cis-activated by a 
trans-acting viral function presumed to be a structural protein (Batterson and Roizman, 
1983).  There appears to be a different mechanism in the regulation of the gamma genes.  
The gamma gene products form the structural components of the virion.  Most late CMV 
genes, do not require viral DNA synthesis for transcription.  Evidence suggests that gamma 
genes are transcriptionally active at early times, thus their delayed appearance must depend 
on post-transcriptional mechanisms.  These mechanisms may involve the precursor viral 
RNA being retained in the nucleus at early times, the stability of the viral RNAs, the Chapter One  
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transport of mRNAs to the cytoplasm or the translation of these RNAs in the cytoplasm 
(DeMarch, 1983; Geballe et al., 1986; Mocarski, 1996). 
 
1.3.1.4 Viral genes and Gene Products 
Immediate Early Genes 
The IE genes play a major role in viral replication since they are able to influence the 
expression of other viral genes, their own genes and cellular genes.  IE1 (UL123) and IE2 
(UL122) encode a series of proteins which function as transactivators of viral and cellular 
genes (Stenberg and Kerry, 1995).  The IE1 gene is known as the major IE gene.  This gene, 
of approximately 2.8kb, codes for a 1.95kb poly(A) mRNA.  The molecular weight of the 
viral gene product is approximately 72kDa.  The IE1 proteins of HCMV, MCMV and simian 
CMV are heavily phosphorylated and moderately acidic in nature, with glutamine and/ or 
aspartic amino acid rich regions at the carboxy terminal end.  Though the IE1 genes are 
highly diverged, there is evidence of residual nucleotide homologies at the 5’ end of the 
genes and some weak amino acid homologies.  The IE1 protein of HCMV is found in 
infected cells within 1 hour of infection.  A 1.4kb mRNA molecule originating from the IE 
region 2a (and possibly exon 1 of IE region 1) is thought to encode IE2, a protein of 28kDa.  
The IE2 antigens can be detected in the nucleus (Stinski, 1990). 
Early Genes 
The most abundantly transcribed early gene is a diploid gene located in the large repeat 
sequence.  Transcription of this gene coincides with a general stimulation of host cell 
transcription.  In the absence of protein synthesis inhibitors a 2.7kb mRNA is transcribed 
within 2 hours of infection and this continues to be expressed throughout infection.   
However, no viral gene product has yet been attributed to this viral mRNA.  Transcribed at 
lower abundance but in the same direction is another unidentified 1.2kb early viral mRNA.  
The location of these genes, their duplicate nature and abundant transcriptional activity Chapter One  
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suggests that they may play an important role in virus replication (Stenberg and Kerry, 1995; 
Mocarski, 1996).  Known early CMV genes, encoding for DNA binding proteins (DBPs), 
include the 52kDa protein known as DBP52, or infected cell protein 36 (ICP36), and a 
140kDa protein (EDBP140).  The latter gene has homology with the ICP8, required for DNA 
replication in HSV, and is known as the ICP8 homolog.  Another early gene is the DNA 
polymerase gene.  It is transcribed as an unspliced 4.7kb mRNA, codes for a protein of 
approximately 140kDa and is known as DNA Pol p140. 
Late Genes 
The late genes of CMV encode proteins for the viral capsid, envelope and glycoproteins.  
The viral envelope is comprised of a lipid bilayer membrane containing glycoproteins on the 
outer surface.  One of the CMV genes encoding a major envelope glycoprotein located in a 
cluster of genes with homology to other herpesviruses is glycoprotein B (gB).  This is an 
ancestral gene that is generally conserved in herpesviruses of all subgroups.  The viral gene 
product is encoded by an unspliced mRNA of approximately 3.9kb, which is equivalent to a 
protein of approximately 95kDa (Mocarski, 1996).   
 
1.3.2 Epidemiology of Human CMV (HCMV) 
It is estimated that during their lifetimes, 60-80% of individuals in developed countries and 
virtually 100% of individuals in developing countries will become infected with CMV 
(Griffiths  et al., 1985; Griffiths et al., 2000).  Generally, these infections remain 
asymptomatic in immunocompetent individuals while in immunocompromised hosts 
(transplant recipients, AIDS patients and neonates) CMV poses a major pathogenic concern.  
Transmission can occur by direct or indirect person-to-person contact.  Sources of virus 
include oropharyngeal secretions (saliva), urine, cervical and vaginal secretions, semen, 
breast milk, tears, feces and blood (Lang and Krummer, 1975; Reynolds et al., 1973; Stagno 
et al., 1980; Griffiths et al., 2000).  Secretion of infectious virus can persist for years Chapter One  
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following primary infection, which may enhance the spread of HCMV.  There are generally 
two ways that virus can be encountered: hospital acquired or community acquired. Hospital 
acquired CMV is generally transmitted by organ allograft, in fact, CMV infection is a major 
cause of mortality and morbidity in patients with renal allografts (Glenn, 1981, 
Griffiths1987) or via transfusion with unscreened blood products.  Community acquired 
CMV is contracted either via contact with young children, or sexual transmission. 
Surprisingly, congenital CMV infection occurs in 0.4-2.3% of all live births (30,000-40,000 
infants in the US annually).  Of these, 10% are symptomatic at birth – these children have a 
mortality rate of 10% while the survivors have a  high rate of developing microcephaly, 
seizures, mental retardation and sensorineural hearing loss.  In addition, 10-15% of children 
asymptomatic at birth will develop sequelae (Bourne et al., 2001).  In fact, intrauterine CMV 
infections are second only to Down’s Syndrome as a known cause of mental retardation 
(Stern and Tucker, 1973; Stagno et al., 1983). CMV infection can result in myocarditis, 
pneumonitis, retinitis, colitis, esophagitis, myelitis, ureteritis and sometimes encephalopathy 
(Alford and Britt, 1990; Salmon-Ceron, 2001; Thomas et al., 2001).  In addition to this, 
CMV pneumonitis is the most common single cause of death affecting bone marrow 
transplant patients (Watson, 1983). 
 
In humans, CMV characteristically infects ductal epithelial cells and seldom involves 
fibroblasts.  In 8-32% of infants and young children, the salivary glands become infected.  
Viruria is a consistent feature of CMV infection in all age groups and results from renal 
involvement.  Mononuclear cell infiltrates have been observed in the absence of typical 
cytomegalic cells in infected adults and children.  In addition, in adults, hepatocytes may 
contain inclusion-bearing cells.  The lung is another site commonly involved in older, 
immunosuppressed individuals.  Recently, the central nervous system (CNS) has been 
involved more frequently as a complication of AIDS, in addition, fetal infection of the brain 
is implied by the frequent occurrence of microcephaly, and less frequent occurrence of 
periventricular calcifications, hydrocephalus and various other growth disturbances.   Chapter One  
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Detection of gastrointestinal (GI) involvement is increasing and can involve all areas of the 
GI tract with the colon being the most common site.  Sensorineural hearing loss is another 
feature of both subclinical congenital infection and cytomegalic inclusion disease.  It may be 
present at birth or develop as a late sequela, cytomegalic cells have been seen in a number of 
different structures in the inner ear.  Other organs frequently affected during CMV infection 
include adrenals, spleen, ovaries, bones, pancreas and skin (Alford and Britt, 1990). 
 
1.3.3 Myocarditis 
Myocarditis is the term given to the inflammatory heart disease characterised by focal 
myocardial lesions consisting of densely packed inflammatory cell infiltrate surrounding 
necrotic myofibres (Martino et al., 1994).  Infectious myocarditis is a condition, which 
commonly passes unrecognised, and therefore the true frequency remains unknown.  Viral 
infection is a common cause of myocarditis, though other causes include bacteria such as 
Chlamydia psittaci and Mycoplasma pneumoniae and parasites such as Trichinella spiralis.  
The World Health Organisation (WHO) completed a survey of viral infection relating to 
cardiovascular disease during the period 1975-1980 and revealed that Coxsackie virus B 
(CB) carries the highest incidence of cardiovascular disease, 34.6 per 1000, followed by 
influenza B (17.4 per 1000), influenza A (11.7 per 1000), Coxsackie virus A (9.1 per 1000) 
and CMV (8.0 per 1000) (Friman et al., 1995).  In one study, CMV-specific nucleotide 
sequences were detected in myocytes of endomyocardial biopsy specimens, this was found 
in up to 15% of patients with acute myopericarditis by in situ hybridisation (Maisch et al., 
1993).  Subsequently, the CMVs have proven a more common cause of myocarditis than 
previously recognised. 
 
Myocarditis generally results in a decrease in myocardial function with concomitant 
enlargement of the heart and an increase in the end diastolic volume.  Normally the heart 
compensates for dilation with an increase in contractility however, in a heart affected by Chapter One  
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myocarditis, inflammation and muscle damage inhibits the response to the increase in 
volume.  In addition, inflammatory mediators such as cytokines and adhesion molecules, as 
well as apoptotic mechanisms are activated.  The progressive increase in left ventricular end 
diastolic volume increases left atrial, pulmonary venous and arterial pressures, resulting in 
increasing hydrostatic forces.  This leads to both pulmonary edema and congestive heart 
failure and without treatment, may progress to end-stage cardiac failure and death. 
 
1.3.4 Murine CMV and Myocarditis 
Due to the strict host specificity of CMV a direct animal model for HCMV is not available, 
instead animal models such as MCMV have been developed to enable detailed study of 
CMV infection and disease. HCMV and MCMV are similar in terms of viral proteins, tissue 
tropism (Mocarski et al., 1990) and pathological sequelae such as development of 
pneumonitis, hepatitis and myocarditis (Jordan, 1978; Olver et al., 1994; Lawson et al., 
1989). In addition, both viruses induce a latent infection affecting multiple organs (Collins et 
al., 1993).   
 
MCMV-induced myocarditis is well characterised with susceptibility to disease influenced 
by genetic factors of the host and virus (Lawson et al., 1990; Price, 1991).  In susceptible 
BALB/c mice, the disease is biphasal with an acute phase occurring between days 3 and 21 
post infection (p.i.) and a chronic phase at day 28 through until day 100 p.i. (Fig. 1.3).  
However, resistant strains such as C57BL/6 mice develop mild myocarditis between days 5 
and 7 p.i. with no evidence of a chronic phase of disease (Fairweather et al., 1998).   
Evidence suggests that susceptibility is conferred by the presence of the b or d allele at the 
H-2 complex (Lawson et al., 1990). 
 
Whilst MCMV is the trigger for myocarditis, the mechanisms involved are unclear.   
Proposed mechanisms include: i) direct viral destruction of cardiac muscle cells; ii) virus-  Chapter One  
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Figure 1.3.  MCMV induces biphasal myocarditis in susceptible BALB/c mice. 
This disease is characterised by two distinct phases known as the acute phase and 
the chronic phase.  The acute phase occurs between days 3 and 21 following 
MCMV infection while onset of chronic disease commences at day 28 through to 
day 100 p.i.  (Adapted from Fairweather et al., 2001; Lenzo et al., 2002). 
Days p.i. Chapter One  
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induced immune responses directed at infected myocytes; iii) ‘mimicked’ epitopes shared 
between viral and cardiac antigens. Cells bearing viral inclusions can be found in the heart 
during the acute phase of disease (days 3-10 p.i.) at which point, infectious virus can also be 
detected.  However, replicative virus is undetectable beyond day 10 p.i. despite the fact that 
chronic myocarditis is evident until day 100 p.i. (Bartholomaeus et al., 1988; Lawson et al., 
1990; Lenzo et al., 2002). Immunopathogenicity may be associated with effector 
mechanisms of the virus, immune cells and cytokines (Lawson, 2000). 
 
The finding that athymic nude mice do not develop myocarditis following MCMV infection, 
despite the production of high viral titres, demonstrated a potential role for T cells (Lawson 
et al., 1989).  More recently, the inflammatory cell infiltrate typically associated with CMV-
induced myocarditis has been characterised and confirms the role of T cells. A mixed 
cellular infiltrate is reported during the acute phase while a mononuclear cell infiltrate 
composed of predominantly CD8+ T cells, macrophages and neutrophils is evident during 
the chronic phase (Lenzo et al., 2002).  In addition, inflammation may be associated with 
necrosis of the myofibres within areas of myocardial inflammation, which can vary from 
focal to diffuse infiltration. 
 
The humoral response to CMV infection has proven to significantly contribute to 
myocarditis.  Antibodies reactive to MCMV antigens and autoantibodies to heart antigens 
including heart contractile proteins, troponin, tropomyosin, myosin and actin are found 
during acute myocarditis, while during chronic myocarditis, the predominant autoantibodies 
are to the heavy chain of cardiac myosin (O’Donoghue et al., 1990; Lawson et al., 1992; 
Lawson et al., 1988).  Autoantibodies to cardiac myosin are found in both BALB/c and 
C57BL/6 mice in the acute phase of disease, however, only the BALB/c mice produce 
specific cardiac myosin autoantibodies in the chronic phase.  Interestingly, studies have 
shown that some antibodies produced against structural determinants of MCMV cross-react 
with cardiac myosin (Lawson et al., 1991).  Also, a nona-peptide reveals homologies Chapter One  
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between murine cardiac myosin heavy chain and the large tegument protein M48 of MCMV 
with 6 of 9 aa identical (Lawson, 2000).  This was found in the rat and HCMV models.  The 
authors propose a mechanism of molecular mimicry between the virus and cardiac myosin 
molecules in the development of MCMV-induced myocarditis.  Indeed, passive transfer of 
autoantibodies against cardiac myosin from MCMV-infected BALB/c mice at day 56 p.i. 
induced inflammation and necrosis of the myocardium in uninfected mice (Lawson et al., 
1992). 
 
Recently, the immunopathological nature of MCMV-induced myocarditis has been 
highlighted by several studies demonstrating the immunoregulatory role of cytokines in 
disease progression.  A pathogenic role for proinflammatory cytokines was reported 
following induction of myocarditis in normally resistant C57BL/6 mice by administration of 
TNF (Lenzo et al., 2001).  Similarly, over-expression of IL-6 in EMCV-infected IL-6 
transgenic mice accelerated the development of myocarditis (Tanaka  et al., 2001).  Reports 
have indicated that the induction of a Th1-like response is protective against development of 
myocarditis, indeed, transgenic mice expressing IFNγ in their pancreatic β cells do not 
develop coxsackievirus B3 (CB3) -induced myocarditis (Horwitz et al., 2000).  Similarly, 
IL-18 has been shown to reduce the severity of EMCV-induced myocarditis by increasing 
NK cell activity and the production of IFNγ (Kanda et al., 2000).  Interestingly, MCMV 
infection induces endogenous IFNα/β production in multiple strains of mice with peaks at 6 
and 48h following virus infection and reduced susceptibility to virus infection correlating 
with IFN titres (Grundy et al, 1982; Allan and Shellam, 1985). 
 
1.3.5 Treatment 
Therapeutics currently approved for the treatment of CMV associated infections include the 
antiviral drugs ganciclovir, foscarnet and cidofovir (Zaia, 2000).  These are most commonly 
used in CMV-induced retinitis in immunocompromised patients, particularly AIDS patients Chapter One  
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(DeArmond, 1991; Salmon-Ceron, 2001).  However, ganciclovir and foscarnet are also used 
to treat other CMV complications such as esophagitis, colitis and pneumonia.  These 
antiviral drugs work by slowing the progression of the virus, most commonly by inhibiting 
the action of DNA polymerase (Freitas et al., 1985; Xiong et al., 1996).  They are generally 
administered i.v. and are often associated with harmful side effects.  For example, 
ganciclovir can cause neutropenia, nausea, vomiting and reduced levels of testosterone.   
Foscarnet can cause kidney problems due to dehydration and sodium depletion sometimes 
leading to kidney failure, while cidofovir is also associated with kidney problems and is 
generally co-administered with probenicid which reduces the risk of kidney failure. 
 
The potential therapeutic benefits of antiviral drug treatment in virally induced myocarditis 
are currently being examined.  Trials of the antiviral drug, ribavirin, in a murine model of 
CB3-induced myocarditis are promising (Kishimoto et al., 1988).  Administration of 
ribavirin early in the acute phase of infection resulted in inhibition of viral replication, 
reduction in acute myocarditis and increased survival, however, delayed administration of 
the drug was not effective (Kishimoto et al., 1988).  More recently, studies investigating the 
therapeutic effects of ganciclovir and cidofovir in MCMV-induced myocarditis have 
demonstrated some success.  Both drugs showed significant reductions in acute myocarditis 
in addition to reducing the severity of chronic myocarditis when mice were treated 24h p.i. 
(Lenzo et al., 2001).  
 
Research into DNA vaccines for CMV is underway.  Several approaches aimed at eliciting 
an immune response against viral antigens have proven effective.  Administration of 
plasmid-encoded CMV proteins including gB (Endresz et al., 1999; Hwang et al., 1999; 
Schleiss  et al., 2000), UL83 (pp65) (Endresz et al., 1999; Schleiss et al., 2000), IE1 
(Gonzalez Armas et al., 1996) and M84 (Morello et al., 2000) has demonstrated varying 
degrees of success in generating antibody responses, CTL responses and conferring Chapter One  
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protection against viral replication.  These studies show that DNA vaccination using selected 
CMV genes may provide an alternative to current therapies.  
 
1.4 Introduction to Thesis 
The antiviral and immunomodulatory properties of the type I IFNs make them ideal 
candidates for therapeutic use in the CMV model of infection and disease since the 
pathogenesis of viral myocarditis is believed to be immune-mediated.  Due to the strict host-
specificity of CMV, MCMV is used in an experimental murine model for HCMV infection 
and myocarditis.  The studies presented in this thesis comprise an investigation of the murine 
type I IFN subtypes via naked DNA transfer in a model of MCMV infection and MCMV-
induced acute and chronic myocarditis in susceptible BALB/c mice.   
 
The hypothesis that the type I IFN subtypes exhibit differential biological activity was 
evaluated with emphasis on their antiviral and immunomodulatory capacity.  A panel of 
DNA expression vectors was prepared for in vivo expression of murine type I IFN proteins 
including IFNα1, α2, α4, α5, α6, α9 and β in a pkCMVint mammalian expression vector 
(Vical, Inc.).  It was postulated that the type I IFNs would exhibit differential efficacy in 
reducing MCMV replication and altering disease pathogenesis following i.m. inoculation.  
This thesis describes investigations demonstrating differential antiviral and 
immunomodulatory activity within the murine type I IFN subtype family.  Furthermore, 
mechanisms of action were investigated by examination of antibody and cytokine profiles.  
In addition, the effect of IFN on the development of myocarditis following adoptive T-cell 
transfer was evaluated.  Determination of the immune cell infiltrate following effective IFN 
transgene treatment was also investigated.  Finally, the synergistic properties of type I IFN 
subtypes for therapy were determined.  Increased knowledge obtained from detailed 
investigation of the individual biological activities of each type I IFN subtype may lead to 
improved clinical application of type I IFNs.   Chapter Two
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2.1  Materials 
2.1.1 Mice 
Specific pathogen-free inbred male BALB/c mice of 4-6 weeks of age were supplied by the 
Animal Resources Centre (Murdoch University, Western Australia) and housed under 
minimal disease conditions.  Mice were known to be free of MCMV by serological typing. 
 
2.1.2 Cell Lines 
COS-7  monkey  kidney  cells  Prof. P. Klinken, University of Western 
Australia, Perth, WA. 
J2E  erythroid  cells  Prof. P. Klinken, University of Western 
Australia, Perth, WA. 
L929  murine  fibroblast  cells  Prof. G. Shellam, University of Western 
Australia, Perth, WA. 
M2-10B4 murine bone stromal cells  American type culture collection (ATCC), 
VA, USA. 
 
2.1.3 Viruses 
EMCV  Prof. G. Shellam, University of Western 
Australia, Perth, WA. 
MCMV (K181 laboratory strain)  Dr D. J. Lang, Duke University, NC, USA. 
 
2.1.4 Tissue Culture Media  
Dulbecco’s Modified Eagles Medium 
(DMEM) 
Gibco BRL, Auckland, New Zealand. 
 
Rosewell Park Memorial Institute Medium 
1640 (RPMI) 
Gibco BRL, Auckland, New Zealand. 
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2.1.5 Chemicals and Reagents 
Acetone Aldrich,  USA. 
3-amino-9-ethylcarbazole (AEC)   Sigma Chemical Co., MO, USA. 
Antibodies:  
Goat Anti-Mouse IgG1 alkaline-
phosphatase conjugated antibody 
Santa Cruz Biotechnology, CA, USA. 
Goat Anti-Mouse IgG2a alkaline-
phosphatase conjugated antibody 
Santa Cruz Biotechnology, CA, USA. 
Goat Anti-Rat Horseradish Peroxidase  Santa Cruz Biotechnology, CA, USA. 
Extravidin-peroxidase  Sigma Chemical Co., MO, USA. 
Hamster Anti-Mouse CD11c (Integrinαx 
chain), biotin conjugated monoclonal 
Pharmingen, CA, USA. 
Rat Anti-Mouse CD8b.2 (Ly-3.2) 
monoclonal 
Pharmingen, CA, USA. 
Rat Anti-Mouse CD4 (L3T4) monoclonal  Pharmingen, CA, USA. 
Rat Anti-Mouse CD45R/220 monoclonal  Pharmingen, CA, USA. 
Rat Anti-Mouse Ly-6G (Gr-1), biotin 
conjugated monoclonal 
Pharmingen, CA, USA. 
Rat Anti-Mouse Mac-3 monoclonal  Pharmingen, CA, USA. 
Adenosine Tri-Phosphate (ATP)  Promega, Madison, USA. 
Avian Myeloblastosis Virus (AMV) Reverse 
Transcriptase 
Promega, Madison, USA. 
Biorad Protein Assay  Biorad Laboratories, CA, USA. 
Bovine Serum Albumin (BSA) (Fraction V)  ICN Biomedicals Inc., Ohio, USA. 
Bupivacaine (Marcain 0.5%)  Astra, USA. 
Calf Intestinal Alkaline Phosphatase (CIAP)  Promega, Madison, USA. 
Chloroform  APS Chemicals Ltd, NSW, Australia. Chapter Two  
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Dimethyl Sulphoxide (DMSO)  BDH AnalaR, Merck Pty Ltd, Vic, Australia. 
DNase1  Promega, Madison, USA. 
dNTPs  Fisher Biotec, WA, Australia. 
E. coli DH5α Competent Cells  Promega, Madison, USA. 
Ethanol  Scott Scientific, WA, Australia. 
Faramount Aqueous Mounting Media   Dako, Botany, Australia. 
Fetal Bovine Serum  Trade Scientific Ltd, Vic, Australia. 
Formaldehyde  Ramprie Laboratories, WA, Australia. 
Gigaprime DNA Labelling Kit  Geneworks, SA, Australia. 
Glycerol  BDH AnalaR, Merck Pty Ltd, Vic, Australia. 
Herring Sperm DNA  Gibco BRL, Auckland, New Zealand. 
Hydrogen Peroxide  BDH AnalaR, Merck Pty Ltd, Vic, Australia. 
Interferon-α (IFNα) ELISA Kit  PBL, NJ, USA. 
IFNα/β International Standard (murine)  Lee Biomolecular, CA, USA. 
Isopropanol  APS Chemicals Ltd, NSW, Australia. 
Isopropyl Alcohol  APS Chemicals Ltd, NSW, Australia. 
Kanamycin  ICN Biomedicals Inc., Ohio, USA. 
1Kb DNA Ladder  Promega, Madison, USA. 
λ/HindIII Standard  Promega, Madison, USA. 
Ligase (T4 DNA Ligase)  Gibco BRL, Auckland, New Zealand. 
Lysosyme  Sigma Chemicals Co., MO, USA. 
Magnesium Chloride (Mg)
 2+  Promega, Madison, USA. 
Mayer’s haematoxylin (Lillie’s modification)  Dako, Botany, Australia. 
Methoxyfluorane  Medical Developments Pty Ltd, Australia. 
OptEIA Cytokine ELISA Kits  
(IFNγ, IL-2, IL-4, IL-6, IL-10, IL-18, 
TNFα) 
Pharmingen, CA, USA. Chapter Two  
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32-P-dCTP Amersham,  Uppsala,  Sweden. 
Penicillin  ICN Biomedicals Inc., Ohio, USA. 
Phosphatase Substrate Buffer Tablets  Sigma Chemicals Co., MO, USA. 
Primers (forward and reverse DNA primers)  Geneworks, SA, Australia. 
Pyrogen-free saline (sodium chloride 0.9%)  Astra, USA. 
Restriction Endonucleases  Fisher Biotec, WA, Australia. 
RNase (Dnase-free)  Roche Diagnostics, USA. 
RNasin  Promega, Madison, USA. 
Silane (3-Aminopropyltriethoxy-Silane)  Sigma Chemicals Co., MO, USA. 
Streptomycin  ICN Biomedicals Inc., Ohio, USA. 
Taq DNA Polymerase  Promega, Madison, USA. 
Tissue-Tek OCT (Optimal Cutting 
Temperature) Compound 
Sakura Finetek, Torrance CA, USA. 
Tetramethylbenzidine (TMB) Substrate 
Reagent Set 
Pharmingen, CA, USA. 
Trizol  Gibco BRL, Auckland, New Zealand. 
Trypsin-Ethylenediaminetetraacetic          
acid (Trypsin-EDTA) 
Gibco BRL, Auckland, New Zealand. 
Tween 20  Sigma Chemicals Co., MO, USA. 
Water (for irrigation)  Baxter, NSW, Australia. 
Wizard Purification Kit  Promega, Madison, USA. 
   
2.1.6 Materials and Equipment   
Cassette Box  Kodak, NY, USA 
Cryovials (1mL)  Nunc, Denmark 
Insulin Syringes  Becton Dickinson, NJ, USA 
Kodak Scientific Imaging Film  Kodak, NY, USA Chapter Two  
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Magna Nylon Transfer Membrane  Micron Separations Inc., MA, USA 
Maxi-sorp Immunoplates  Nalge, Nunc International, Denmark 
Micro Bio-spin 6/30 Chromatography 
Columns 
Biorad Laboratories, CA, USA 
Needles (25G)  Terumo Medical Corporation, USA 
Syringe Barrels  Terumo Medical Corporation, USA 
Tissue Culture Flasks  
(75cm
2, 175cm
2) 
Falcon, Becton Dickinson, NJ, USA 
Tissue Culture Trays   
(6-well; 24-well; 96-well) 
Falcon, Becton Dickinson, NJ, USA 
  
2.1.7 Buffers and Solutions 
Antibiotic Solution  
(for Tissue Culture Media) 
0.48% Penicillin (w/v); 0.68% Streptomycin (w/v); 
prepared in media, filter sterilised and aliquotted.  
Stored at –20
oC.   
Assay Diluent (for cytokine ELISA)  10% FCS in PBS, pH to 7.0.  Made fresh. 
BBS  (x2)  50mM BES (N,N-bis (hydroxyethyl)-2-
aminoethanesulfonic acid); 280mM NaCl; 1.5mM 
Na2HPO4, pH 6.95. 
Bouin’s  Fixative  71.4% Picric Acid (v/v); 23.8% Formaldehyde 
(40%) (v/v); 4.8% Glacial Acetic Acid (v/v). 
Carbonate-Bicarbonate Buffer  15mM Na2CO3; 27mM Na2HCO3, pH to 9.5.   
(For myosin ELISA, 50mM of sodium 
pyrophosphate was added) 
Carbonate Buffer (0.1M)  78.5mM  NaHCO3; 33.6mM Na2CO3, pH to 9.5.   
Made fresh. 
Denhardt’s Solution (x10)  2%  Ficol  400 (w/v); 2% polyvinylpyrrolidine Chapter Two  
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(w/v); 2% BSA (w/v), filtered and stored at –20
oC. 
Diethanolamine  Substrate  Solution  11.1% diethanolamine (v/v); 3.5mM NaN3 (for 
storage); 596µM MgCl2.6H2O, pH to 8.0.   
1 phosphatase substrate buffer tablet added per 
5mL buffer. 
DNA Loading Dye (x10) 
Dark (300bp) 
 
Light (4kb) 
 
0.25% Bromophenol Blue (w/v); 40% Sucrose 
(w/v). 
0.25% Bromophenol Blue (w/v); 0.25% Xylene 
Cyanol (w/v); 40% Sucrose (w/v). 
ELISA Dilution Buffer  1% BSA (w/v); 0.05% Tween 20 in PBS. 
ELISA Wash Buffer  0.1% BSA (w/v); 0.05% Tween 20 in PBS. 
Formaldehyde-Agarose  Gel  1.2% Agarose (w/v); 1x MOPS; 18% 
Formaldehyde (37%) (v/v). 
High Salt Neutralisation Buffer  2.5M KOAc; 5% Formic acid (v/v). 
Hybridisation Buffer  6 x SSC; 10mM sodium phosphate buffer, pH 7.0; 
1mM EDTA; 1 x Denhardt’s; 5% dextran sulphate 
(w/v); 0.1% SDS (w/v). 
Luria Bertoni Broth (LB)/ Agar  1%  Bacto-tryptone; 0.5% Yeast extract; 171mM 
NaCl, adjust pH to 7.0.   
For agar, 1.5% bacto agar added to LB broth..   
LiCl Solution  5M LiCl; 1% MOPS (w/v), pH to 8.0. 
Lysing Buffer (Mini-Prep)  50mM Tris; 62.5mM EDTA; 0.4% Triton-X-100 
(v/v); 2.5M LiCl. 
Lysis Buffer (Midi Prep)  0.2M NaOH; 1% SDS.  Made fresh. 
Methyl  Cellulose  3.9% Methyl Cellulose (w/v).  Autoclaved.   
Shaken until temperature reached RT.  Diluted 1/2 Chapter Two  
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with 2xRPMI and stored at 4
oC. 
Methylene  Blue/  Formaldehyde  Stain  0.5% Methylene Blue powder (w/v).  Stirred 
overnight, filtered through 3MM Whatman paper.  
Made up to 10% Formaldehyde (v/v). 
MOPS  (x10)  0.2M MOPS; 50mM NaOAc.3H2O; 10mM 
Na2EDTA. 
Phenol: Chloroform:Isoamyl alcohol 
(25:24:1) 
Phenol was equilibrated under 1M Tris, pH8.0.   
An equal volume of chloroform/ isoamyl alcohol 
(24:1 v/v) was added and stored under 0.1M Tris, 
pH8.0 at 4
oC in the dark. 
Phosphate Buffered Saline (PBS)  16mM Na2HPO4.2H2O; 3.97mM NaH2PO4.2H2O; 
149mM NaCl.   
Potassium  Chloride  Solution  300mM KCl; 100mM KH2PO4; 50mM K2HPO4; 
10mM Na4P2O7; 2mM 2β-mercaptoethanol. 
Potassium  Phosphate  Buffer  Equal volumes of 50mM KH2PO4 and 50mM 
K2HPO4 were combined and made up to 10mM 
Na4P2O7; 1mM EDTA; 2mM 2β-mercaptoethanol. 
Pyrophosphate Buffer (0.05M)  50mM Na4P2O7; 1mM EDTA; 2mM 2β-
mercaptoethanol, pH7.5, 2mM ATP, added 
immediately prior to use. 
Red Blood Cell Lysis Buffer  154nM NH4Cl; 7.2mM K2CO3; 83nM Tetrasodium 
EDTA; and pH to 7.2-7.4.  
RNA  Loading  Dye  0.25% Bromophenol Blue (w/v); 0.25% Xylene 
cyanol (w/v); 30% Glycerol (v/v). 
Sample Buffer (Northern Analysis)  1x MOPS; 17.5% (37%) Formaldehyde (v/v); 50% 
Formamide. 
SOB  Media  2% Bacto-tryptone (w/v); 0.5% Yeast Extract Chapter Two  
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(w/v); 8.55mM NaCl; 2.5mM KCL, pH to 7.0.   
Autoclaved.  10mM MgCl2  added immediately 
prior to use. 
Sodium Acetate (3M)  3M anhydrous NaOAc, pH4.8. 
Sodium Phosphate Buffer (0.2M)  83mM  Na2HPO4; 134mM NaH2PO4, pH to 6.5.   
Made fresh (used within 7 days).  
SSC (x20)  3M NaCl; 300mM Na3C6H5O7.2H2O, pH to 7.0. 
Stop Solution  1M HCl. 
TEG Swelling Buffer (Midi Prep)  25mM Tris, pH8.0; 10mM EDTA; 0.9% Glucose 
(w/v). 
Terrific Broth  1.3% Bacto-tryptone (w/v); 2.67% Yeast extract; 
0.44% Glycerol (v/v).   
719mM K2HPO4; 169mM KH2PO4.  Autoclaved. 
Combine the two solutions (9:1) respectively. 
Tissue Culture Media (DMEM; MEM; 
RPMI) 
Make up 1 packet (~10g) powdered media to 1L 
and 23.8mM NaHCO3; 1.5% antibiotic solution 
(v/v), pH 7.2. Filter-sterilised. 
Transformation Buffer (competent cells)  10mM PIPES; 15mM CaCl2; 250mM KCl, pH to 
6.7 with KOH.  Add 50mM MnCl2.  Filter-
sterilised.  Stored at 4
oC. 
Tris-HCl Buffer (0.025M)  25mM Tris; 300mM KCl; 1mM MgCl2, pH 7.5. 
2YT  Broth  1.6% Bacto-tryptone (w/v); 1% Yeast Extract 
(w/v); 85.5mM NaCl .   
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2.2 Methods 
2.2.1 Animal Handling 
All animal experimentation was given prior approval by the Animal Experimentation Ethics 
Committee (Murdoch University) which complies with the guidelines from the National 
Health and Medical Research Council, Australia. Mice were sacrificed at specific time-
points by cervical dislocation following inhalation of a methoxyfluorane anaesthetic. 
 
2.2.1.1 Viral Inoculation 
Viral inoculation was performed in mice via the i.p.  route.  MCMV (K181 strain) stock was 
diluted to a concentration of 1x10
4pfu in 100µL of sterile non-pyrogenic saline 
(approximately 0.3 LD50) before administration.  
 
2.2.1.2 DNA Inoculation Schedule 
The standard DNA inoculation procedure was as follows, unless otherwise specified.  To 
induce muscle regeneration, mice were administered with 20µL 0.5% bupivacaine via the 
tibialis anterior (TA) muscle 5 days prior to inoculation of DNA constructs (200µg/mouse) 
diluted in a 50µL volume of pyrogen-free saline also injected bilaterally in TA muscles.  The 
DNA constructs were allowed to express protein intra-muscularly for 14 days prior to viral 
challenge (Fig 2.1.).  
 
2.2.1.3 Tissue Homogenisation 
Tissues were harvested on ice at specific time-points and 20% (w/v) tissue homogenates 
prepared in tissue culture growth media or PBS.  Homogenates were clarified by 
centrifugation at 1,800g for 10min at 4
oC.  Supernatants were then aliquotted and stored at –
70
oC. 
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2.2.1.4 Sera Preparation 
Whole blood was obtained from mice by bleeding from the retro-orbital venus plexus of 
anaesthetised mice.  Blood was allowed to clot for 1h at 4
oC before centrifugation at 13,000g 
for 10min to separate serum from erythrocytes.  Serum was aliquotted and stored at –70
oC.   
 
2.2.2 Cell Culture 
2.2.2.1 Growth and Maintenance 
Cells were stored frozen under liquid nitrogen.  Prior to use, the cells were rapidly thawed to 
RT, washed in tissue culture media and pelleted at 200g for 5min at 4
oC.  The pellet was 
resuspended in tissue culture growth media and the cells grown in 75cm
2 tissue culture flasks 
at 37
oC in 5% CO2.  L929 cells and COS-7 cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM).  M2-10B4 cells were cultured in RPMI.  Growth media contained 
10% fetal bovine serum and antibiotic solution.  The cell monolayers were passaged every 3-
5 days by washing with PBS before incubation with 0.25% trypsin-EDTA that was 
subsequently inactivated by the addition of growth medium.  The cells were split 1/5, seeded 
into sterile 75cm
2 tissue culture flasks containing growth medium and incubated at 37
oC/ 5% 
CO2. 
 
2.2.2.2 Cryopreservation 
Cryopreservation was performed by centrifugation of cells at 200g for 5min and pellets 
resuspended in appropriate growth media supplemented with 20%FCS and an equal volume 
of DMSO-20%FCS added slowly to a final concentration of 5x10
6 cells/mL.  Cell samples 
were then aliquotted in cryovials and packaged in polystyrene racks for freezing at –80
oC 
overnight.  The cryovials were transferred to liquid nitrogen the following day for long-term 
storage. Chapter Two  
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Figure 2.1.  Diagrammatic representation of the DNA construct inoculation schedule prior to 
viral challenge. 
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2.2.2.3 Transfections 
Transfection of COS-7 cells with the IFN plasmid constructs was performed by the calcium 
phosphate precipitation method.  Firstly, 20µg DNA was resuspended in 0.5ml 0.25M CaCl2 
and added to an equal volume of 2 x BBS dropwise with aeration.  This was then allowed to 
stand for 10min at RT and sprinkled over COS-7 cells grown to 70% confluency.  Cells were 
incubated at 37
oC in 5% CO2 for 24 h and then washed twice in DMEM/ 10%FCS and 
overlaid with minimal amount of DMEM/10% FCS and incubated at 37
oC in 5% CO2 for 
48h. Supernatants were collected and acid treated (pH 2.0) to remove acid labile proteins. 
 
2.2.2.4 pH2.0 Treatment 
Tissue culture supernatants or tissue homogenates can be acid-treated to remove type II IFN 
proteins and other acid-labile cytokines.  Samples were titrated with 5.8M HCl until they 
reached pH 2.0, placed at –20
oC for 1h and centrifuged at 2,300g for 5min.  The supernatants 
were then transferred to fresh tubes and neutralised with an equivalent volume of 5M NaOH.  
The samples were then centrifuged at 13,000g for 15min and the supernatants aliquotted and 
stored at –80
oC until use. 
 
2.2.2.5 Virus Propagation 
EMCV 
EMCV, required for use in the IFN bioassay, was prepared as a tissue culture stock using 
L929 cells.  Briefly, EMCV stock was diluted 1x10
-7 in a minimal volume of 10%FCS-
DMEM, added to L929 cell monolayers and incubated at 37
oC/ 5% CO2 for 18h or until viral 
CPE was observed.  The supernatant was collected and centrifuged at 1800g for 10min, 
aliquotted and stored at –70
oC.  
 
MCMV 
The K181 laboratory strain of MCMV was prepared as a salivary gland homogenate by 
passage through 3-week-old female BALB/c mice.  MCMV stock was diluted to 1x10
3 Chapter Two  
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pfu/100µL and 3w.o. BALB/c mice inoculated with 1x10
3 pfu i.p.  At day 17 p.i., mice were 
sacrificed, salivary glands harvested and a 20% homogenate (w/v) prepared in RPMI growth 
medium.  Following centrifugation at 1,800g for 10min, the supernatant was aliquotted into 
Nunc cryovials and stored under liquid nitrogen.  Viral titre was determined by plaque assay 
in M2-10B4 cells. 
 
2.2.2.6 Viral Quantitation 
MCMV Plaque Assay 
MCMV titres were quantitated by plaque assay using murine M2-10B4 stromal cells. M2-
10B4 cells were seeded into 24-well tissue culture plates (2x10
5 cells/ well) and grown to 
90% confluency.  Tissue sample dilutions were prepared in RPMI-2% FCS.  Cell 
monolayers were washed with PBS, overlaid with sample dilutions (200µL/well) and 
incubated for 1 hour at 37
oC/ 5% CO2.  Tissue samples were then aspirated and the cells 
were overlaid with methyl cellulose/RPMI-1%FCS and incubated at 37
oC/ 5% CO2 for 3 
days.  Methylene blue/formaldehyde stain was then added over the methyl cellulose overlay 
and plates stained overnight.  Methylene blue stain and methyl cellulose were removed by 
washing with H2O, plates were air-dried and monolayers examined microscopically for 
evidence of plaque formation.  Virus titres are expressed as mean pfu/g tissue ± SEM (5 
mice per group). The limit of detection was 100 pfu/g for liver and spleen and 6400 pfu/g for 
salivary gland tissue. 
 
2.2.2.7 IFN Bioassay 
The antiviral activity of IFN was quantitated using a bioassay for the reduction of CPE 
following EMCV challenge.  IFN activities were titrated against the IFN-α/β international 
standard.  L929 cells were grown to ~70% confluency in 96-well trays, with PBS and 
samples were added in duplicate to the first well of each row, including the IFN-α/β 
international standard at 10
3 IU/mL.  The samples were then serially two-fold diluted in Chapter Two  
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DMEM-2%FCS.  DMEM-2% FCS only was added to the control wells.  The cells were 
incubated at 37
oC/ 5% CO2 for 24h, washed in PBS and 100µL EMCV diluted to 10
-6 in 
DMEM-2%FCS added to each well (with the exception of half the control wells).  The cells 
were then incubated for a further 16 hours and examined for cytopathic effect (CPE), stained 
overnight with methylene blue/formaldehyde stain and scored either positive (+) or negative 
(-) for CPE.  The end-point for the IFN was the dilution at which 50% of the cells were 
protected from viral CPE.  
 
2.2.3 Molecular Biology 
2.2.3.1 Plasmid DNA Preparation 
Mini-Preparation of Plasmid DNA 
Overnight cultures of transformant colonies were grown in 2YT broth (10µg/mL Kan) at 
37
oC with shaking.  The bacteria were harvested by centrifugation at 2,300g for 2min.  Cells 
were then resuspended in Lysing buffer and incubated on ice for 5min.  Freshly prepared 
lysosyme was added to the mixture to 1mg/mL and vortexed before being boiled for 1min.  
The cells were returned to ice for 5min and centrifuged at 13,000g for 20min.  The pellet was 
removed and 2 volumes 100% ethanol added to precipitate plasmid DNA.  DNA was 
pelleted by centrifugation at 13,000g for 30min and the pellet rinsed with 1mL 70% ethanol, 
briefly dried and resuspended in 20µL H2O.  The DNA was then treated with RNase (0.5µg) 
at 37
oC for 30min.  The samples were then digested with the appropriate restriction 
endonucleases to confirm plasmid identification.  
 
Large-Scale Preparation of Plasmid DNA  
Bacterial cultures containing the required plasmid were prepared by inoculating a loopful of 
glycerol stock plasmid into 1L of terrific broth (10µg/mL Kan) and incubating overnight at 
37
oC with shaking.  The bacterial cells were harvested by centrifugation at 2,500g for 10min 
at 4
oC.  The pellet was resuspended in TEG swelling buffer at 4
oC followed by the addition Chapter Two  
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of 2 volumes Lysis Buffer.  The cells were left on ice for 10min before the addition of 0.5 
volumes High Salt Neutralisation Buffer.  This mixture was centrifuged at 2,500g for 10min 
at 4
oC and the supernatant then filtered through sterile gauze and an equal volume of 
isopropanol added prior to re-centrifugation.  The pellet was then resuspended in H2O and an 
equal volume LiCl solution at 4
oC.  This mixture was left on ice for 10min before 
centrifugation at 2,500g, 4
oC for 15min, and the supernatant then extracted with phenol: 
chloroform: IAA and centrifuged at 1,800g for 5min at 20
oC.  The aqueous phase was 
transferred to a fresh tube and an equal volume of isopropanol added and mixed by inversion 
before centrifugation at 2,500g for 10min at 4
oC.  The pellet was then briefly dried and 
dissolved in ddH2O before RNase treatment (2µg) at 37
oC, 15min.  The DNA was 
precipitated with 2.5 volumes ethanol and 1/10 volume 3M sodium acetate, placed at -20
oC 
for 30min and centrifuged at 13,000g for 20min.  The pellet was washed in 70% ethanol, 
briefly air-dried and resuspended in ddH2O.  DNA concentration was determined by 
spectrophotometric analysis at 260nm and 280nm. 
 
Restriction Endonuclease Analysis 
All restriction endonuclease reactions were performed according to manufacturer’s 
instructions.  Briefly, 1µg DNA was cut with 1U restriction endonuclease in the 
corresponding 1x Reaction Buffer at 37
oC for 1h. 
 
Wizard DNA Purification 
DNA was purified using the Wizard DNA Purification system according to manufacturer’s 
instructions.  Briefly, 1mL Wizard Purification Resin was added to the sample (50ng-16µg 
in up to 500µL) and left for 1min at RT.  This slurry was pushed through a mini-column, 
washed with 2mL 80% isopropanol and centrifuged at 10,000g for 2min to dry the resin 
before elution of DNA with ddH2O and centrifugation for 20sec.  
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DNA/ RNA Quantitation 
The concentration and purity of DNA and RNA was determined by spectrophotometrically 
measuring the absorbance of DNA/ RNA solutions at 260nm and 280nm.  For DNA at a 
concentration of 50µg/mL, A260 is 1.0, similarly, RNA at a concentration of 40µg/mL gives a 
reading of 1.0 at A260.  Pure preparations of DNA and RNA have an A260/A280 ratio of 1.8 
and 2.0 respectively. 
 
2.2.3.2 Preparation of Competent Cells 
The DH5α strain of E. coli was streaked onto LB Agar and grown overnight at 37
oC.  A 
single colony was used to inoculate SOB media and grown at RT with vigorous shaking for 
24-30h until absorbance (A600nm) of 0.4-0.6 was reached.  The culture was kept on ice for 
20min before centrifugation at 2,500g for 10min at 4
oC.  The pellet was resuspended in ice-
cold transformation buffer and incubated on ice for 10min prior to centrifugation at 2,500g 
for 10min at 4
oC.  The pellet was gently resuspended in 1/10 volume transformation buffer 
and DMSO added dropwise to a final concentration of 7%.  The cells were then placed on 
ice for 10min before aliquotting and freezing at –80
oC or under liquid nitrogen.  
 
2.2.3.3 Alkaline Phosphatase Treatment  
Vectors used for cloning were treated with alkaline phosphatase to remove the 5’ phosphate 
group, thus reducing the tendency for the vector to re-ligate to itself.  Restriction 
endonuclease digestion reactions (section 2.2.3.1.3) were supplemented with 1U CIAP and 
left at 37
oC for 1h.  The reaction was then Wizard purified to remove the CIAP. 
 
2.2.3.4 Ligation Reactions 
The molar ratio used in all ligation reactions was 3:1 insert:vector and DNA concentrations 
were determined visually by comparison to a λ/HindIII standard following agarose gel 
electrophoresis.  The ligation mix comprised 3-30fmol CIAP-treated vector; 9-90fmol insert Chapter Two  
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DNA; 1U T4 DNA ligase; 1x Ligation Buffer in a final volume of ≤ 20µL.  The sample was 
left at RT for 2h to ligate before transformation into competent cells. 
 
2.2.3.5 Transformation of Competent Cells 
Competent DH5α E. coli cells were gently thawed and dispensed into 50µL aliquots in 
eppendorfs, on ice.  Plasmid DNA (10-200ng) was then added to the cells and the mixture 
was incubated on ice for 30min.  The cells were then heat-shocked at 42
oC for 30sec and 
returned to ice for 20min.  An aliquot of the transformation mix was then spread onto LB-
Kan plates (10µg/mL) and the plates were incubated overnight at 37
oC. 
 
2.2.3.6 PCR Amplification of IFN Genes 
Type I IFN subtype genes were amplified by RT-PCR from BALB/c liver tissue.  RNA was 
extracted using the Trizol method (outlined in section 2.2.3.10) and the RNA treated with 
DNase1.  The cDNA was generated in a reaction containing 1µL RNA (~1µg DNase-treated 
RNA); 2µL decanucleotides (random primers, Gigaprime labelling kit, Geneworks); 500µM 
dNTPs; 1x buffer.  This was denatured at 65
oC, 5min before adding 20U RNasin and 10U 
AMV reverse transcriptase.  The reaction was then incubated at 42
oC for 90min and 1µL of 
resulting cDNA amplified by PCR. 
 
In the PCR, 1µL cDNA; 1x Taq buffer; 2.4mM Mg
2+; 800µM dNTPs; 25pMol forward and 
reverse primers; 0.8U Taq; were combined to a total volume of 100µL (Table 2.1).  The 
reaction mix was then subjected to thermal cycling comprising: 95
oC 5min; 95
oC 2min; 40
oC 
1min; 72
oC 3min; 5 cycles, followed by: 95
oC 2min; 65
oC 1min; 72
oC 2min; 25 cycles; 72
oC 
for 10min; soak at 4
oC.  
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2.2.3.7 DNA Sequencing 
Wizard purified dsDNA was added to a reaction comprising 400-600ng dsDNA, 4µL dye 
termination reaction mix and 1.6pmol forward or reverse primer and made up to 10µL 
volume.  The mixture was then subjected to a PCR cycle of 96
oC 10sec; 50
oC 5sec; 60
oC 
4min; for 25 cycles followed by a 4
oC soak period.  The PCR product was then ethanol 
precipitated with 1/10 volume 3M sodium acetate (pH 4.6) and 2.5 volumes 100% ethanol, 
incubated on ice for 10min and centrifuged at 13,000g for 30min.  The pellet was then 
washed in 70% ethanol, carefully aspirated and vacuum-dried.  The DNA samples were 
sequenced by the State Agricultural and Biotechnology Centre (SABC), WA. 
 
2.2.3.8 Radiolabelling Probes 
DNA probes were radiolabelled using a Gigaprime kit according to the manufacturer’s 
instructions to high specific activity (>1x10
6cpm).  Briefly, DNA was diluted to 100ng in a 
10-30µL volume and denatured before the addition of 6µL decanucleotide solution, 6µL 
nucleotide/buffer cocktail, 3µL 
32P-dCTP label (3000Ci/mMol) and 5U Klenow Enzyme (as 
provided) and incubated at 37
oC for 20min.  Labelled probe was purified using a biospin 
chromatography column and specific activity determined using a Bioscan QC 2000 counter. 
 
2.2.3.9 RNA Preparation 
RNA extractions were performed using Trizol according to the manufacturer’s instructions.  
Briefly, 1mL Trizol was added to 1x10
7 cells and incubated for 5min at RT.  Next, 0.2mL 
chloroform was added and the mixture vigorously shaken for 15 sec and incubated for 2-
3min at RT.  The mixture was then centrifuged at 10,000g for 15min at 4
oC and the aqueous 
phase removed and an equal volume of isopropyl alcohol added before incubation at RT for 
10min and centrifugation at 10,000g for 10min at 4
oC.  The pellet was then washed in 75% 
ethanol and centrifuged at 13,000g f o r  5 m i n  a t  4
oC.  The pellet was briefly dried and 
resuspended in ddH2O.  Chapter Two  
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Table 2.1.  Primers for amplification and cloning of IFN genes into the pkCMVint 
mammalian expression vector. 
IFN Genes
a Forward  Primer
b Reverse  Primer 
IFNA1 5’-actggatccgaagctttggcaaca-3’ 5’-cgcagatcttcctctacactttgg-3’ 
IFNA2 5’-gcgtctagatcaacctctgcaaga-3’ 5’-agaggatcctctctccacactttg-3’ 
IFNA4 5’-tctctgcagccagcatctacaaga-3’ 5’-tcagtcgacctctccacactttgt-3’ 
IFNA5 5’-ttggtcgacgcattggcaacattc-3’ 5’-gcgagatctctctccacactttgt-3’ 
IFNA6 5’-ttactgcagccagaagcattggca-3’ 5’-gacagatcttccacacttggtctc-3’ 
IFNA9 5’-gcatctagaagcagcagcatcttc-3’ 5’-cggtctagacctctccattttggt-3’ 
IFNB 5’-catgtcgacggcttcccatcatgaa-3’  5’-gcgtctagatgacaggtcttcagt-3’ 
aType I IFN subtype cDNA was prepared from BALB/c liver for amplification by PCR. 
bForward and reverse primers are shown, 5’-3’, for each gene. 
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2.2.3.10 Northern Analysis 
Northern Blotting 
Total RNA was separated on a 1.2% formaldehyde-agarose gel. The RNA samples (10µg) 
were diluted 1/2 in RNA sample buffer.  The samples were then heated to 65
oC for 5 min, 
quenched on ice, and made up to 1x RNA Loading Dye prior to loading.  RNA was 
electrophoresed at 60-80V, and the gel soaked in two changes of ddH2O.  The RNA was then 
transferred to nylon membranes (MSI) in 10x SSC overnight.  Finally, the membrane was 
UV cross-linked (UV Stratalinker, Biorad) and baked at 80
oC for 2h.  
 
Hybridisation 
Membranes were pre-wet in 2x SSC, rolled and placed in hybridisation bottles.   
Hybridisation buffer (20mL) was added to the bottle with 100µg freshly denatured herring 
sperm DNA and incubated for 2h in the hybridisation oven at 65
oC.  The [
α32-P]-
radiolabelled DNA probes and herring sperm DNA (100µg) were denatured before addition 
to hybridisation buffer.  Membranes were incubated for 12-18h at 65
oC.  Following 
hybridisation membranes were washed to high stringency (0.2xSSC/0.1%SDS for 15min) 
and visualised by autoradiography. 
 
2.2.4 Immunological Methods 
2.2.4.1 Antigen Preparation 
Preparation of MCMV Antigen 
M2-10B4 cells were grown to ~80% confluency and MCMV added to the monolayer at 
MOI=1.  The cells were then incubated at 37
oC/ 5% CO2 until 20% cell lysis (approx. 2 
days).  The media was then removed, replaced with RPMI-2%FCS and left for 48h.  The 
supernatant was harvested and centrifuged at 2,500g for 20min followed by ultra-
centrifugation at 30,000g for 2h.  The pellet was then resuspended in 4% of its initial 
volume, aliquotted and stored at –20
oC.   Chapter Two  
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Preparation of Cardiac Myosin   
The hearts from normal uninfected BALB/c mice were washed in potassium phosphate 
buffer and roughly cut in a mincing pot.  The hearts were then washed 3 times in 4 volumes 
of potassium phosphate buffer and homogenised in 4 volumes potassium phosphate buffer.  
The mixture was then centrifuged for 5min at 5,000g at 4
oC.  The pellet was gently stirred 
for 2h at 4
oC in initial volume with potassium chloride solution, centrifuged for 30min at 
10,000g at 4
oC, and the supernatant filtered through 4 layers of gauze.  The supernatant was 
precipitated with 9x volume of cold 1mM EDTA added dropwise while stirring vigorously 
for ~20min, followed by centrifugation for 10min at 10,000g at 4
oC.  The pellet was 
dissolved in 25mM Tris-HCl buffer and gently stirred overnight at 4
oC.  The next day, the 
solution was made up to 2mM ATP and continuously stirred for 20min at 4
oC, followed by 
centrifugation for 3h at 80,000g at 4
oC.  The supernatant was then diluted in 14 volumes of 
cold EDTA whilst stirring at 4
oC and then allowed to stand at 4
oC for 30min.  Following 
centrifugation for 10min at 10,000g at 4
oC, the pellet was resuspended in 50mM 
Pyrophosphate buffer.  Saturated Ammonium Sulphate (pH7.0) was added dropwise to 36% 
while stirring for 1h at 4
oC followed by centrifugation at 10,000g for 10min at 4
oC. Saturated 
Ammonium Sulphate was then added to the supernatant dropwise to 45% and the solution 
incubated overnight at 4
oC with stirring.  The following day the mixture was centrifuged for 
10min at 10,000g and the pellet dissolved in potassium phosphate buffer.  The concentration 
of myosin was determined using the Biorad protein assay and the molecular weight 
confirmed for myosin with no contamination due to actin.   
 
2.2.4.2 ELISA 
Anti-MCMV and Anti-Cardiac Myosin ELISAs 
Serum antibody titres toward MCMV and cardiac myosin antigens were determined by 
ELISA.  Maxi-sorp immunoplates were coated with MCMV antigen diluted in carbonate-
bicarbonate buffer (1/500), or myosin (0.5µg/well) diluted in carbonate-bicarbonate buffer Chapter Two  
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(and 50mM tetrasodium pyrophosphate), and incubated overnight at 4
oC.  Plates were then 
washed 3 times with ELISA wash buffer.  Sera samples were serially 2-fold diluted in 
ELISA dilution buffer (100µL/well) and incubated for 2h at 37
oC. Negative control serum 
consisted of pooled sera from uninfected adult BALB/c mice, whereas positive control serum 
consisted of MCMV hyper-immune serum. Plates were washed, as previously, prior to the 
addition of alkaline-phosphatase conjugated anti-mouse antibody (IgG1 and IgG2a, diluted 
1/250) in ELISA dilution buffer (100µL/well) and incubated at RT for 1h.  Plates were 
washed before the addition of diethanolamine substrate solution (100µL/well).  Colour 
production was allowed to develop for ~15min and measured at 405nm.   
 
Antibody titres are expressed as the reciprocal of the highest serum dilution having an OD 
greater than that of the negative control serum plus three standard errors, log2 serum 
antibody titre ± SEM. Limit of detection was 2.0 log2.  
 
Cytokine ELISAs 
Serum concentrations of the cytokines, IFN-γ, IL-2, IL-4, IL-6, IL-10 and IL-18 were 
quantitated using murine cytokine ELISA kits (Pharmingen) performed according to 
manufacturer’s instructions.  Briefly, maxi-sorp immunoplates were coated with anti-
cytokine capture antibody diluted in coating buffer (0.1M carbonate buffer, IFNγ, IL-6, IL-4 
and IL-2; 0.2M sodium phosphate buffer, IL-10).  Plates were sealed and incubated 
overnight at 4
oC and washed (5x IFNγ; 3x others) in PBS/ 0.05% Tween-20.  Plates were 
blocked with assay diluent at RT for 1h and washed as previously.  Standards and samples 
were prepared in assay diluent, added to the plate as per manufacturer’s instructions and the 
plate incubated at RT for 2h.  Plates were washed 5 times and working detector (detection 
antibody and enzyme diluted in assay diluent) added (100µL/ well) followed by incubation 
at RT for 1h.  Plates were washed (10x IFNγ; 7x others) and TMB substrate solution added 
(100µL/ well) prior to incubation at RT for 30min in darkness.  The reaction was terminated Chapter Two  
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by the addition of stop solution (50µL/ well) and the absorbance read at 450nm (within 
30min). 
 
IFN-α ELISA 
Murine type I IFN proteins were quantitated using an IFN-α ELISA kit (PBL, NJ, USA), 
designed to detect murine and rat type I IFN in the range 10-500pg/mL without cross-
reactivity to murine IFN-β or-γ or human IFN-α.  All solutions and materials were provided 
and the procedure was performed according to manufacturer’s instructions.  Briefly, 
standards and samples were diluted in dilution buffer and added to the plate (100µL/ well), 
which was sealed and incubated for 1h at RT.  The plate was washed once in final wash 
solution, antibody solution added (100µL/ well) and the plate covered and incubated for 24h 
at RT.  The plate was washed 3 times with final wash solution, horse-radish peroxidase 
(HRP)-conjugate solution added (100µL/ well) and the plate covered and incubated for 1h at 
RT.  The plate was washed 4 times with final wash solution, TMB substrate solution added 
(100µL/ well) and the plate covered and incubated for 15min at RT in darkness.  Stop 
solution was added (100µL/ well) and the absorbance read at 450nm (within 5min). 
 
2.2.4.3 T cell Harvesting 
T cells were harvested from the spleens of mice for adoptive transfer.  Briefly, spleens were 
harvested and mashed through a sieve in saline with the blunt end of a syringe.  The resulting 
splenocyte population was rinsed in saline and centrifuged at 200g for 5min at 4
oC.  The 
cells were then resuspended in red blood cell lysis buffer and incubated at RT for 5min 
before centrifugation at 200g for 5min at 4
oC.  The unfractionated splenocyte population was 
then resuspended in saline for i.v. inoculation into animals at 9x10
6 cells/50µL. 
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2.2.4.4 Cell Staining 
Histology 
Hearts were removed, transected along the midline and fixed overnight in Bouin’s fixative 
fluid, transferred to 70% ethanol and then processed into paraffin blocks (Histology 
Department, Murdoch University).  Hearts for staining of immune cell subsets were first 
sectioned along the midline, embedded in OCT Compound and then snap frozen in liquid 
nitrogen.  Sections were cut for immunohistochemistry by Dr Jason Lenzo (Murdoch 
University) using a cryostat at –20
oC and mounted on silane-coated  glass  slides.   Slides 
were stored at  –20
oC until use. 
 
Haematoxylin and Eosin (H&E) Staining 
Paraffin-embedded sections were stained with Haematoxylin and Eosin (H&E) (Histology 
Department, Murdoch University) and evaluated for evidence of myocarditis.  A 
classification of myocarditis was based upon the Dallas Criteria definition of inflammation 
associated with necrosis of myocytes (Aretz, 1987).  Two heart sections were scored for each 
animal. Myocarditis was evaluated histologically as the mean number of inflammatory foci 
per heart section ± SEM (5 mice/group).  The number of foci was determined from 
examination of eight fields of view at x160 magnification per mouse (representing the 
average size of a mouse heart section), and included focal and dispersed inflammation.   
Sections were evaluated blindly, often by up to three independent observers.   
 
Immunohistochemistry 
Frozen sections of mouse heart were stained for immune cell subsets including CD4+ and 
CD8+ T cells, B cells, neutrophils, macrophages and DCs.  Tissue sections on slides were 
allowed to thaw before desiccation at 37
oC for 1h.  Slides were fixed with cold (–20
oC) 
acetone for 10min before blocking endogenous peroxidase with 1% hydrogen peroxide (30% 
w/v) and 10% normal goat serum (NGS) for 20min at RT.  Sections were then equilibrated 
with PBS/ 1%BSA for 5min at RT and incubated with monoclonal antibodies to various Chapter Two  
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immune cell surface markers, diluted in PBS/ 1%BSA, for 1h at RT (Table 2.2).  Slides were 
washed twice in PBS before incubation with secondary antibody at RT for 1h followed by 
twice washing in PBS, and development with AEC (positive staining is red).  The slides 
were then counter-stained with Mayer’s haematoxylin (Lillie’s modification), rendering the 
cellular morphology and nuclei blue. Slides were mounted with Faramount aqueous 
mounting media and viewed under light microscopy.      
 
2.2.5 Statistical Analysis 
Statistical analysis was performed using the Microsoft Excel Data Analysis programme.   
Levels of significance (p<0.05) were determined by the unpaired student t-test assuming 
unequal variance between the means.  All figures and tables are representative of a single 
experiment comprising n=5 mice unless otherwise specified. 
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Table 2.2.  Antibodies for detection of immune cell subsets by immunohistochemical 
staining. 
Cell Type
a 1
o Antibody  Dilution
b 2
o Antibody  Dilution 
CD8+ T Cell  CD8b.2 (Ly-3.2) 
Rat anti-mouse monoclonal
d 
1:200 Anti-rat  HRP 1:300 
CD4+ T Cell  CD4 (L3T4) 
Rat anti-mouse monoclonal
e 
1:300 Anti-rat  HRP 1:300 
B Cell  CD45R/220 
Rat anti-mouse monoclonal
f 
1:300 Anti-rat  HRP 1:300 
Macrophage Mac-3 
Rat anti-mouse monoclonal
g 
1:300 Anti-rat  HRP 1:300 
Dendritic Cell  CD11c (Integrin αx chain) 
Biotin-conjugated Hamster anti-mouse
h 
1:200 Extravidin-
peroxidase  
1:300 
Neutrophil Ly-6G  (Gr-1) 
Biotin-conjugated Hamster anti-mouse
i 
1:300 Extravidin-
peroxidase 
1:300 
aHeart sections from BALB/c mice infected with 1x104 pfu MCMV were stained for 
immune cell infiltration at day 7 p.i.  
bPrimary and secondary antibodies were diluted in PBS/ 1%BSA. 
cHorse-radish peroxidase (HRP)  
dLedbetter and Herzenberg, 1979; Ledbetter et al., 1980. 
eNitta et al., 1997. 
fHathcock et al., 1992; Coffman et al., 1982. 
gFlotte et al., 1983; Ho & Springer, 1983. 
hMetlay et al., 1990. 
iLewinsohn et al., 1987; Lagasse & Weissman, 1996. 
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3.1 Introduction 
The type I IFNs are well established as potent antiviral cytokines produced as part of the 
innate immune response.  Previous studies have demonstrated the therapeutic efficacy of 
type I IFNs in high dosage (Baron et al., 1991) and low dose oral (Beilharz, 2000) delivery 
systems.  Recently, the advent of naked DNA transfer technology has provided an alternative 
approach to IFN delivery (Yeow et al., 1998; Horton et al., 1999; Noisakran and Carr, 2001), 
however, studies have been limited and the potential for efficacious type I IFN DNA therapy 
remains to be fully explored.  It is unknown whether the multiple subtypes are simply the 
result of evolution and essentially interchangeable or whether each subtype has an individual 
biological function.  To date, studies have examined a limited panel of type I IFN subtypes.  
We propose that more extensive examination of the type I IFN family will demonstrate the 
unique properties of each subtype which may potentially lead to enhancement of their 
therapeutic applications. 
 
Previous studies in our laboratory have contributed to the hypothesis that the type I IFNs 
exert differential biological functions.  Expression of type I IFN protein, via i.m. inoculated 
DNA expression vectors revealed localised antiviral activity for IFNA1-,  IFNA4- and 
IFNA9- expressing DNA constructs with each subtype affording a differential level of 
protection against MCMV challenge (Yeow et al., 1998).  However, the expression vectors 
used in this study were not consistent between subtypes studied. The IFNA1 construct 
contained the amp R, known to contain CpG repeats which stimulate a Th1-like response, 
while IFNA4 and IFNA9 constructs contained the kan R.  In addition, inserted IFN transgene 
sequences contained variable length 5’ and 3’ untranslated regions, which may affect 
message stability between subtypes. 
 
In this chapter, an extensive panel of murine type I IFN DNA-expressing constructs was 
designed and the IFN genes cloned into the same expression vector, lacking the amp R and 
with similar 5’ and 3’ untranslated regions for further examination of the function and Chapter Three  
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therapeutic efficacy of individual IFN subtypes.  More specifically, the full-length type I IFN 
genes (IFNA1, A2, A4, A5, A6, A9 and B) were sub-cloned into the mammalian expression 
vector pkCMVint (Vical Inc.) containing the kan R.  Subsequently, analysis of IFN protein 
expression and antiviral efficacy in vitro, and protein expression and persistence in vivo will 
be described. 
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3.2 Results 
3.2.1 Construction of Type I IFN-Expressing DNA Vectors 
DNA constructs containing individual murine type I IFN subtype proteins were prepared for 
in vivo expression in murine skeletal muscle.  All DNA constructs were prepared in 
conjunction with Dr Vanessa Cull.  The mammalian expression vector pkCMVint (Vical, 
Inc.) (Fig. 3.1B) was chosen due to several essential features.  Firstly, the vector contains 
kan R which is preferable to amp R, previously associated with an adjuvant-like effect in 
vivo due to immunogenic CpG motifs (Sato et al., 1996).  The polylinker site contains a 
panel of unique restriction endonuclease sites.  Finally, the vector has a HCMV IE1 
enhancer/ promoter and a HCMV intron A, for enhancement of gene expression in 
mammalian skeletal muscle, and the SV40 int polyA tail, to provide consistency in mRNA 
stability across the IFN subtypes.   
 
The panel of seven type I IFN DNA constructs was designed for consistency in stability and 
expression levels of mRNA transcripts.  Primers were designed to incorporate unique 
restriction endonuclease sites for insertion into the polylinker (Fig. 3.1C and Table 2.1) such 
that each IFN gene could be identified by specific restriction endonuclease digestion.  In 
addition, primers were designed 10-25 nucleotides up-stream of the first ATG start codon 
and 10-24 nucleotides down-stream of the TGA stop codon to provide similar lengths of 5’ 
and 3’ untranslated regions and proximity to the pkCMVint promoter/ enhancer and poly(A) 
tail respectively (Fig. 3.1C).  The type I IFN subtype genes were amplified from mRNA 
obtained from BALB/c liver by RT-PCR (Fig. 3.1A) (section 2.2.3.6) using specific primers 
with incorporated restriction endonuclease sites.  Subsequent to digestion with appropriate 
restriction endonucleases, PCR products were sub-cloned into the pkCMVint mammalian 
expression vector using standard ligation and transformation protocols (section 2.2.3.4 and 
2.2.3.5).  Fragments incorporated were: IFNA1 –21 to +525bp, IFNA2 –21 to +596bp, 
IFNA4 –21 to +584bp, IFNA5 –18 to +593bp, IFNA6 –24 to +590bp, IFNA9 –25 to 
+595bp, and IFNB –10 to +559bp.  All constructs were analysed by agarose gel  Chapter Three  
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A4 
5’tctctgcagccagcatctacaaga 
Pst I 
acaaagtgtggagaggtcgactga
3’ 
Sal I 
A1 
-21 +69  +501  +525 
5’actggatccgaagctttggcaaca  ccaaagtgtagaggaagatctgcg
3’ 
BamHI  Bgl II 
-21 +69  +573  +596 
A2 
5’gcgtctagatcaacctctgcaaga 
Xba I 
caaagtgtggagagaggatcctct
3’ 
Bam HI 
-21 +81  +561  +584 
acaaagtgtggagagagatctcgc
3’’ 
-18 
A5  5’ttggtcgacgcattggcaacattc 
Sal I 
+69  +570  +593
Bgl II 
B 
A9  5’gcatctagaagcagcagcatcttc 
-25  +69  +573 
accaaaatggagaggagatctcgg
3’ 
Bgl II  Xba I 
+595 
+590 
-24 
A6 
5’ttactgcagccagaagcattggca 
+69  +570 
aagacgctgcagcaa
3’ 
+697 
5’gagaccaagtgtggaagatctgtc
3’ 
Bgl II 
Pst I 
Sal I 
-10  +63  +549 
Xba I 
+559 
actga agacctgtcatctagacgc
3’ 
    5’catgtcgacggcttccatc atgaa 
C 
Figure 3.1. Design of type I IFN DNA constructs. RT-PCR was used to amplify IFN DNA 
from BALB/c liver mRNA prior to cloning into the pkCMVint mammalian expression 
vector.  (A) PCR product was run on an agarose gel using a 1kb DNA ladder to confirm 
fragment sizes (sizes of the individual fragments in the 1kb standard are: 10,000, 8,000, 
6,000, 5,000, 2,500, 2,000, 1,500, 1,000, 750, 500, 253/250bp) including positive and 
negative (DNA-free) controls.  Murine IFN transgenes were cloned into the polylinker of 
(B) the mammalian expression vector, pkCMVint (Vical).  (C) MuIFNA1, A2, A4, A5, A6, 
A9  and B  carrying the full-length MuIFN subtype genes (black) including the signal 
sequence (shaded grey) located upstream of the mature protein. Flanking primer sequences 
with incorporated unique restriction enzyme sites used for subcloning of each transgene 
cassette are shown.  Chapter Three  
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electrophoresis and sequenced in both directions to ensure sequence identity (section 
2.2.3.7).   
 
3.2.2 Expression of Type I IFN DNA Subtypes In Vitro 
Transcription of the type I IFN transgenes was confirmed in vitro by northern analysis.  
COS-7 cells were transiently transfected with the type I IFN transgenes for analysis of 
mRNA and protein expression (section 2.2.2.3).  Northern blot analysis using 
32-P-labelled 
DNA probes encoding full-length IFNA1,  IFNB, and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was used to confirm mRNA expression in COS-7 cells (Fig. 3.2).  
Indeed, all IFNA mRNAs were detected by IFNA1 probe whilst the IFNB probe detected 
solely IFNB mRNA.  No type I IFN mRNA was detected in Blank-transfected COS-7 cell 
RNA (Fig. 3.2).  The control gene, GAPDH, was consistently detected in the COS-7 cells 
(Fig. 3.2).  
 
Translation of the type I IFN transgenes into biologically active protein was also confirmed 
in vitro.  IFN bioassay and IFNα ELISA were used for detection of type I IFN proteins in the 
supernatants of type I IFN DNA-transfected COS-7 cells at 48h post-transfection (Fig. 3.3).  
Supernatants were pH 2.0-treated to remove acid-labile type II IFN (IFNγ).  The IFN 
bioassay which measures the biological activity of IFN by reduction in EMCV-induced cpe 
of L929 cells, as compared to the international IFNα/β standard, confirmed IFN activity in 
all COS-7 cell supernatants.  Type I IFN subtype expression was detected for IFNα1 (80,000 
IU/mL), IFNα2 (2,500 IU/mL), IFNα4 (160,000 IU/mL), IFNα5 (160,000 IU/mL), IFNα6 
(20,000 IU/mL), IFNα9 (40,000 IU/mL), and IFNβ (80,000 IU/mL) (Fig. 3.3A).  In addition, 
a low level of IFN expression was detected in Blank-transfected COS-7 cells (156.25 IU/mL) 
(Fig. 3.3A).  Type I IFN protein expression in transiently transfected COS-7 cells was also 
confirmed by IFNα ELISA (PBL, sample kit) and compared to the international IFNα/β 
standard (Fig. 3.3B).  IFNα protein, adjusted to 1000 IU/mL before being added to the  Chapter Three  
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IFNA6 IFNA9 IFNB 
IFNA1 
IFNB 
GAPDH 
Blank IFNA1 IFNA2 IFNA4 IFNA5 
Figure 3.2.  IFN DNA constructs express type I IFN in vitro. Protein expression was 
confirmed by plasmid transfection of COS-7 cells using the calcium phosphate method. 
At 48h post-transfection, mRNA was extracted (10µg) from the COS-7 cells and 
northern blotted. Membranes were probed for IFNA subtype mRNA using IFNA1 
which is highly homologous to all IFNAs, and IFNB mRNA with IFNB, or GAPDH
loading control as indicated. Chapter Three  
  81
  
 
 
 
 
 
 
 
 
 
A 
B 
1
10
100
1000
10000
100000
1000000
Blank IFNA1 IFNA2 IFNA4 IFNA5 IFNA6 IFNA9 IFNB
0
500
1000
1500
2000
2500
3000
3500
IFNa/b IFNA1 IFNA2 IFNA4 IFNA5 IFNA6 IFNA9 IFNB
I
F
N
 
(
l
o
g
1
0
 
I
U
/
m
L
)
 
I
F
N
 
(
p
g
/
m
L
)
 
Figure 3.3.  IFN protein expression in COS-7 cells.  COS-7 cells were transfected 
with 20µg IFN DNA and at 48h post-transfection, supernatants were harvested, pH 
2.0-treated and type I IFN expression levels quantitated by (A) IFN bioassay and (B) 
IFNα cytokine ELISA and expressed as IU/mL and pg/mL respectively. Chapter Three  
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ELISA, was detected in all IFNA-transfected cell supernatants, IFNα1 (2583 pg/mL), IFNα2 
(1549 pg/mL), IFNα4 (1294 pg/mL), IFNα5 (3111 pg/mL), IFNα6 (371 pg/mL), and IFNα9 
(94 pg/mL) with no detection of IFNβ, as expected (Fig. 3.3B).  The IFNα/β standard which 
was added to the ELISA at 1,000 IU/mL, and is comprised of approximately 85% IFNβ 
equated to 255 pg/mL as determined by IFNα ELISA (Fig. 3.3B).  In vitro type I IFN protein 
expression in COS-7 cells was confirmed for all type I IFN transgenes and ranged 64-fold as 
detected by IFN bioassay and 33-fold as detected by IFNα ELISA. 
 
3.2.3 Expression of Type I IFN DNA Subtypes In Vivo 
The in vivo activity of the type I IFN transgenes was next determined.  BALB/c mice were 
inoculated with the IFN constructs bilaterally in the TA muscles (section 2.2.1.2).  Two 
weeks later mice were challenged with 1x10
4 pfu MCMV i.p. (Fig. 2.1).  Sera were 
harvested at day 3 p.i. (section 2.2.1.4) and at day 7 p.i. TA muscles were harvested (section 
2.2.1.3).   
 
Biologically active IFN was measured in both the sera and TA by IFN bioassay (Table 3.1).  
In vivo IFN protein expression was confirmed for all IFN transgenes with activity typically 
ranging 4-fold in the sera (10.4 ± 2.6 IU/mL to 41.0 ± 13.3 IU/mL) and 3-fold in the TA 
muscle (13.0 ± 4.0 IU/mL to 40.0 ± 14.3 IU/mL) (Table 3.1).  Thus, biologically active IFN 
was detectable at sites both local and systemic to the site of DNA inoculation and was 
similar in titre amongst the various subtypes. 
 
3.2.4 Persistence of Type I IFN Transgenes In Vivo 
The kinetics of persistence of vector-driven protein expression have been investigated in 
several models of DNA gene therapy.  Most studies report a peak in transgene expression 1-
2 weeks following inoculation, however, persistence of transgene expression depends on the Chapter Three  
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antigenicity of the protein with non-immunogenic proteins having longer persistence 
(Prud’homme et al., 2001).  Due to variation in the duration of persistence of i.m. inoculated 
Table 3.1. Interferon activity in the sera and TA muscle of mice following DNA injection 
and viral challenge as determined by IFN bioassay. 
IFN Subtype
a  Sera (IFN IU/mL)
b TA  (x10
3 IU/g) 
pkCMVint.blank  0.0 ± 0.0 (5/5)  0.0 ± 0.0 (5/5) 
pkCMVint.IFNα1 18.2  ± 6.9 (3/5)  35.3 ± 14.8 (5/5) 
pkCMVint.IFNα2 15.6  ± 4.4 (5/5)  40.0 ± 14.3 (5/5) 
pkCMVint.IFNα4 25.0  ± 2.9 (5/5)  15.9 ± 4.6 (5/5) 
pkCMVint.IFNα5 41.0  ± 13.3 (4/5)  13.0 ± 4.0 (5/5) 
pkCMVint.IFNα6 10.4  ± 2.6 (3/5)  16.9 ± 3.6 (5/5) 
pkCMVint.IFNα9 18.2  ± 2.6 (3/5)  16.2 ± 3.6 (5/5) 
pkCMVint.IFNβ 30.2  ± 0.0 (2/5)  15.6 ± 3.7 (5/5 
aDNA (200µg) was injected bilaterally into regenerating TA muscles of adult mice 5 days 
after bupivacaine treatment. 
 Fourteen days following DNA injections mice were challenged 
with 1x10
4 pfu of MCMV i.p. 
bSera harvested at day 3 and TA muscle harvested at day 7 p.i.  Data are expressed as mean 
(IU/mL or IU/g, respectively) ± SEM, number of mice positive given in parentheses. 
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transgenes, the kinetics of expression of the type I IFN transgenes was determined. 
 
The expression levels and persistence of the type I IFN transgenes in vivo was determined in 
uninfected BALB/c mice.  Mice were inoculated with Blank vector and the IFNA6 transgene 
following bupivacaine treatment (section 2.2.1.2) and sera and TA samples were harvested at 
7 day intervals to 84 days p.i.  Mice inoculated with the Blank vector demonstrated low or 
undetectable levels of type I IFN (Fig. 3.4).  Biologically active IFN was detected in mice 
inoculated with the IFNA6 transgene at days 14, 21 and 28 with levels declining from days 
35 to 84p.i.  Specifically, systemic IFNα6 expression peaked in the sera at day 28 (40 ± 13.6 
IU/mL) (Fig. 3.4A) while localised IFN expression in the TA muscle peaked at day 21 
(15.5x10
3 ± 3.9x10
3 IU/mL) (Fig. 3.4B).   
 
3.2.5 IFN Transgene Expression Induces ISG Activation 
The biological activity of IFNs is mediated in the cell via the transcriptional activation of 
ISGs following binding of the IFN to its cognate receptor and subsequent activation of the 
JAK-STAT pathway.  Type I IFNs activate ISGs such as PKR and 2’5’OAS.  These ISGs 
are involved in mediating the antiviral, antiproliferative and immunomodulatory effects of 
type I IFN (Sokawa et al., 1994; Kumar et al., 1995).  Activation of ISG mRNA expression 
by each IFN transgene was determined for further confirmation of biological function of IFN 
protein produced in COS-7 cells (Fig. 3.5). J2E cells were stimulated with IFN subtypes and 
mRNA extracted and examined by Northern blot analysis for expression of PKR and 
2’5’OAS.  J2E cells were stimulated with 100 IU/mL IFN (IFNα1, α2, α4, α5, α6, α9 and 
β) and mRNA was extracted at 0h, 2h and 5h.  Northern blot analysis of PKR and 2’5’OAS 
gene expression confirmed that all type I IFN subtypes activated PKR and 2’5’OAS gene  
 Chapter Three  
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Figure 3.4.  IFN expression persists in the sera and TA muscle of IFN-treated mice up 
to one month following DNA inoculation.  BALB/c mice were injected with 200µg of 
either  Blank or IFNA6 DNA bilaterally in the TA muscle.  Muscle and sera were 
harvested at the indicated time-points and IFN expression was determined by IFN 
bioassay and expressed as (A) mean IU/mL sera or (B) mean IU/g TA ± SEM (n=5). 
*Statistical significance (p≤0.05) compared with control groups of mice inoculated 
with the Blank vector. 
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Figure 3.5.  Type I IFNs stimulate expression of anti-viral ISGs in J2E cells. J2E 
cells were seeded at 1 x 10
5 cells/ml, stimulated with type I IFN proteins (100 
IU/ml) and RNA extracted at 0h, 2h and 5h post-stimulation. RNA (20µg) was 
electrophoresed on formaldehyde gels, northern blotted and hybridized with (A) 
PKR, or (B) 2'5'OAS and GAPDH loading control as indicated. Chapter Three  
  87
transcription in the J2E cell system (Fig. 3.5).  More specifically, all subtypes induced PKR 
expression by 5h, with higher expression of PKR detected at 2h following IFNα9 and IFNβ 
stimulation (Fig. 3.5A) and 2’5’OAS expression was detected following stimulation by all 
IFN subtypes at 2 and 5h (Fig. 3.5B).  Therefore, type I IFN transgene expression is efficient 
in activating antiviral ISGs at a concentration of 100 IU/mL in J2E cells. 
 
3.2.6 Type I IFN Subtypes Differentially Modulate MCMV Replication In Vitro  
Type I IFNs have previously proven effective in suppression of herpesvirus replication (Leib 
et al., 1999; Cui and Carr, 2000).  In this study, we analysed the antiviral efficacy of the type 
I IFN COS-7 cell supernatants against MCMV in vitro.  M2-10B4 cells were treated with 
100 IU or 1000 IU type I IFNs (Blank, IFNα1, α2, α4, α5, α6, α9 and β) for 24h prior to 
viral challenge.  MCMV was added at an MOI of 0.1 and cells incubated for 1h with virus 
prior to washing.  The following day MCMV titres in M2-10B4 cell supernatants were 
quantitated by plaque assay. 
 
The type I IFNs demonstrated differential levels of antiviral activity in this study (Fig. 3.6).  
At both concentrations, all type I IFNs, with the exception of IFNα6, significantly reduced 
MCMV titres in comparison to the Blank treatment group.  IFNα1 and α2 were most 
efficacious, reducing titres by 3.3- and 3-fold respectively following treatment with 100 
IU/mL and reducing titres by 4.6- and 4.7-fold respectively with 1000 IU/mL treatment.  At 
100 IU/mL of IFN, viral titres were also reduced with: IFNα4 (2.5-fold), α5 (1.44-fold), α9 
(1.56-fold) and β (2.8-fold).  Similarly, at 1000 IU/mL of IFN, viral titres were reduced with: 
IFNα4 (4.4-fold), α5 (2-fold), α9 (2.25-fold) and β (2.5-fold).  Although IFNα6 reduced 
MCMV titres, this was not significant at 100 IU (p=0.06) or 1000 IU (p=0.08).  This data 
confirms the direct differential antiviral activity of the subtypes in vitro in a MCMV model. Chapter Three  
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Figure 3.6.  Type I IFNs reduce MCMV replication in vitro.  M2-10B4 cell 
monolayers were treated with type I IFN subtypes at (A) 100 IU and (B) 1000 IU 
for 24h prior to challenge with MCMV (MOI=0.1).  Cells were incubated for 1h 
with virus before being washed (x3) and incubated for 24h.  Virus was quantitated 
in the supernatants by plaque assay in M2-10B4 cells.  Each treatment group was 
performed in triplicate and significance is denoted by * p≤0.05; ** p≤0.005. Chapter Three  
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3.3 Discussion 
The panel of type I IFN-expressing DNA constructs described here comprises seven 
individual murine type I IFN subtypes.  Each subtype was chosen for specific characteristics, 
which indicated potentially distinct biological activities.  Specifically, IFNα1, α4, α5, and 
α6 were chosen due to their position within a cluster of IFN genes in a 28kb region on 
mouse chromosome 4, while IFNα2, α9 and β are positioned outside of this gene cluster 
(Kelley and Pitha, 1985).  Furthermore, IFNα4 and IFNα2 encode for proteins of 161aa and 
165aa respectively compared with 166aa for all other murine type I IFN subtypes.  In 
addition, IFNβ is distinct to IFNα subtypes due to sequence homology.  These 
characteristics represent potential for variability within this group of type I IFN subtypes. 
  
The type I IFN DNA constructs were prepared for optimal stability and consistency in 
expression.  The pkCMVint vector has previously been used as an expression vector for IFN 
DNA inoculation in this laboratory and was found to efficiently express biologically active 
IFN in vivo (Lawson et al., 1997).  The type I IFN DNA constructs detailed in this chapter 
were evaluated for expression in vitro.  Confirmation of IFN mRNA expression in 
transiently transfected COS-7 cells correlated with detection of biologically active IFN in 
COS-7 cell supernatants.  The level of IFN expression varied 64-fold in the IFN bioassay 
and 33-fold in the IFNα ELISA, however, the sensitivity of these detection systems for 
individual subtypes has not been determined.  The IFN bioassay relies on antiviral efficacy 
against EMCV and, given that the type I IFN subtypes may indeed have differential antiviral 
efficacy, there is potential for inherent variation in detection of the individual type I IFN 
subtypes.  Furthermore, the sensitivity of the IFNα ELISA to individual subtype epitopes 
may vary as the ELISA kit was developed based on the international standard for mouse 
IFNα (provided by the National Institutes of Health; PBL).  Importantly no IFNβ was 
detected by the IFNα ELISA.    
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Endogenous expression of IFN transgenes persists up to one month following IFN 
inoculation.  Biologically active type I IFN protein was detected following inoculation with 
each IFN DNA construct and, in addition, minimal variation (3-fold in the TA muscle and 4-
fold in the sera) confirmed consistency of expression in vivo.  Reports of persistence of 
transgene expression vary, one report demonstrated the persistence of luciferase expression 
for at least 60 days following pRSVL DNA injection (Danko and Wolff, 1994).  In another 
study, authors report serum expression of IFN-γR-Fc persisting >4 months following 
inoculation (Chang and Prud’homme, 1999; Prud’homme and Chang, 1999).  In addition, 
plasmid administrated IL-10 was shown to be detectable by ELISA for over two weeks 
following i.m. injection (Nitta et al., 1998).  The short-term persistence of the IFN 
transgenes may be preferential in a clinical setting where type I IFN expression may not be 
desirable once viral infection is cleared or the threat of disease is eliminated.  
 
Previous studies firmly establish increased PKR and 2’5’OAS in response to both IFNα and 
IFNβ via the JAK-STAT signalling pathway (Reich and Pfeffer, 1990; Jaramillo et al., 
1995).  More specifically, increased ISG expression following IFNα (Zhou et al., 1999); 
IFNα 2b (Harcourt and Offermann, 2001) and IFNβ 1a (Buchwalder et al., 2000) has been 
demonstrated.  ISGs are thought to mediate the biological effects of IFN.  PKR plays a role 
in mediating the antiviral and antiproliferative effects of type I IFN (Kumar et al., 1995) and 
is a regulator of IFNβ via NF-κB activation, inducing activation of other ISGs (Jaramillo et 
al., 1995).  2’5’OAS mediates the antiviral and antiproliferative actions of IFN, in addition 
to its immunomodulatory mechanisms (Sokawa et al., 1994).  In this chapter, stimulation of 
J2E cells with IFN proteins produced from transiently transfected COS-7 cells efficiently 
induced transcription of these ISGs with slight variation in the kinetics of induction.   
Thereby, the type I IFN induction of antiviral genes was confirmed.   
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Previous studies demonstrate a protective role for type I IFN in herpesvirus infections.   
Increased susceptibility to MCMV following administration of type I IFN-specific antiserum 
has been demonstrated (Grundy et al., 1982).  Data presented here demonstrates that all IFN 
subtypes significantly reduced MCMV replication with the exception of IFNα6.  IFNα1 and 
IFNα2 were most effective in suppressing MCMV replication with reductions in viral load 
varying between subtypes and dosage.  Similarly, recent studies in HSV-1 replication in vitro 
revealed differential antiviral properties of the type I IFNs.  IFNβ was far more superior than 
the IFNα subtypes (IFNα1, α4, α5, α6 and α9) in reducing HSV-1 replication (Harle et al., 
2002a).  It is important to note that the individual subtypes exert variable levels of antiviral 
efficacy in this and other models of virus infection.  Thus specific subtypes may be more 
effective in certain disease conditions.     
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3.4 Summary 
An extensive panel of type I IFN subtype-expressing DNA constructs (IFNA1, A2, A4, A5, 
A6, A9 and B) was designed and produced for expression of biologically active IFN in the 
mouse.  The type I IFN constructs were evaluated for both in vitro and in vivo expression. 
COS-7 cells transiently transfected with the type I IFN DNA constructs consistently 
expressed type I IFN mRNA and biologically active IFN protein.  Furthermore, in vivo IFN 
expression following i.m. inoculation was confirmed both locally (15,000 IU/g) and 
systemically (40 IU/mL) with IFN titres ranging 3- and 4-fold respectively with systemic 
IFN expression persisting up to one month following DNA inoculation.  Importantly, IFN 
proteins expressed by the transgenes were found to effectively induce transcription of the 
antiviral ISGs PKR and 2’5’OAS.  Indeed, in vitro analysis of antiviral efficacy in a MCMV 
model determined that the type I IFN subtypes antagonise MCMV replication in M2-10B4 
cells. 
 
 
 
Some of the findings presented in this chapter are presented in the following publications: 
 
Cull V.S., Bartlett E.J., and James C.M.  (2002)  Type I interferon gene therapy protects 
against cytomegalovirus-induced myocarditis.  Immunology.  106:428-437. 
 
Bartlett E.J., Cull V.S., Brekalo N.L., Lenzo J.C., and James C.M.  (2002)  Synergy of type I 
interferon-A6 and interferon-B naked DNA immunotherapy for cytomegalovirus infection.  
Immunology and Cell Biology.  80:425-435. 
 
Cull V.S., Tilbrook P.A., Bartlett E.J., Brekalo N.L., and James C.M.  (2003)  Type I 
interferon differential therapy for erythroleukemia: specificity of STAT activation.  Blood.  
101(7): in press (pre-published online November 21, 2002).  
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4.1 Introduction 
Type I IFN has previously been proven effective against MCMV infection.  Previous studies 
in our laboratory have demonstrated reduced localised MCMV replication following 
intramuscular IFNA1, A4, and A9 DNA inoculation in both susceptible and resistant mouse 
genotypes (Yeow et al., 1998).  Earlier studies demonstrated that administration of type I 
IFN-specific antiserum resulted in increased susceptibility of adult mice to MCMV infection 
(Grundy et al., 1982).  The type I IFNs have been established as a pivotal link between the 
innate and adaptive immune response due to various immunomodulatory properties which 
include enhanced NK cell cytotoxicity and DC maturation, and potentiation of the clonal 
expansion and survival of CD8+ T cells (Biron, 1998; Tough, 1996).  Furthermore, type I 
IFNs promote Th1-type immune responses by enhancing cytokines such as IFNγ, IL-12 and 
IL-15 and suppressing IL-4 and IL-5 production by CD4+ T cells.  They also enhance IgM, 
IgG2a and IgA, but not IgG1 antibody production by B cells (Estes et al., 1998).  
 
MCMV is able to establish early infection in target organs including the spleen and liver, 
where viral titres are detectable from days 2-4 p.i., after which infectious virus is 
undetectable (Hudson, 1979).  The salivary glands are also a major target organ for persistent 
MCMV infection with infectious virus detectable from day 7 p.i, peaking at days 14-28 p.i. 
and resolving by day 35 p.i. (limit of detection reached by day 56 p.i.) in susceptible 
BALB/c mice (Lenzo et al., 2001b; D. Fairweather, unpublished data).  Although the 
myocardium is a target site for MCMV-induced disease, it is not a major site of viral 
infection.  Low levels of infectious virus can be detected by plaque assay at days 3-10 p.i., 
beyond which viral transcripts are detectable by PCR through to day 100p.i. (Lawson et al., 
1990).  The effect of individual type I IFN subtype treatment of MCMV infection in the 
spleen, liver and salivary glands will be investigated in this chapter. 
 
CMV is well established as an aetiological agent for myocarditis in humans (Maisch et al., 
1993a).  Similarly, MCMV induces myocarditis in susceptible BALB/c mice Chapter Four  
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(Bartholomaeus et al., 1988).  Myocarditis is a biphasal disease characterised by an acute 
phase associated with a mixed cellular infiltrate in the heart at days 3-21 p.i. and a chronic 
phase associated with an infiltrate of predominantly mononuclear cells at days 28-100 p.i. 
(Lawson et al., 1990; Lenzo et al., 2002).  Accumulating evidence suggests that the chronic 
phase of the disease is autoimmune in nature (Lawson, 2000).  Indeed, infectious virus is 
undetectable in the heart beyond day 10 p.i. (Lawson et al., 1990) and during the chronic 
phase of disease, susceptible BALB/c mice produce predominantly autoantibodies reactive 
against the S2 region of the heavy chain of cardiac myosin (O’Donoghue et al., 1990; 
Lawson  et al., 1992).  Interestingly, monoclonal antibodies raised against structural 
determinants of MCMV exhibit cross-reactivity with cardiac myosin and have been shown to 
contribute to the onset of myocarditis (Lawson et al., 1992).  Low dose orally administered 
IFNα/β has previously been shown to effectively reduce acute and chronic myocarditis 
(Lawson and Beilharz, 1999).  Therefore, it is hypothesised that the type I IFNs may reduce 
viral replication and/ or MCMV-induced disease via immunomodulatory effects. 
 
Hypotheses surrounding the inflammation and necrosis of cardiac tissue, which is 
characteristic of myocarditis, suggest that cytotoxic immune responses following viral 
infection may cause necrosis of myocytes (Neumann et al., 1993; Rose, 1996).  The onset of 
myocarditis is increasingly associated with the production of proinflammatory cytokines 
(TNFα, IL-6 and IL-1) (Ikeda, 1992; Lenzo et al., 2001b) and Th2-associated cytokines (IL-
4 and IL-10) (Afanasyeva et al., 2001; Schmidtke et al., 2000). 
 
The data presented in this chapter demonstrates the immunomodulatory efficacy of type I 
IFN subtype DNA therapy on MCMV replication and MCMV-induced myocarditis.  Several 
aspects of acute and chronic disease induction are examined including, the effect of IFN 
subtype therapy on the antibody isotype responses and cytokine profiles.  Since distinct 
mechanisms of disease pathogenesis are involved in the onset of acute and chronic disease, Chapter Four  
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these phases will be examined separately.  Results highlight the importance of gaining 
knowledge of the type I IFN subtypes with regard to improving the efficacy of IFN 
treatment. 
 
4.2 Results 
4.2.1 Type I IFN DNA Treatment Reduces MCMV Replication 
A panel of individual type I IFN subtypes was examined for effect on systemic virus 
replication in target organs assessed during the acute stage of MCMV infection.  BALB/c 
mice were inoculated with individual type I IFN expressing-DNA constructs (section 
2.2.1.2) and challenged two weeks later with 1x10
4 pfu MCMV (Fig. 2.1).  Viral replication 
was determined in the spleen and liver at day 3 p.i. (Fig. 4.1A and B) and in the salivary 
glands at the onset of replication at day 7 p.i., which corresponds with the peak of acute 
phase myocarditis (Fig. 4.1C), by MCMV plaque assay in M2-10B4 cells.   
 
In the spleen, MCMV titres were markedly reduced at day 3 p.i. following IFNA2 treatment, 
and significantly reduced following IFNA6 treatment (Fig. 4.1A).  Interestingly, IFNA5 
treatment significantly increased MCMV titres in the spleen (Fig. 4.1A).  No change in viral 
titres was observed following treatment with IFNA1, IFNA4, IFNA9, or IFNB in comparison 
to mice treated with the Blank vector (Fig. 4.1A).  Similarly, viral replication in the liver at 
day 3 p.i. was significantly reduced following IFNA6 treatment (Fig. 4.1B).  However, no 
other IFN DNA construct afforded any protection against viral replication in this organ (Fig. 
4.1B).  Treatment with both IFNA5 and IFNA6 transgenes significantly reduced viral load in 
the salivary glands at day 7 p.i. (Fig. 4.1C).  No other IFN DNA constructs demonstrated any 
significant effect on viral replication in the salivary glands (Fig. 4.1C). 
 
Interestingly,  IFNA6 DNA inoculation was the sole IFN subtype treatment protective in 
significantly reducing acute MCMV replication in spleen, liver and salivary glands at the Chapter Four  
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time-points observed.  In addition, it is important to note that the type I IFN subtypes 
demonstrated differential effects against viral replication in each tissue type examined.       
 Chapter Four  
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Figure 4.1.  IFN DNA subtype treatment has a differential effect on MCMV replication in 
vivo.  Following bupivacaine treatment, mice were treated with 200µg of either Blank or 
IFNA/B bilaterally in the TA muscle.  At two weeks post DNA inoculation, mice were 
challenged with 1x10
4 pfu MCMV i.p.  MCMV titres in (A) spleen and (B) liver at day 3 
p.i. and (C) salivary glands at day 7 p.i. were evaluated by plaque assay. Viral titres are 
expressed as a percentage of titre (average pfu/g tissue, 5 mice per time point ± SEM) for 
mice vaccinated with the Blank vector. *, Statistically significant differences between 
treatment groups and Blank  vector (p≤0.05) are shown and are representative of two 
independent experiments. 
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4.2.2 Type I IFN DNA Inoculation Modulates Acute-Phase Myocarditis 
The induction of cytokines during disease pathogenesis appears crucial to the development 
of virally-induced myocarditis and disease severity.  In this study, cytokine gene therapy, 
namely type I IFN DNA inoculation was characterised for immunomodulatory effects on 
skewing the development of myocarditis towards a protective outcome.  BALB/c mice were 
inoculated with IFN DNA constructs and, two weeks later, challenged with 1x10
4 pfu 
MCMV as previously described (section 2.2.1.2).  Hearts were harvested at day 7 p.i. for 
analysis of acute myocarditis by histological examination of H&E stained heart sections and 
subsequent quantitation of foci of inflammatory cells.  Mice were scored for myocarditis as 
determined by the number of foci of inflammatory cells observed in each heart section.  
Hearts from “normal”, untreated, uninfected animals did not show any evidence of 
myocarditis (Fig. 4.2).  Mice receiving the blank vector and previously challenged with 
MCMV demonstrated acute phase myocarditis characterised by a mononuclear cell infiltrate 
and necrosis of adjacent myofibres, foci of infiltrating cells were of moderate size with many 
foci scattered throughout the myocardium (Fig. 4.2).  Treatment with IFN DNA resulted in 
distinct patterns of infiltrating cells for each subtype.  IFNA1, IFNA6 and IFNB treatment 
resulted in small foci, specifically, IFNA1 treatment resulted in many small, dense foci, 
while IFNA6 treatment resulted in few very small, diffuse foci, and IFNB also caused few 
small, diffuse foci of inflammatory cells.  Moderately sized foci were seen following IFNA2 
and  IFNA5 treatment, IFNA2 treatment caused moderate sized, very dense foci, IFNA5 
caused moderately sized diffuse cellular infiltration.  Finally, IFNA4 and IFNA9 treatment 
caused large foci with IFNA4 showing a combination of large, dense foci and diffuse foci, 
and IFNA9 resulting in a small number of very large, dense foci.  Mice treated with the 
IFNA6,  IFNA9, and IFNB DNA constructs demonstrated a significant reduction in 
myocarditis in the acute phase of disease (78.6%, 46.9% and 58.2% respectively) (Fig. 4.3).  
Treatment with IFNA2 and IFNA4 constructs slightly increased the degree of myocarditis 
observed in mice in comparison to the Blank vector treatment group, however, this was not 
significant (Fig. 4.3).  IFNA1 and IFNA5 inoculation had no effect on disease (Fig. 4.3). Chapter Four  
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Normal Blank IFNA1
IFNA2 IFNA4 IFNA5
IFNA6 IFNA9 IFNB
Figure 4.2.  Histopathology of MCMV-infected murine cardiac tissue demonstrate 
representative foci of infiltrating immune cells following IFN  DNA inoculation. 
Hearts were taken from mice treated with DNA constructs and infected with MCMV at 
day 7 p.i. and H&E stained. Histopathology of heart sections for normal, uninfected 
mice and Blank vector, IFNA1,  IFNA2,  IFNA4,  IFNA5,  IFNA6,  IFNA9 and IFNB
treated mice are shown (x160) and demonstrate distinct patterns of infiltration for each 
treatment group.  Chapter Four  
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Figure 4.3. DNA treatment with IFNA6, IFNA9 and IFNB reduces acute-phase 
myocarditis. Following bupivacaine treatment, BALB/c mice were treated with 
200µg of either Blank or IFNA/B bilaterally in the TA muscle.  Mice were 
challenged with 1x10
4 pfu of MCMV i.p. at 2 weeks post-DNA inoculation.  At day 
7 p.i., myocarditis was scored as the number of foci/heart section.  Data is 
expressed as the mean number of foci per heart section from groups of 5 mice per 
time point ± SEM. *, Statistically significant differences between treatment groups 
and Blank vector (p≤0.05) are shown and are representative of two independent 
experiments.  Chapter Four  
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4.2.3 Modulation of the Antibody Isotype Response Following IFN DNA 
Treatment in MCMV Infection 
Considering that the immunological response to MCMV infection involves a strong antibody 
response to MCMV and cardiac myosin antigens, we hypothesised that type I IFN DNA 
inoculation may alter the humoral immune response.  The antibody response to MCMV 
antigen was determined by ELISA with analysis of IgG1 and IgG2a antibody isotypes 
(section 2.2.4.2) (Table 4.1).  Sera were harvested from mice, which had previously been 
treated with IFN DNA and challenged with 1x10
4 pfu MCMV, at day 7 p.i.  The antibody 
response to MCMV antigen was determined to be predominantly of the IgG1 isotype (Table 
4.1).  Interestingly, IFNA6 and IFNB treatment significantly reduced IgG1 titres against 
MCMV antigen (Table 4.1).  Surprisingly, treatment with IFNA9 elicited high titres of IgG2a 
antibodies against MCMV antigen (Table 4.1).  No other type I IFN subtype had any effect 
on altering IgG2a antibody production against MCMV antigen (titres shown were at limit of 
detection, log2 2.0). 
 
Previous studies have demonstrated a strong antibody response to MCMV infection, which is 
directed not only against viral antigens but also towards the auto-antigen, cardiac myosin.  
The titres of IgG1 and IgG2a autoantibody isotypes produced in response to murine cardiac 
myosin were also determined in the mice described above (Table 4.1).  The early 
autoantibody response to cardiac myosin was predominantly IgG1 for all groups.  Notably, 
IFNB treatment significantly reduced IgG1 autoantibody titres against cardiac myosin at day 
7 p.i. (Table 4.1). 
 
Treatment with IFN subtypes which were effective in reducing acute-phase MCMV-induced 
myocarditis,  IFNA6 and IFNB, displayed a reduction in IgG1 antibody titre against MCMV 
antigen with IFNB also reducing IgG1 antibody titres against cardiac myosin.  Interestingly, 
IFNA9 treatment, also effective in the acute phase of MCMV-induced myocarditis increased Chapter Four  
  103
Table 4.1.  Antibody isotype production against MCMV and cardiac myosin during acute 
MCMV infection. 
IFN Subtype
a Anti-MCMV  antibody
b   Anti-Myosin  antibody 
  IgG1 IgG2a    IgG1 IgG2a 
pkCMVint.blank  6.8 ± 0.1  2.0 ± 0.0    4.0 ± 0.0  2.2 ± 0.1 
pkCMVint.IFNα1  6.8 ± 0.2  2.0 ± 0.0    3.8 ± 0.2  2.4 ± 0.2 
pkCMVint. IFNα2  6.2 ± 0.2  2.0 ± 0.0    3.4 ± 0.2  2.2 ± 0.2 
pkCMVint.IFNα4  7.0 ± 0.0  2.0 ± 0.0    3.8 ± 0.2  2.2 ± 0.2 
pkCMVint.IFNα5  6.0 ± 0.0*  2.0 ± 0.0    3.8 ± 0.2  2.4 ± 0.2 
pkCMVint.IFNα6    5.6 ± 0.2**  2.0 ± 0.0    3.0 ± 0.4  2.0 ± 0.0 
pkCMVint.IFNα9  7.0 ± 0.0    7.0 ± 0.0**    4.6 ± 0.2  2.0 ± 0.0 
pkCMVint.IFNβ    5.8 ± 0.2**  2.0 ± 0.0       2.8 ± 0.2**  2.0 ± 0.0 
a DNA (200µg) was injected bilaterally into regenerating TA muscles of adult mice 5 days 
after bupivacaine treatment. Fourteen days following DNA injection, mice were challenged 
with 1 x 10
4 pfu MCMV i.p.  
b Sera harvested at day 7 and antibody isotypes, IgG1 and IgG2a, determined by ELISA 
using either MCMV or cardiac myosin antigen as indicated.  Data presented as mean log2 
serum antibody titre ± SEM. 
Statistically significant differences between IFN  treatment groups and Blank vector are 
shown, * p≤0.05 and ** p≤0.01. 
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IgG2a antibody production.  Potentially, an antibody profile with reduced IgG1 or increased 
IgG2a may skew the immune response towards a predominant Th1 type phenotype. 
 
4.2.4 Type I IFN DNA Treatment Immunomodulates the Cytokine Response to 
MCMV Infection 
The introduction of exogenous cytokine will ultimately skew the immune response to a viral 
pathogen and determine disease outcome with respect to severity of viral infection and 
disease.  Cytokine profiles in response to exogenous type I IFN transgene expression and 
MCMV challenge were determined in vivo (Fig. 4.4).  BALB/c mice were inoculated with 
IFN DNA constructs and two weeks later challenged with 1x10
4 pfu MCMV as described 
previously (section 4.2.1).  At day 7 p.i. serum samples were harvested and cytokine levels 
were determined by ELISA for Th1- (IFNγ, IL-2 and IL-18) and Th2- (IL-4 and IL-10) like 
cytokines and the pro-inflammatory cytokine, IL-6 (Fig. 4.4). 
 
A general increase in the circulating levels of the Th1-like cytokine, IFNγ, was observed 
with effective treatment groups.  A significant increase in IFNγ levels was demonstrated in 
IFNA6-treated mice, while a slight increase was also observed in IFNA1, IFNA5, IFNA9, and 
IFNB-treated mice (Fig. 4.4A).  Conversely, IFNA2 treatment significantly reduced IFNγ 
levels and IFNA4 treatment slightly reduced IFNγ levels (Fig. 4.4A).  Within the limits of 
detection of the ELISA, no change in production of other Th1-like cytokines tested, IL-2 or 
IL-18, was detected in the sera at day 7 p.i. 
 
A reduction in the circulating levels of Th2-like cytokines was observed for some effective 
IFN treatment groups.  Notably, low IL-4 titres were observed following IFNA9 and IFNB 
treatment (Fig. 4.4B).  However, all other IFN treatment groups demonstrated slightly 
elevated IL-4 levels (Fig. 4.4B).  No change in cytokine levels was observed for IL-10, with 
all IFN subtype treatment groups examined at or close to the limits of detection, with the Chapter Four  
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Figure 4.4. Cytokine expression profiles are altered following IFN DNA treatment in 
MCMV-infected mice.  Following bupivacaine treatment, mice were treated with 200µg of 
either Blank or IFN DNA bilaterally in the TA muscle.  Mice were inoculated with 1x10
4 pfu 
MCMV i.p. at 2 weeks post-DNA vaccination. The expression of cytokines (A) IFN-γ, (B) 
IL-4, (C) IL-10 and (D) IL-6 were determined in the sera at day 7 p.i. by ELISA and are 
expressed as the average serum titre (pg/ml) ± SEM (5 mice per group). *, Statistically 
significant differences between treatment groups and Blank vector (p≤0.05) are shown.  
 
C 
0
50
100
150
200
250
Blank IFNA1 IFNA2 IFNA4 IFNA5 IFNA6 IFNA9 IFNB
I
L
-
1
0
 
(
p
g
/
m
L
)
 Chapter Four  
  106
exception of IFNA2 treatment, which elevated IL-10 levels to 162.4 ± 49.98 pg/mL (limit of 
detection = 92 pg/mL) (Fig. 4.4C).  Increased IL-10 production may correlate with the 
suppression of IFNγ production also observed with IFNA2 treated MCMV-infected mice. 
 
IL-6, a pro-inflammatory cytokine, has also been associated with a Th2-like immune 
response.  IL-6 levels were significantly increased following IFNA4 treatment, which 
correlated with an increase in myocarditis (Fig. 4.4D).  Increased IL-6 levels were also 
observed with IFNA1, IFNA5 and IFNA6 treatment (Fig. 4.4D).         
 
4.2.5 Differential Effects of Type I IFN DNA Therapy in Chronic Phase MCMV 
Infection 
Previous studies demonstrate that replicative MCMV reaches peak titre in the salivary glands 
at the onset of chronic myocarditis, day 28 p.i., and that by the late stage of chronic 
myocarditis, day 56 p.i., viral titres decline to undetectable levels (Lenzo  et al., 2001).  The 
salivary glands act as immune privileged sites for viral replication and may be responsible 
for viral dissemination and onset of chronic myocarditis.  We examined the effect of type I 
IFN DNA inoculation on viral replication both early (day 30 p.i.) and late (day 56 p.i.) 
during the chronic phase of disease. 
 
Surprisingly, IFNA2 and IFNB treatment significantly increased MCMV titres in comparison 
to the blank vector control group whilst IFNA4 and IFNA6 treatment had no effect on viral 
replication (Fig. 4.5).  Virus was undetectable in all treatment groups by day 56 p.i. (data not 
shown).  As observed in the acute phase of disease, viral titres in the chronic phase did not 
correlate with myocarditis. 
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Figure 4.5. Effect of IFN DNA treatment on viral titre in the chronic phase of MCMV 
infection. Following bupivacaine treatment, mice were treated with 200µg of either Blank 
or IFN DNA bilaterally in the TA muscle.  BALB/c mice were inoculated with 1x10
4 pfu of 
MCMV i.p. at 2 weeks post-DNA vaccination.  MCMV titre was determined in the salivary 
glands at day 30 p.i. Viral titres are expressed as percentage control titre (average pfu/g 
tissue, 5 mice per time point ± SEM) found for mice in the Blank treatment group.  *, 
Statistically significant differences between treatment groups and Blank vector are shown 
(p<0.05). Chapter Four  
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4.2.6 Type I IFN DNA Therapy Differentially Modulates Chronic Phase 
Myocarditis 
A reduced panel of subtypes (IFNA2, A4, A6, A9 and B) were chosen for further study of the 
chronic phase of MCMV-induced myocarditis, due to their diverse effects on the acute phase 
of myocarditis.  We examined the effects of type I IFN DNA treatment on both early (day 30 
p.i.) and late (day 56 p.i.) stage chronic MCMV-induced myocarditis (Fig. 4.6).  The type I 
IFN subtypes had a differential effect on disease severity, with IFNA6 treatment reducing 
disease at both chronic-phase time-points examined (Fig. 4.6).  Treatment with IFNA9 
reduced early stage chronic phase myocarditis and was not examined at the later stage (Fig. 
4.6A).  Treatment with IFNB had no effect in reducing early stage chronic myocarditis (Fig. 
4.6A) but was effective in reducing late stage chronic myocarditis (Fig. 4.6B).  Neither 
IFNA2 nor IFNA4 treatment had any effect on chronic myocardial disease similar to their 
ineffectiveness during acute phase myocarditis.  Therefore, effective subtypes in the acute 
phase of disease reduced inflammation in the chronic stage of myocarditis, with IFNA6 
proving most efficacious in the treatment of myocarditis. 
 
4.2.7 Type I IFN DNA Treatment Differentially Modulates Antibody Titre in the 
Chronic Stage of MCMV Infection 
Mice treated with IFN subtypes (IFNA2, A4, A6 and B) were studied for chronic phase 
antibody isotype production against MCMV and cardiac myosin antigens (Table 4.2 and 
4.3).  During the onset of chronic disease (day 30 p.i.), there was no change in antibody titres 
to MCMV antigen amongst IFN treatment groups, however later, at day 56 p.i., anti-MCMV 
IgG1 antibody titres increased with IFNA6 and IFNB treatment (Table 4.2).   
 
Interestingly, anti-cardiac myosin IgG1 antibody titres were significantly reduced with 
IFNA6 treatment at the onset of chronic myocarditis (Table 4.3), whilst no change in IgG2a 
titres was observed at this time-point with all treatment groups.  In addition, at the peak of  
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Figure 4.6.  IFNA6, IFNA9 and IFNB DNA inoculation reduce the chronic phase 
of myocarditis following MCMV infection. Following bupivacaine treatment, mice 
were treated with 200µg of either Blank or IFN DNA bilaterally in the TA muscle. 
BALB/c mice were inoculated with 1x10
4 pfu of MCMV i.p. at 2 weeks post-DNA 
vaccination.  Myocarditis was determined as the average number of foci per heart 
section from groups of 5 mice per time point ± SEM at (A) day 30 and (B) day 56 
p.i.  IFNA9 treatment was evaluated only at day 30 p.i.  *, Statistically significant 
differences between treatment groups and Blank vector are shown (p<0.05). 
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Table 4.2.  Antibody isotype production to MCMV at day 30 and day 56p.i. 
  Anti-MCMV antibody 
  Day 30
b Day  56 
IFN subtype 
a  IgG1 IgG2a IgG1 IgG2a 
pkCMVint.blank  6.8 ± 0.2  6.0 ± 0.0  6.2 ± 0.2  10.2 ± 0.4 
pkCMVint.IFNα2  7.0 ± 0.0  6.0 ± 0.0  6.2 ± 0.2  10.2 ± 0.6 
pkCMVint.IFNα4  7.0 ± 0.0  6.0 ± 0.0  6.6 ± 0.2  10.8 ± 0.2 
pkCMVint.IFNα6  6.8 ± 0.2  6.2 ± 0.2  7.2 ± 0.2**  9.8 ± 0.4 
pkCMVint.IFNβ  6.8 ± 0.2  6.2 ± 0.4  7.0 ± 0.0*  10.4 ± 0.2 
aDNA (200µg) was injected bilaterally into regenerating TA muscles of adult mice 5 days 
after bupivacaine treatment. Fourteen days following DNA injection mice were challenged 
with 1 x 10
4 pfu MCMV i.p.  
bSera harvested at day 30 and 56. Data presented as mean log2 serum antibody titre ± SEM 
for IgG1 and IgG2a.  
Statistically significant differences between IFN  treatment groups and Blank vector are 
shown, * p≤0.05 and ** p≤0.01. 
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Table 4.3. Antibody isotype production to cardiac myosin at day 30 and day 56p.i. 
 Anti-cardiac  myosin  antibody 
 Day  30
b Day  56 
IFN subtype 
a  IgG1 IgG2a IgG1 IgG2a 
pkCMVint.blank  5.6 ± 0.2  6.2 ± 0.5  4.4 ± 0.2  7.4 ± 0.5 
pkCMVint.IFNα2  3.3 ± 0.7  6.0 ± 0.6  3.2 ± 0.4*  5.2 ± 0.4* 
pkCMVint.IFNα4  4.4 ± 0.7  7.0 ± 0.3  3.0 ± 0.3*  5.0 ± 0.4* 
pkCMVint.IFNα6  3.4 ± 0.2*  5.4 ± 0.4  3.4 ± 0.2*  4.8 ± 0.2* 
pkCMVint.IFNβ  5.0 ± 0.5  5.8 ± 0.6  2.8 ± 0.2*  4.8 ± 0.4* 
aDNA (200µg) was injected bilaterally into regenerating TA muscles of adult mice 5 days 
after bupivacaine treatment. Fourteen days following DNA injection mice were challenged 
with 1 x 10
4 pfu MCMV i.p.  
bSera harvested at day 30 and 56. Data presented as mean log2 serum antibody titre ± SEM 
for IgG1 and IgG2a.  
Statistically significant differences between IFN  treatment groups and Blank vector are 
shown, * p≤0.05 and ** p≤0.01. 
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chronic myocarditis (day 56 p.i.), all IFN subtypes examined significantly suppressed both 
IgG1 and IgG2a antibody titres to cardiac myosin (Table 4.3).  Finally, the type I IFN 
subtype most effective at reducing chronic myocarditis, IFNA6, induced a lower titre of anti-
cardiac myosin antibodies both during the onset and during the late stage of chronic 
myocarditis.  Therefore, enhanced anti-MCMV IgG1 antibody titres concurrent with reduced 
anti-cardiac myosin IgG1 and IgG2a antibodies appear to correlate with efficacy in chronic 
MCMV treatment. 
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4.3 Discussion 
In this chapter, the efficacy of the type I IFN DNA constructs in the MCMV model of 
infection and disease was demonstrated.  In addition, the choice of IFN subtype was shown 
to be essential for disease outcome.  Further to previous work, this study demonstrates 
systemic reduction of MCMV replication with effective type I IFN subtypes in vivo.  
Treatment of MCMV-infected mice with DNA encoding for IFN subtypes including IFNA1, 
A2, A4, A5, A6, A9 and B showed that low level in vivo expression, was differentially 
effective with antiviral and immunomodulatory functions.   
 
MCMV replication was differentially regulated in target tissues following type I IFN DNA 
treatment.  IFNA6 was most efficacious, reducing viral titres in all target tissues.  Previous 
studies indicate that there may be alternative immune mechanisms at work in different 
tissues.  Evidence suggests that different NK cell responses regulate MCMV replication in 
either the spleen or liver.  Perforin and cytolytic mechanisms operate in the spleen while in 
the liver, NK-cell production of IFNγ and nitric oxide synthase intermediates regulate virus 
replication (Tay and Welsh, 1997).  Thus, systemic IFN may modulate the immunological 
milieu in target tissues thus determining the response to viral replication.  In the salivary 
gland, regarded as a site of systemic dissemination of virus, initiation of efficient 
immunomodulation to viral infection may potentially reduce viral titre thus reducing viral 
dissemination.  Evaluation of the efficacy of type I IFN subtype therapy on viral titre in the 
salivary gland in the chronic phase of MCMV-induced disease revealed no reduction in 
MCMV titre for IFNA6 treatment and significantly increased viral titre with IFNB treatment. 
Interestingly, in the previous chapter , IFNA6 was shown to be a poor antiviral agent in vitro.  
It is hypothesised that IFNA6 may act via an intricate cytokine and immunological milieu, 
which is inaccessible in an in vitro setting.    
 
Type I IFN subtype DNA therapy was differentially effective in MCMV-induced 
myocarditis.  Reduction of acute phase myocarditis following IFNA6 treatment correlated Chapter Four  
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with reduced viral load in all target tissues during the acute phase.  Contrastingly, IFNA9 and 
IFNB induced reduction of acute phase myocarditis was not associated with a reduction in 
viral titres.  Reduction of chronic myocarditis with IFNA6 and IFNB treatment showed no 
correlation with viral titre in fact, IFNB enhanced viral titre during the chronic phase.  The 
finding that infectious virus does not correlate with disease severity is not novel.  Indeed 
viral models of myocarditis, including CB3, also demonstrate that the severity of myocarditis 
does not necessarily correlate with the presence of infectious virus (Rose, 1996).  In fact, 
during both CMV and CB3 infections, infectious virus can be isolated from cardiac tissue 
only during the earliest stage of disease (Lawson et al., 1990; Rose, 1996; Lenzo et al., 
2002).  Furthermore, the fact that patients with myocarditis generally respond favourably to 
immunosuppressive drugs (Lieberman, 1991) supports the hypotheses that i) myocarditis is 
an autoimmune disease and ii) immune responses to viral infection regulate disease 
progression.  These hypotheses are not mutually exclusive, both incorporate the recognition 
of virus as the trigger for disease, although viral titre is not the defining factor.  Interestingly, 
in MCMV-induced myocarditis, levels of infectious virus in the heart are almost 
undetectable beyond day 10 p.i. in both susceptible BALB/c and resistant C57BL/6 mouse 
strains, yet only susceptible mice develop chronic disease (Fairweather et al., 2001).   
Therefore, acute phase cytokine production may immunomodulate the response to viral 
infection via induction by type I IFN expression, thus determining the outcome of 
myocarditis development. 
 
Earlier research shows that BALB/c mice produce antibodies reactive to MCMV antigen and 
the auto-antigen, cardiac myosin, in both the acute and chronic stages of MCMV-induced 
myocarditis (O’Donoghue et al., 1990).  In this chapter, reduced IgG1 or enhanced IgG2a 
antibody titres was demonstrated in IFN treatment groups which effectively reduced acute-
phase myocarditis (IFNA6, IFNA9 and IFNB).  Thus, effective IFN treatment skewed the 
humoral immune response towards a Th1-like response.  In addition, IFNA6 and IFNB Chapter Four  
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effectively reduced antibody titres in the chronic phase of the disease.  Therefore, a 
correlation between antibody production and disease pathogenesis was demonstrated. 
 
The chronic phase of MCMV-induced myocarditis is thought to be autoimmune in nature.  
This is likely due to molecular mimicry whereby antibodies reactive to structural 
determinants of MCMV cross-react with the self-antigen cardiac myosin (Lawson et al., 
1992).  In addition, autoimmune reactivity has been demonstrated in patients with 
myocarditis and 30% of patients with dilated cardiomyopathy (Maisch et al., 1983; Maisch 
et al., 1993a; Maisch et al., 1993b).  In this study, treatment with IFNA6 effectively reduced 
chronic myocarditis and suppressed IgG1 antibody isotype production against cardiac 
myosin.  IFNB reduced anti-cardiac myosin antibody production in the late phase of chronic 
myocarditis, however, IgG1 and IgG2a reduction was similar in all IFN treatment groups at 
this stage.  Therefore, subtypes effective in reducing acute and chronic MCMV-induced 
myocarditis induced a Th1-associated humoral immune response directed against cardiac 
myosin.   
 
Cytokines have been associated with immunomodulation of the pathogenesis of myocarditis 
in other viral models.  Administration of the cytokines IL-1 or IL-2 augmented disease in a 
CB3 model (Huber et al., 1994).  Previously in this model of CMV-induced myocarditis, 
treatment with LPS or the proinflammatory cytokine, TNFα, enhanced disease development 
in normally resistant mice (Lenzo et al., 2001b).  In this chapter, the hypothesis that 
constitutively expressed type I IFNs would alter the production of Th1, Th2 and 
proinflammatory cytokines in the MCMV model was evaluated. 
 
IFNA6 treatment, which effectively reduces both acute and chronic myocarditis, enhanced 
IFNγ levels during acute MCMV infection.  Interestingly, IFNγ, a Th1-associated cytokine 
and the sole member of the type II IFNs, is a well established antiviral cytokine (Baron et al., Chapter Four  
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1991).  Furthermore, IFNγ has proven protective in the development of autoimmune 
myocarditis in a model of experimental autoimmune myocarditis (EAM) (Afanasyeva et al., 
2001; Eriksson et al., 2001) and is thought to be essential for inhibition of autoreactive 
CD4+ T cell expansion (Chu et al., 2000; Eriksson et al., 2001).  Therefore, enhanced IFNγ 
production may contribute to the efficacy of IFNA6 DNA treatment in MCMV infection.  
 
IL-4, a Th2-associated cytokine, is implicated to have a degenerative role in the pathogenesis 
of myocarditis.  Afanasyeva and colleagues (2001) demonstrated that blocking IL-4 with 
anti-IL-4 monoclonal antibody reduced the severity of EAM in A/J mice (Afanasyeva et al., 
2001).  Similarly, in this chapter IFNA9 and IFNB treatment markedly reduced serum IL-4 
levels in acute MCMV infection, and this correlated with reduced acute phase myocarditis.  
IL-10, another Th2-associated cytokine, is implicated in the enhancement of chronic virally-
induced diseases including HIV, Epstein Barr Virus, CB3 and CMV (Schmidtke et al., 
2000).  More specifically, enhanced production of IL-10 by infected human monocytes has 
been associated with disease development in a CB3 model of viral infection and chronic 
myocarditis (Schmidtke et al., 2000).  IL-10 also contributes to trypanosoma cruzi-induced 
myocarditis via inhibition of IL-12 production and depletion of NK cells (Reed et al., 1994; 
Silva  et al., 1998).  This study demonstrates low levels of IL-10 in the acute phase of 
myocarditis with the exception of the IFNA2 treatment group.  The latter correlated with 
significantly reduced IFNγ levels, inefficacy against the acute phase of myocarditis and 
significantly enhanced disease in the chronic phase suggesting a Th2-like response provides 
a poor prognosis for disease outcome. 
 
Elevated levels of the proinflammatory cytokine, IL-6, have been reported in acute 
myocardial infarction (Ikeda et al., 1992).  In our model of MCMV, significantly increased 
IL-6 titres followed IFNA4 treatment and marked increases were induced by IFNA1, A5 and 
A6 treatment.  Interestingly, IL-6 administration at the time of viral infection improves Chapter Four  
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survival rate, decreases cardiac viral titre and reduces myocardial necrosis and lymphocytic 
infiltration during EMCV-induced myocarditis (Kanda et al., 1996).  Conversely, the 
severity of myocarditis is reduced in concurrence with inhibition of IL-6 production (Ito et 
al., 2001).  Over-expression of IL-6 however, promotes myocardial injury and accelerates 
tissue damage in both an EMCV-induced myocarditis model (Tanaka et al., 2001), and a 
CB3 model (Schmidtke et al., 2000).  Alternatively, Kanda and colleagues (1996) 
demonstrated that early IL-6 production may be beneficial early in disease and deleterious at 
later stages (Kanda et al., 1996).  IL-6 levels, however, did not appear to correlate with 
disease in our CMV model.  As with TNFα, timing and dose of cytokine may be relevant to 
the expected outcome of disease (Lenzo et al., 2001b).  Indeed, preliminary studies in this 
laboratory demonstrate that IL-6 peaks earlier in the hearts of resistant C57BL/6 mice than 
susceptible BALB/c mice in response to MCMV infection. 
 
This chapter describes the protective effects of a broad panel of type I IFN subtypes on acute 
and chronic MCMV-induced myocarditis.  The novel finding that the type I IFNs exert 
differential effects on virus replication, myocarditis and subsequent immune responses 
implicates the divergent immunomodulatory capacity of the individual subtypes.  Low level 
endogenous IFN expression following DNA inoculation has proven effective in the treatment 
of MCMV infection and myocarditis.  This type of therapy is capable of maintaining 
responsiveness to IFN over time and has great potential as a form of naked DNA therapy, 
particularly for patients at risk of acquiring CMV infection such as transplant recipients and 
AIDS patients.  
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4.4 Summary 
Data presented in this chapter demonstrates the differential efficacy of seven type I IFNs via 
DNA therapy on MCMV replication, antibody production, cytokine levels and subsequent 
myocarditis in both the acute and chronic stages of MCMV infection in susceptible BALB/c 
mice.  Importantly, IFNA6, IFNA9 and IFNB were efficacious in reduced both acute and 
chronic phase myocarditis.  Reduction of acute disease correlated with skewing toward a 
Th1-like response via IgG1 antibody suppression or enhanced IgG2a antibody production, 
elevation of Th1-like cytokines or suppression of Th2-like cytokines.  No association 
between viral titres and acute myocarditis was determined although IFNA6 inoculation did 
result in reduced viral titres in all target organs.  During the chronic stage of myocarditis, 
efficacious subtypes, IFNA6 and IFNB, did not reduce viral titres, in fact, IFNB treatment 
enhanced viral replication in the salivary gland.  Interestingly, IFNA6 inoculation suppressed 
anti-cardiac myosin IgG1 antibodies during chronic disease.  Induction of a Th1-like 
response was protective against the onset of acute and chronic myocarditis and this was 
irrespective of viral titre.  Alternatively, a reduction in acute stage viral replication appeared 
beneficial since IFNA6 was the most efficacious subtype during both acute and chronic 
myocarditis. 
 
 
 
The findings presented in this chapter are presented in the following publication: 
 
Cull V.S., Bartlett E.J., and James C.M.  (2002)  Type I interferon gene therapy protects 
against cytomegalovirus-induced myocarditis.  Immunology.  106:428-437. 
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5.1 Introduction 
Optimisation of delivery is an important aspect of vaccine development.  Specifically in the 
case of DNA vaccines, factors including route of delivery, timing of DNA administration 
and DNA dosage can influence the immune response following vaccination.  Previous 
reports have demonstrated that the timing of DNA inoculation determines the type of T 
helper response induced.  This was first demonstrated with plasmid encoded GM-CSF 
(pGM-CSF) co-administered with DNA encoding the envelope protein of HIV.  Inoculation 
of pGM-CSF 3 days prior to DNA vaccination induced a predominantly Th2-type immune 
response, simultaneous administration with antigen induced both a Th1 and Th2 type 
response and inoculation 3 days after DNA vaccination stimulated a predominantly Th1 
response (Kusakabe, 2000).  A similar effect has since been observed with plasmid 
administered IL-12 in models of HIV and leishmania vaccination (Gherardi et al., 2000; 
Noorhammadi et al., 2001).  This chapter investigates the timing of cytokine expression and 
the resultant immune response.  
 
Many studies have found that effective DNA vaccination occurs in a dose-dependent 
manner, generally with a dose range of 25-200µg plasmid DNA (Gherardi et al., 2000; 
Noorhammadi et al., 2001; Prud’homme et al., 2001; Min et al., 2002).  Previously, in our 
laboratory, in vivo expression of IFNA genes following i.m. inoculation of 200µg naked 
DNA has been proven effective against localised MCMV infection (Lawson et al., 1997; 
Yeow  et al., 1998).  Other groups using type I IFN-expressing plasmids have reported 
effective inoculation with 100µg i.m. (Horton et al., 1999) or 100µg/ eye (Noisakran et al., 
1999) in cancer and HSV infection respectively.  In addition, investigators have found a 
dose-response effect of pCMV-IFNα1 plasmid on HSV-1 replication in the range 25-100µg/ 
eye (Noisakran et al., 1999).  Optimisation of dose using the type I IFN DNA constructs 
prepared in this thesis was therefore investigated in MCMV infection.   
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Treatment with bupivacaine, an anaesthetic which destroys myofibres and induces 
myogenesis, is reported to enhance protein expression following DNA inoculation since 
regenerating muscle is thought to encourage DNA uptake  (Danko and Wolff, 1994).   
Reports of the effect of bupivacaine pre-treatment on transgene expression demonstrate 
conflicting evidence with some reports suggesting no effect and some observing up to 40-
fold increases in gene expression (Lawson et al., 1997; Danko and Wolff, 1994).  The effect 
of bupivacaine treatment on IFN transgene efficacy in systemic MCMV infection will 
therefore be evaluated. 
 
DNA vaccination to date has mostly been used prophylactically with cytokine or viral DNA 
administration prior to encountering the pathogen.  Therapeutic vaccination which involves 
transgene inoculation after the acute phase of viral infection for protection from chronic 
disease has not been very successful.  However, IFN cytokine therapy is currently used 
during the chronic autoimmune stage of several diseases including HCV, HIV and multiple 
sclerosis (Baron et al., 1991; Brod et al., 1996).  Therefore, there may be potential for a 
successful therapeutic vaccine using type I IFN DNA subtypes in the MCMV model of 
chronic phase myocarditis.   
 
The chronic stage of MCMV-induced myocarditis is widely thought to be autoimmune in 
nature (Lawson, 2000).  T cells play a major role in disease, in fact, myocarditis has been 
demonstrated to be T-cell dependent (Lawson et al., 1989; Fairweather et al., 2001).  Most 
notably, the finding that athymic nu/nu mice are resistant to myocarditis following MCMV 
infection is indicative of the central role T cells play in mediating myocarditis (Lawson et 
al., 1989).  Furthermore, studies in the CB3 myocarditis model have demonstrated disease 
transfer following inoculation of autoimmune T cells from virally infected mice (Guthrie et 
al., 1984).  The potential of type I IFN DNA vaccination in reducing T-cell mediated disease 
will be investigated. 
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In this chapter, the optimal vaccination schedule will be determined for type I IFN subtype 
DNA constructs in the MCMV model of infection and disease.  Timing of DNA inoculation, 
DNA dosage and bupivacaine treatment are factors which will be evaluated in this study.  
Finally, the potential of IFN DNA vaccines as intervention therapy and the effect of type I 
IFN subtype transgene inoculation on T-cell mediated transfer of disease will be determined 
using optimal vaccination protocols. 
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5.2 Results 
5.2.1  Timing of DNA Administration Determines Antiviral Efficacy 
The importance of timing of DNA administration on the antiviral efficacy of IFN 
immunisation following MCMV challenge was investigated.  Mice were treated with IFN 
transgenes at day 14 and day 2 prior to viral challenge and 2 days following viral challenge 
with 1x10
4 pfu MCMV. The antiviral effect of IFNA6 and IFNB on early MCMV replication 
in comparison to treatment with the Blank vector was determined by quantitation of virus 
titres in the spleen and liver at day 3 p.i. and the salivary gland at day 7 p.i. (Fig. 5.1) by 
plaque assay. 
 
Consistent with previous findings, IFNA6 inoculation 14 days prior to MCMV infection 
significantly reduced viral titre in the spleen (Fig. 5.1A).  In this study, IFNB treatment also 
significantly reduced viral titre in the spleen when administered 14 days prior to MCMV 
challenge (Fig. 5.1A).  IFN treatment had no significant effect on viral titre in any other 
tissue (Fig. 5.1B and C).  Interestingly, IFN transgene inoculation 2 days prior and 2 days 
following viral challenge did not affect virus replication. 
 
5.2.2  Timing of IFN Transgene Therapy Affects MCMV-Myocarditis 
The timing of DNA administration was evaluated in the development of acute and chronic 
myocarditis.  Mice were treated as outlined in the previous section and hearts were taken at 
days 7 and 30 p.i., sectioned and H&E stained before examination for foci of inflammatory 
cells indicative of myocarditis. 
 
Consistent with previous findings, IFNA6 treatment at 14 days prior to MCMV infection 
significantly reduced acute myocarditis in comparison to treatment with the Blank vector 
(Fig. 5.2).  Treatment with IFN at other time-points did not reduce acute-phase disease, 
however, it is interesting to note that IFNB treatment 2 days prior to viral infection  Chapter Five 
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Figure 5.1. Variations in timing of IFNA6 and IFNB DNA administration affect 
MCMV replication in vivo. Following bupivacaine treatment, BALB/c mice were 
treated with either Blank, IFNA6 or IFNB vector DNA at various time-points: 14 
days prior (-14 days), 2 days prior (-2 days) and 2 days following (+2 days) viral 
challenge with 1x10
4 pfu of MCMV i.p. Viral titres were determined by plaque 
assay in (A) spleen and (B) liver at day 3 p.i. and (C) the salivary glands at day 7 
p.i. Results are expressed as mean pfu/g ± SEM (n=5). *Statistical significance 
(p≤0.05) compared with Blank treatment groups. Chapter Five 
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Figure 5.2. Timing of IFNA6 and IFNB DNA treatment affects MCMV-induced 
acute myocarditis. Following bupivacaine treatment, BALB/c mice were inoculated 
with either Blank, IFNA6 or IFNB vector DNA at various time-points: 14 days prior 
(-14 days), 2 days prior (-2 days) and 2 days following (+2 days) viral challenge with 
1x10
4  pfu of MCMV i.p.  Acute myocarditis was evaluated at day 7 p.i. and is
expressed as the average number of foci/heart section ± SEM (n=5). *Statistical 
significance (p≤0.05) compared with the Blank treatment group. Chapter Five 
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significantly enhanced disease (Fig. 5.2).  Similarly, IFNA6 and IFNB administered 14 days 
prior to MCMV infection significantly reduce chronic phase myocarditis as demonstrated 
previously (Fig. 5.3).  Interestingly, treatment with IFNA6 and IFNB just 2 days before viral 
challenge also results in suppression of chronic stage myocarditis (Fig. 5.3).  Treatment 2 
days after viral infection had no effect on myocarditis. 
 
5.2.3  Timing of Treatment Affects Autoantibody Production 
The immunological response to MCMV infection involves a humoral antibody response 
directed against both MCMV structural antigens and autoantibodies reactive against cardiac 
myosin.  The effect of timing of IFN DNA administration on antibody responses against 
these antigens was determined.  Mice were treated as described in section 5.2.1 and sera 
were harvested at days 7 and 30 p.i. for determination of IgG1 and IgG2a antibody titres by 
ELISA (Table 5.1 and 5.2). 
 
Timing of DNA treatment had little effect on antibody titres to MCMV antigen in either the 
acute or chronic phases (Table 5.1).  Significant increases in IgG1 antibody levels were 
observed following IFNA6 inoculation 14 days prior to viral infection and Blank vector 
treatment 2 days post viral infection, in comparison to mice treated with Blank vector 14 
days prior to challenge at day 7 p.i.   In addition, a significant reduction in IgG1 anti-MCMV 
titres was noted at day 30 p.i. for Blank treatment 2 days before virus infection compared to 
Blank vector treatment 14 days prior to viral challenge.  Anti-MCMV IgG2a titres were low 
for all treatment groups at both day 7 and day 30 p.i.  This does not correlate with results 
presented in chapter 4 which demonstrated reduced IgG1 titres against MCMV for IFNA6 
and IFNB at day 7 p.i. 
 
Autoantibody titres were affected by variations in the timing of DNA inoculation (Table 
5.2).  At day 7 p.i., IFN treatment had no effect on IgG1 and IgG2a anti-cardiac myosin 
antibody levels.  However, at day 30 p.i., IFNA6 and IFNB treatment 14 days prior to  Chapter Five 
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Figure 5.3. Timing of IFNA6 and IFNB DNA treatment affects MCMV-induced 
chronic myocarditis. Following bupivacaine treatment, BALB/c mice were treated 
with either Blank, IFNA6 or IFNB vector DNA at various time-points: 14 days prior 
(-14 days), 2 days prior (-2 days) and 2 days following (+2 days) viral challenge 
with 1x10
4 pfu of MCMV i.p.  Chronic myocarditis was evaluated at day 30 p.i. and
is expressed as the average number of foci/heart section ± SEM (n=5). *Statistical 
significance (p≤0.05) compared with Blank treatment groups. Chapter Five 
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Table 5.1.  Variations in timing of IFN  transgene treatment affects  antibody isotype 
production against MCMV antigen during myocarditis. 
    Anti-MCMV Antibody Titres
c 
    Day 7  Day 30 
DNA
a 
Time of 
Treatment
b  
IgG1 IgG2a IgG1 IgG2a 
Blank  - 14 days  5.50 ± 0.29   2.00 ± 0.00  5.40 ± 0.40  3.00 ± 0.00 
  - 2 days  5.80 ± 0.20  2.00 ± 0.00  3.40 ± 0.40
* 3.00  ± 0.00 
  + 2 days  6.40± 0.24
*   2.00 ± 0.00  4.60 ± 0.98   3.00 ± 0.00 
IFNΑ6  - 14 days  6.40 ± 0.24
* 2.00  ± 0.00  4.60 ± 0.68  3.00 ± 0.00 
  - 2 days  6.00± 0.32  2.00 ± 0.00  3.00 ± 0.00  3.00 ± 0.00 
  + 2 days  7.00 ± 0.00  2.00 ± 0.00  3.00 ± 0.00  3.00 ± 0.00 
IFNB  - 14 days  5.80 ± 0.20  2.00 ± 0.00  4.20 ± 0.73  3.00 ± 0.00 
  - 2 days  5.75 ± 0.25  2.00 ± 0.00  4.20 ± 0.73  3.00 ± 0.00 
  + 2 days  6.40 ± 0.40  2.00 ± 0.00  3.75 ± 0.75  3.00 ± 0.00 
aBlank vector, IFNA6 and IFNB DNA (200µg) was inoculated into regenerating TA muscles 
of adult BALB/c mice. 
bMice were inoculated with DNA at 14 days (- 14 days) and 2 days (-2 days) prior and 2 
days (+2 days) following viral challenge with 1x10
4pfu MCMV i.p.  
cSera was harvested at day 7 and day 30 p.i. and IgG1 and IgG2a antibody titres to MCMV 
antigen were determined by ELISA.  Data presented as mean log2 serum antibody titre ± 
SEM for IgG1 and IgG2a. *, Statistical significance (p≤0.05) compared with Blank treatment 
groups. 
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Table 5.2. Variations in timing of IFN  transgene treatment affects  antibody isotype 
production against cardiac myosin during myocarditis. 
   Anti-Myosin  antibody  Titres
c 
    Day 7  Day 30 
DNA
a 
Time of 
Treatment
b 
IgG1 IgG2a IgG1 IgG2a 
Blank  - 14 days  4.67 ± 0.33  2.00 ± 0.00  6.00 ± 0.47  6.60 ± 0.24 
  - 2 days  3.80 ± 0.20  3.60 ± 0.98  4.60 ± 0.51  4.60 ± 0.51
* 
  + 2 days  4.40 ± 0.60  4.80 ± 1.16  5.00 ± 0.63  4.20 ± 0.58
* 
IFNA6  - 14 days  5.00 ± 0.32  3.80 ± 1.11  3.80 ± 0.37
* 2.80  ± 0.37
* 
  - 2 days  4.80 ± 0.49  3.60 ± 0.98  4.20 ± 0.37  3.80 ± 0.37 
  + 2 days  4.00  0.32  2.50 ± 0.29  4.20 ± 0.20  4.00 ± 0.32 
IFNB  - 14 days  5.00 ± 0.63  5.00 ± 1.22  3.40 ± 0.24
* 3.00  ± 0.48
* 
  - 2 days  4.50 ± 0.29  2.50 ± 0.29  4.20 ± 0.20  4.40 ± 0.24 
  + 2 days  4.20 ± 0.20  2.60 ± 0.60  4.80 ± 0.37  5.20 ± 0.37 
aBlank vector, IFNA6 and IFNB DNA (200µg) was injected into regenerating TA muscles of 
adult BALB/c mice. 
bMice were inoculated with DNA at 14 days (- 14 days) and 2 days (-2 days) prior and 2 
days (+2 days) following viral challenge with 1x10
4 pfu MCMV i.p.  
cSera was harvested at day 7 and day 30 p.i. and IgG1 and IgG2a antibody titres to cardiac 
myosin antigen were determined by ELISA.  Data presented as mean log2 serum antibody 
titre ± SEM for IgG1 and IgG2a. *, Statistical significance (p≤0.05) compared with Blank 
treatment groups. 
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MCMV challenge significantly reduced autoantibody titres (both IgG1 and IgG2a) compared 
with  Blank vector-treated mice.  As noted previously, antibody isotype production was 
slightly biased towards an IgG1 response.  IFN treatment 2 days prior or 2 days following 
virus had no significant effect on autoantibody titres.  Therefore, the timing of IFN transgene 
treatment determined the autoantibody response in the chronic phase of MCMV infection. 
 
5.2.4  Low Doses of IFN DNA are Ineffective In Vivo 
Previously, we have demonstrated therapeutic efficacy using 200µg  IFN transgenes 
inoculated i.m.  Here, IFN transgene inoculation using lower doses of DNA was evaluated 
for therapeutic efficacy.  Mice were treated with either 50µg or 100µg Blank, IFNA6 or 
IFNB DNA and challenged with 1x10
4 pfu MCMV. The effect of low doses of IFNA6 and 
IFNB on early MCMV replication, acute-phase myocarditis and antibody responses to 
MCMV antigen were evaluated in comparison to the Blank vector. 
 
Acute-phase viral titres were determined by plaque assay of spleen and liver homogenates at 
day 3 p.i. and salivary gland homogenates at day 7 p.i. (Fig. 5.4).  The antiviral efficacy 
previously demonstrated by these IFN subtypes at 200µg per mouse was suppressed at these 
lower doses of 50µg or 100µg.  Indeed, IFNA6 and IFNB inoculation had no effect on viral 
titres in any tissue examined (Fig. 5.4). 
 
The effect of inoculating lower dose IFN DNA was next evaluated during acute-phase 
MCMV-induced myocarditis.  Interestingly, disease was significantly reduced with 
inoculation of 50µg/ mouse of either IFNA6 or IFNB DNA in comparison to Blank vector-
treated mice.  Treatment with 100µg IFN however, had no effect on acute-phase MCMV-
induced myocarditis (Fig. 5.5).  Similar to the findings presented in chapter 4, viral titre did 
not reflect disease. 
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Figure 5.4.  The effect of varying doses of IFN  DNA on MCMV infection. 
Bupivacaine treated BALB/c mice were inoculated with varying doses of either 
Blank, IFNA6 or IFNB vector DNA (50µg and 100µg) at 14 days prior to viral 
challenge with 1x10
4 pfu of MCMV i.p. Viral titres were determined by plaque 
assay in (A) spleen and (B) liver at day 3 p.i. and (C) salivary glands at day 7 p.i. 
Results are expressed as mean pfu/g ± SEM (n=5).  *, Statistical significance 
(p≤0.05) compared with Blank treatment groups. 
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Figure 5.5.  The effect of varying doses of IFN  DNA on MCMV induced 
myocarditis.  Bupivacaine treated BALB/c mice were treated with varying doses 
of either Blank, IFNA6 or IFNB vector DNA (50µg and 100µg) at 14 days prior 
to viral challenge with 1x10
4 pfu of MCMV i.p.  Myocarditis was evaluated at 
day 7 p.i. and is expressed as number of foci per heart section ± SEM (n=5). *, 
Statistical significance (p≤0.05) compared with Blank treatment groups. 
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Antibody production directed against MCMV antigen was next determined by ELISA in 
mice treated with low dose IFN DNA.  No significant effect on antibody levels (day 7p.i.) 
was observed following treatment with 50µg or 100µg  IFNA6 (Table 5.3).  However, 
inoculation of 100µg IFNB resulted in significantly reduced levels of both IgG1 and IgG2a 
antibody against MCMV antigen, whereas 50µg  IFNB had no effect on antibody levels 
(Table 5.3).  Notably, anti-MCMV antibody titres did not correlate with the level of 
myocarditis or reduction in MCMV titre in target tissues. 
 
In brief, reducing the dose of IFN DNA to 50µg/ mouse or 100µg/ mouse reduced the 
therapeutic efficacy of IFNA6 and IFNB observed with the higher dose of 200µg/ mouse in 
the treatment of infection and disease. 
 
5.2.5  IFNA6 Inoculation Without Bupivacaine Pre-treatment Is Ineffective in 
MCMV Infection and Disease 
Vaccination with IFNA6 was shown in chapter 4 to have potent antiviral effects and to 
reduce disease pathogenesis in the MCMV model.  These animals were injected 5 days prior 
to DNA treatment with 20µL 0.5% bupivacaine.  Here, the necessity of bupivacaine 
treatment prior to IFNA6 administration is evaluated.  Mice were either untreated or treated 
with bupivacaine 5 days prior to IFNA6 DNA inoculation and subsequent challenge with 
1x10
4 pfu MCMV.  The effect of bupivacaine treatment on antiviral response and 
myocarditis was evaluated at day 7 p.i. 
 
Treatment with the IFNA6 transgene demonstrated reduced MCMV titres in the spleen and 
liver at day 3 p.i. and the salivary gland at day 7 p.i. (Fig. 5.6).  However, without the 
administration of bupivacaine, a significant reduction in MCMV was observed only in the 
liver at day 3 p.i. (Fig. 5.6B) with no effect observed in other tissues.  Similarly, IFNA6 
inoculation significantly reduced acute-phase myocarditis (Fig. 5.7).  However, IFNA6  Chapter Five 
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Table 5.3.  Varying the dosage of IFN transgene treatment affects antibody isotype 
production to MCMV antigen. 
Anti-MCMV Antibody Titres
b 
DNA Constructs  Dose
a IgG1 IgG2a 
Blank 50µg 6.0  ± 0.0  6.0 ± 0.0 
  100µg 5.4  ± 0.4  5.6 ± 0.98 
IFNA6 50µg 4.8  ± 0.73  4.4 ± 0.98 
  100µg 4.6  ± 0.51  3.6 ± 0.98 
IFNB 50µg 5.0  ± 0.0  6.2 ± 0.2 
  100µg 3.4  ± 0.6
* 2.0  ± 0.0
* 
aBlank vector, IFNA6 and IFNB DNA was inoculated into regenerating TA muscles of adult 
BALB/c mice at varying doses (50µg and 100µg). 
b14 days following DNA vaccination mice were challenged with 1x10
4pfu MCMV i.p. and 
sera harvested at day 7.  Data presented as mean log2 serum antibody titre ± SEM for IgG1 
and IgG2a. 
*, Significance in comparison to corresponding Blank treatment group. 
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Figure 5.6.  IFN DNA inoculation without bupivacaine treatment has a limited 
effect on MCMV infection.  BALB/c mice were either not treated (No Bp) or 
treated (Bp) with bupivacaine 5 days prior to DNA inoculation with 200µg of either 
Blank or IFNA6 vector DNA and subsequently challenged with 1x10
4  pfu of 
MCMV i.p 14 days later. Viral titres were determined by plaque assay in (A) spleen 
and (B) liver at day 3 p.i. and (C) salivary glands at day 7 p.i. Results are expressed 
as % Blank treatment group ± SEM (n=5).  *, Statistical significance (p≤0.05) 
compared with Blank treatment groups. Chapter Five 
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Figure 5.7.  IFN DNA inoculation without bupivacaine treatment does not 
significantly reduce acute-phase MCMV-induced myocarditis.  BALB/c mice 
were either not treated (No Bp) or treated (Bp) with bupivacaine 5 days prior to 
DNA inoculation with 200µg of either Blank or IFNA6 and subsequent challenge 
with 1x10
4 pfu of MCMV i.p 14 days later.  Myocarditis was evaluated at day 7 
p.i. and is expressed as number of foci per heart section ± SEM (n=5). *, 
Statistical significance (p≤0.05) compared Blank treatment groups. 
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administration without bupivacaine had no effect on disease severity in the myocardium 
(Fig. 5.7).  Therefore, maximal therapeutic efficacy for MCMV infection is achieved when 
mice are pre-treated with bupivacaine. 
 
5.2.6 Post-viral IFNB Inoculation Reduces Chronic-Phase Viral Replication 
In order to establish whether IFN transgene inoculation would be efficacious when 
administered after acute-phase MCMV infection, mice were inoculated with Blank, IFNA6 
or IFNB DNA 14 days following challenge with 1x10
4 pfu MCMV.  Viral titres in the 
salivary gland were determined at day 30 p.i. by plaque assay.  Interestingly, IFNB therapy 
significantly reduced salivary gland MCMV replication during the chronic phase of disease 
in comparison to Blank DNA treated mice (Fig. 5.8).  IFNA6 inoculation had no effect on 
virus titres (Fig. 5.8). 
 
5.2.7  Post-viral IFNA6 Administration Protects Against Chronic Myocarditis 
Mice treated as described in the previous section were examined for early (day 30 p.i.) and 
late phase (day 56 p.i.) chronic myocarditis (Fig. 5.9).  No difference in myocarditis at day 
30 p.i. was observed with IFN treatment (Fig. 5.9A).  However, late-stage chronic 
myocarditis (day 56p.i.) was significantly reduced in mice inoculated with IFNA6 in 
comparison to Blank vector treated mice (Fig. 5.9B).  No difference in myocarditis at day 56 
p.i. was observed with IFNB transgene treatment (Fig. 5.9B).  Interestingly, histopathology 
of MCMV infected heart sections at day 56 p.i. demonstrates distinct patterns of cellular 
infiltration following DNA inoculation (Fig. 5.10).  Blank vector treatment groups display 
large foci with high numbers of infiltrating cells in the myocardium, while IFNA6 treated 
mice show diffuse cardiac infiltration and IFNB inoculation results in dense foci of 
infiltrating cells.  Therefore, post-IFN treatment reduced the total number and affected the 
form of foci within the myocardium in the chronic stage of disease. 
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Figure 5.8.  Post-viral treatment with IFNB DNA reduces chronic-phase salivary 
gland MCMV titres.  BALB/c mice were inoculated with 1x10
4 pfu of MCMV i.p. 
and 9 days later  treated bilaterally with bupivacaine in the TA muscle followed 5 
days later by inoculation with 200µg Blank, IFNA6 or IFNB vector DNA at day 14 
p.i.  Viral titre was determined by plaque assay of salivary gland homogenates at day 
30 p.i. and is expressed as the average number of foci/heart section ± SEM (n=5). *, 
Statistical significance (p≤0.05) compared Blank treatment groups. Chapter Five 
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Figure 5.9.  Post-viral treatment with IFNA6 DNA protects against chronic 
phase myocarditis.  BALB/c mice were inoculated with 1x10
4 pfu of MCMV 
i.p. and 9 days later  treated bilaterally with bupivacaine in the TA muscle 
followed 5 days later by inoculation with 200µg Blank, IFNA6 or IFNB vector 
DNA at day 14 p.i. Myocarditis was evaluated at (A) day 30 and (B) day 56 p.i. 
and is expressed as the average number of foci/heart section ± SEM (n=5). *, 
Statistical significance (p≤0.05) compared Blank treatment groups. 
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Figure 5.10.  Histopathology demonstrates post-viral IFNA6 DNA treatment reduces 
the development of chronic myocarditic foci.  BALB/c mice were inoculated with 
1x10
4 pfu of MCMV i.p. and 9 days later  treated bilaterally with bupivacaine in the 
TA muscle followed 5 days later by treatment with 200µg Blank, IFNA6 or IFNB
vector DNA at day 14 p.i.  H&E stained heart sections from MCMV-infected mice at 
day 56 p.i. show reduced numbers of infiltrating cells throughout the myocardium with 
IFN treatment and distinctive foci for treatment groups with IFNB treatment resulting 
in dense foci and IFNA6 treatment resulting in diffuse foci (magnification, x 160). 
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5.2.8  Post-Viral IFN Treatment Does Not Affect Cytokine Levels 
Serum cytokine levels of IFNγ, IL-4 and IL-6 were next examined.  Mice were treated with 
DNA two weeks post MCMV infection as outlined in section 5.2.6.  IFN transgene treatment 
has previously been shown to skew cytokine profiles towards a Th1-type response following 
MCMV infection (chapter 4).  However, when administered following the establishment of 
acute phase infection, IFNA6 and IFNB had no significant effect on cytokine levels in 
comparison with Blank vector treated mice (Fig. 5.11).  Possibly, in the absence of antigenic 
infectious virus in the heart during the chronic phase, the second signal for an immune 
response is absent and therefore cytokine production is altered. 
 
5.2.9  Lymphocyte Mediated Myocarditis 
Previous studies have demonstrated a critical role for T cells in the development of virus-
induced myocarditis (Fairweather, 2001).  We therefore examined the development of 
myocarditis mediated by splenocyte cells from IFN DNA treated MCMV-infected mice 
transferred to uninfected BALB/c mice.  BALB/c mice were treated with bupivacaine and 
inoculated with either Blank, IFNA6 or IFNB DNA (200µg/ mouse) (section 2.2.1.2).  Two 
weeks later, mice were challenged with 1x10
4 pfu MCMV (section 2.2.1.3) and spleens 
harvested at day 5 p.i.  Unfractionated splenocyte populations were prepared (section 
2.2.4.3) and injected i.v. into uninfected BALB/c mice (9x10
6 cells/ mouse).  Hearts were 
removed for histological examination of myocarditis (section 2.2.4.2) at day 7 post-transfer. 
Importantly, myocarditis was transferred to uninfected recipient mice following splenic 
adoptive transfer from MCMV-infected mice (Fig. 5.12).  Interestingly, mice inoculated with 
splenocytes from IFNB-treated, MCMV-infected mice demonstrated significantly reduced 
disease at day 7 following transfer in comparison to Blank treatment.  No difference in 
disease severity was observed with IFNA6 treatment at this time-point (Fig. 5.12).  This data 
implicates that IFNB suppresses splenocyte activity for development of myocarditis, 
potentially IFNA6 may act via another mechanism such as the innate immune system. Chapter Five 
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Figure 5.11.  Treatment with IFN DNA following MCMV challenge does not alter the 
cytokine profile during chronic phase myocarditis. BALB/c mice were inoculated with 
1x10
4 pfu of MCMV i.p. and 9 days later  treated bilaterally with bupivacaine in the 
TA muscle followed by treatment with 200µg Blank, IFNA6 or IFNB vector DNA at 
day 14 p.i. Cytokine levels, in day 30 and day 56 sera, were determined by ELISA for 
(A) IFNγ, (B) IL-4 and (C) IL-6. Cytokine levels are presented as mean pg/ml ± SEM 
(n=5).  Chapter Five 
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Figure 5.12.  IFN DNA treatment affects T cell regulation of myocarditis. Following 
bupivacaine treatment, BALB/c mice were inoculated with either Blank, IFNA6 or IFNB 
bilaterally in the TA muscles (200µg/mouse). Fourteen days later BALB/c mice were 
inoculated with 1x10
4 pfu MCMV i.p. and on day 5 p.i., spleens were harvested and a 
single cell suspension of splenocytes prepared and adoptively transferred to uninfected 
BALB/c mice by the i.v. route (9x10
6 lymphocytes/mouse). Myocarditis, expressed as the 
average number of inflammatory foci per heart section, was examined in recipient hearts 
taken 7 days post-splenocyte transfer.  *, Statistically significant differences to Blank 
treatment group are shown (p≤0.05, n=5). 
 
*
0
1
2
3
4
5
6
7
8
9
Blank IFNA6 IFNB
M
y
o
c
a
r
d
i
t
i
s
 
(
n
o
.
 
f
o
c
i
/
 
h
e
a
r
t
 
s
e
c
t
i
o
n
)
 Chapter Five 
  143
5.3  Discussion 
In this chapter, a detailed study comprising optimisation of the inoculation protocol for type I 
IFN subtype DNA constructs is described.  The timing of DNA administration was 
investigated and it was demonstrated that optimal therapeutic efficacy is achieved when mice 
are treated with IFN DNA 14 days prior to viral challenge.  Administration of IFNA6 and 
IFNB at this time resulted in reduced viral titres in the spleen, and reduced acute and chronic 
myocarditis.  Treatment with IFNA6 and IFNB 2 days before and 2 days after viral infection 
proved ineffective during the acute phase of viral infection and disease.  Interestingly, IFN 
DNA treatment 2 days prior to viral infection did reduce chronic myocarditis.  The limited 
efficacy of IFN  treatment at these time-points, however, is largely expected given that 
systemic IFN expression peaks at day 28 following IFN treatment and is not significantly 
increased in comparison to Blank groups until day 14 (chapter 3).  In addition, endogenous 
IFN, produced as part of the immune response to viral invasion, peaks 2 days following 
LCMV infection and may therefore mask IFN transgene expression at this time (Biron, 
1998).  We postulate that type I IFN administrated at later time-points is insufficiently 
expressed prior to endogenous cytokine production in response to virus.  Surprisingly, IFNB 
treatment 2 days prior to virus contributed to a pathogenic immune response.  Indeed, 
another report has demonstrated a distinct role for IFNβ as an ‘immediate-early response 
gene’ following viral infection.  This group suggests that IFNβ must be synthesised for 
induction of a delayed IFN gene set (including α2, α5, α6 and α8) (Marié et al., 1998).  
Potentiation of IFNα cytokines by IFNβ may exacerbate the immune response and lead to 
detrimental responses in this model. 
 
The type I IFN subtype DNA constructs were evaluated for optimal dose determination of 
therapeutic efficacy in MCMV.  Previous studies in our laboratory using plasmid 
administered IFNα have effectively used inoculations of 200µg DNA (Lawson et al., 1997; 
Yeow et al., 1998).  Data presented in this chapter demonstrates that 50µg and 100µg type I Chapter Five 
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IFN DNA inoculated 14 days prior to virus were ineffective in reducing viral replication.  
Interestingly, 50µg DNA effectively reduces acute myocarditis while 100µg IFN has no 
effect.  No effect on anti-MCMV antibody titres is demonstrated with the exception of 
100µg  IFNB which reduced both IgG1 and IgG2a antibody isotypes.  Therefore the 
therapeutic efficacy achieved with 200µg IFN in the MCMV model which led to a reduction 
in viral replication, reduced acute and chronic myocarditis and reduced IgG1 antibody titres 
was the more optimal DNA dosage.  This indicates that effective type I IFN DNA 
inoculation is dose-dependent and timing dependent which is consistent with findings in 
other models of DNA vaccination (Noisakran et al., 1999; Kusakabe et al., 2000). 
 
It is widely believed that inoculation of DNA constructs into regenerating muscle contributes 
to enhanced uptake and expression of transgenes (Danko and Wolff, 1994; Vitadello et al., 
1994).  Bupivacaine treatment is an efficient inducer of myogenesis prior to plasmid 
inoculation (Danko and Wolff, 1994), however, evidence for and against this treatment is 
conflicting (Lawson  et al., 1997).  In this study, plasmid administration without bupivacaine 
treatment was generally ineffective for all aspects evaluated with the exception that IFNA6 
reduced viral titres in the liver.  Despite this, viral titres in the liver were 9.4-fold greater in 
the group not treated with bupivacaine compared to the bupivacaine treated group.   
Similarly, viral titres following IFNA6 inoculation without bupivacaine treatment increased 
7.8-fold and 2.8-fold in the spleen and salivary gland respectively compared to the 
bupivacaine treated group.  Furthermore, myocarditis increased 3.5-fold without bupivacaine 
treatment compared to with bupivacaine treatment following IFNA6 treatment.  Therefore, 
bupivacaine treatment was proven necessary in DNA therapy in this MCMV model. 
 
In this chapter we demonstrate the potential of IFN DNA treatment as an intervention 
therapy in the development of autoimmune myocarditis.  Strikingly, IFNA6 administration 
after the acute phase of viral infection and disease significantly suppressed the late chronic Chapter Five 
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phase of myocarditis.  Interestingly, IFNB treatment reduced salivary gland viral titres at day 
30 p.i. but had no effect on myocarditis, confirming our previous finding that viral titre does 
not correlate with the chronic autoimmune stage of disease.  There was no significant change 
in cytokine levels with either IFNA6 or IFNB treatment.  This may indicate either that 
exogenously expressed IFN acts too late to drive a protective cytokine response or that IFN 
administered at this stage in infection acts through an alternate mechanism, possibly 
enhancing the memory T cell response.  In addition, it may be that there is insufficient 
antigen in the heart for exogenous IFN to stimulate a cytokine response.  This is in 
agreement with the Danger model which states that the presence of pathogenic antigen is 
required for an immune response to be initiated (Anderson and Matzinger, 2000).  IFN 
therapy has previously been proven effective in treating numerous chronic diseases such as 
HCV, HIV and Multiple Sclerosis (Baron et al., 1991; Brod et al., 1996).  However, to our 
knowledge, this is the first report that cytokine DNA therapy can be administered for 
successful treatment of a chronic phase of an autoimmune disease. 
 
Type I IFN has an important role in the generation and maintenance of specific memory T 
cells.  Previous studies have established the role of both CD4+ and CD8+ T cells in 
mediating the pathogenesis of myocarditis (Lawson et al., 1989; Fairweather et al., 2001).  
The involvement of autoimmune T cells in the pathogenesis of CB3-induced myocarditis 
was first inferred from the observation that T-cell depleted mice have less severe disease 
than normal mice (Woodruff and Woodruff, 1974; Fairweather et al., 2001).  More recently 
CD8+ T cells have been shown to comprise the majority of infiltrating cells in the 
myocardium during both acute and chronic phase myocarditis (Lenzo et al., 2002).  In 
addition, CD4+ T cells were also present in the acute phase of the disease (Lenzo et al., 
2002). Here, adoptive transfer of whole splenocyte populations from virus-infected DNA-
treated mice led to the development of myocarditis in uninfected mice.  Interestingly, 
transfer of splenocytes from IFNB-treated mice reduced the severity of myocarditis 
indicating that IFNA6 and IFNB may potentially work via alternative immunomodulatory Chapter Five 
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mechanisms for reduction of acute and chronic myocarditis.  However, further investigation, 
including defining the specific cell populations acting as immune-mediators, is warranted 
before conclusive mechanisms can be determined.  Previously, type I IFNs have been 
demonstrated to induce CD8+ T cell proliferation via IL-15 (Tough et al., 1996; Tough et 
al., 1999) and prevent activated T cell death during infection (Marrack et al., 1999).  Type I 
IFNs also promote B cell antibody repsonses (Le Bon et al., 2001).  Type I IFNs can also 
impair T and B cell development by inhibiting IL-7 induced growth (Lin et al., 1998).   
However, in these studies IFNα/β mixtures were used for analysis.  Data presented here 
establishes a role for IFNB, at least in regulation of splenocyte populations.  Further work to 
investigate the specific role of CD8+ and CD4+ T cells and B cells in the development of 
myocarditis is required. 
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5.4  Summary 
Investigation of the vaccination protocol for the type I IFN constructs demonstrated optimal 
therapeutic efficacy in the MCMV model is achieved with i) bupivacaine treatment prior to 
DNA inoculation, ii) 200µg IFN DNA and iii) inoculation of IFN DNA 14 days prior to 
virus challenge.  Maximal antiviral, anti-myocarditic and humoral responses are achieved 
with this vaccination schedule.  Furthermore, the potential for IFN as an immunotherapeutic 
agent was demonstrated.  Inoculation of IFNA6 DNA post-acute MCMV infection provided 
protection from chronic autoimmune myocarditis.  In addition, further evidence that the type 
I IFN subtypes exert their therapeutic efficacy via alternate mechanisms was demonstrated 
with the finding that IFNB treatment but not IFNA6 treatment reduced the development of 
myocarditis mediated by splenocyte transfer. 
 
 
Some of the findings presented in this chapter are presented in the following publications: 
 
Bartlett E.J., Cull V.S., Mowe E.N., Mansfield J.P., and James C.M.  (2003)  Optimization of 
naked DNA delivery for interferon subtype immunotherapy in cytomegalovirus infection.  
Biological Procedures Online.  5:43-52. 
 
Bartlett E.J., Cull V.S., Brekalo N.L., Lenzo J.C., and James C.M.  (2002)  Synergy of type I 
interferon-A6 and interferon-B naked DNA immunotherapy for cytomegalovirus infection.  
Immunology and Cell Biology.  80:425-435. 
 
Cull V.S., Broomfield S., Bartlett E.J., Brekalo N.L., and James C.M.  (2002)  Co-
immunisation with type I IFN genes enhances protective immunity against cytomegalovirus 
and myocarditis in gB DNA-vaccinated mice.  Gene Therapy.  9:1369-1378. 
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6.1  Introduction 
A proposed mechanism in the pathogenesis of MCMV-induced myocarditis implicates the 
immune response to viral infection as a contributing factor.  Evidence indicates that although 
the immune response to viral infection is critical for antiviral protection, particularly in the 
acute phase of infection, the development of cytotoxic immune responses including 
autoimmune responses, may contribute to disease pathogenesis.  Cytotoxic T cells (Lawson 
et al., 1989), auto-antibody (O’Donoghue et al., 1990; Fairweather et al., 2001), cytokines 
(Huber et al., 2001; Schmidtke et al., 2000; Lenzo et al., 2002) and free radical production 
(Hiraoka  et al., 1993) generated by infiltrating cells have been found to significantly 
contribute to virally-induced disease.  In previous chapters cytokine production and antibody 
titres have been examined following IFN treatment during MCMV infection and 
myocarditis.  Here we investigate the effect of IFN treatment on infiltrating immune cell 
profiles in the myocardium during MCMV-induced myocarditis.  
 
A critical role for immune cells in the development of myocarditis has been established.  In a 
CB3 model of myocarditis, macrophages are the predominant infiltrating immune cells in the 
myocardium with some T cells (mostly CD4+) also present (Rose et al., 1992).  Similarly, 
characterisation of the immune cell infiltrate during acute and chronic MCMV-induced 
myocarditis has revealed a predominant CD8+ T cell response with CD4+ T cells, B cells, 
macrophages and  neutrophils also detected in the myocardium of susceptible BALB/c mice 
(Lenzo et al., 2002).  The importance of both CD8+ and CD4+ T cells in virally-induced 
myocarditis has been previously reported (Lawson et al., 1989; Smith and Allen, 1991; 
Henke et al., 1995).  In addition, B cells (O’Donoghue et al., 1990; Fairweather et al., 2001), 
macrophages (Toyozaki et al., 2001; Rose et al., 1992), neutrophils (Craigen et al., 1997; 
Lenzo et al., 2002) and DCs (Yokoyama et al., 2000) have also been implicated in the 
development of myocarditis. 
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In this chapter, the effect of IFNA6, IFNA9 and IFNB DNA inoculation on immune cell 
profiles in the myocardium of MCMV-infected mice will be investigated.   
Immunohistochemical staining will be used to determine immune cell phenotypes including 
CD8+ and CD4+ T cells, B cells, macrophages, neutrophils and DCs during both the acute 
and chronic stages of myocarditis. 
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6.2  Results 
6.2.1  Effect of IFN subtype DNA treatment on CD8+ T cells in the Myocardium 
During MCMV-Myocarditis 
The effect of IFN treatment on infiltrating CD8+ T cells in the myocardium following 
MCMV infection was investigated.  BALB/c mice were inoculated with Blank, IFNA6, 
IFNA9 and IFNB and 14 days later challenged with 1x10
4 pfu MCMV.  Hearts were 
harvested at day 7 and day 30 p.i.  Heart sections were then immunohistochemically stained 
for CD8+ T cells using a CD8b.2 monoclonal antibody and positive staining cells counted 
under light microscopy.  Since a subset of DCs can also express CD8, cell morphology was 
examined (Shortman et al., 1997).  CD8+ T cells exhibited lymphocyte morphology and 
were therefore assumed to be CD8+ T lymphocytes and are referred to as such hereafter.   
 
CD8+ T cells were observed both scattered throughout the myocardium and within the foci 
of inflammation during acute and chronic myocarditis (Fig. 6.1A and B).  No difference in 
the total number of CD8+ T cells was observed between treatment groups during the acute 
phase.  In the chronic phase of myocarditis, CD8+ T cells were reduced with all IFN 
treatment groups with a significant reduction of 80% following IFNB inoculation (Fig. 6.1C 
and Table 6.2).  Similar numbers of CD8+ T cells were detected in the Blank treatment 
group during the acute and chronic phases of disease.  CD8+ T cells were the predominant 
cell type, comprising 69% and 34% of total cell numbers in the acute and chronic phase of 
disease respectively (Table 6.1 and 6.2).  Interestingly, IFNA6  and  IFNA9 inoculation 
reduced the percentage of CD8+ T cells within the foci of inflammation from 34% (Blank 
treatment group) to 21% during the acute phase of disease (Fig. 6.2 and Fig. 6.1A).   
Therefore, whilst IFN treatment did not affect the total number of cells, IFNA6 and IFNA9 
treatment altered the distribution of CD8+ T cells throughout the myocardium during the 
acute phase of myocarditis. 
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Figure 6.1.  CD8+ T cell response to IFN treatment.  CD8+ T cells are a major 
component of the immune cell infiltrate during myocarditis. BALB/c mice were 
challenged with 1x10
4  pfu of MCMV i.p. at 2 weeks post-DNA inoculation. 
Infiltrating CD8+ T cells were visualised by immunohistochemical staining of 
murine heart sections at day 7 p.i. and day 30 p.i. with CD8b.2 monoclonal 
antibody.  Histopathology of murine cardiac tissue is shown for Blank, IFNA6, 
IFNA9 and IFNB-treated, MCMV-infected mice at (A) day 7 p.i. (x20, original 
magnification) and (B) day 30 p.i. (x10, original magnification).  (C) The number 
of CD8+ T cells per heart section was determined and is expressed as the average 
number of cells per heart section ± SEM (n=2-3).  *Statistical significance 
(p≤0.05) compared with Blank treatment groups. Chapter Six 
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Figure 6.2.  IFN treatment alters the distribution of CD8+ T cells in the heart 
during acute myocarditis.  The percentage of CD8+ T cells in the foci of 
myocarditic hearts is reduced following IFNA6 and IFNA9 DNA treatment. 
BALB/c mice were challenged with 1x10
4 pfu of MCMV i.p. at 2 weeks post-
DNA inoculation.  The percentage of CD8+ T cells in the foci at day 7 p.i. 
were determined by counting total cell numbers and the number of infiltrating 
CD8+ T cells per foci (5 foci per heart section) following 
immunohistochemical staining with CD8b.2 antibody. *, Statistically 
significant differences between treatment groups and the Blank treatment 
group (p≤0.05). 
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6.2.2  Effect of IFN Subtype Treatment on the CD4+ T cell Response During 
Myocarditis  
The effect of IFN  inoculation on the CD4+ T cell response to MCMV infection was 
determined during the acute and chronic phases of myocarditis as described in section 6.2.1 
using CD4 (L3T4) antibody.  Positive staining CD4+ T cells showed lymphocyte 
morphology and were therefore assumed to be CD4+ T lymphocytes and are referred to as 
such hereafter.  CD4+ T cells were observed within the foci of inflammation and throughout 
the myocardium (Fig. 6.3A and B) of all treatment groups and were the second most 
predominant immune cell type found in the myocardium during the acute phase of disease 
(20.2% total cell number, Table 6.1).  At this stage, IFNA9 significantly increased CD4+ T 
cells, IFNB increased CD4+ T cell numbers and IFNA6 had no effect.  Interestingly, CD4+ T 
cell numbers increased 2.5-fold in the chronic phase of disease with Blank treatment which 
accounted for 26.4% of the total cell number (Fig. 6.4C and Table 6.2) with IFN treatment 
associated with suppression of CD4+ T cell numbers compared to the Blank treatment group.  
Therefore, the elevated numbers of CD4+ T cells correlated with protection from 
myocarditis during the acute stage, while during the chronic stage reduced CD4+ T cells 
numbers were associated with reduced disease severity. 
 
6.2.3  IFN DNA Treatment Alters the B Cell Profile During Acute and Chronic 
Myocarditis 
The effect of IFN inoculation on B cells infiltrating the myocardium during the acute and 
chronic phases of MCMV-induced myocarditis was examined as described in section 6.2.1 
using a CD45R/220 antibody.  Positively staining cells were assumed to be B lymphocytes 
and are described hereafter as B cells.  B cells were observed scattered throughout the 
myocardium during MCMV-induced acute and chronic myocarditis with no staining in the 
foci of inflammation (Fig. 6.4A and B).  Low numbers of B cells were observed during the  Chapter Six 
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Figure 6.3.  CD4+ T cell identification following IFN treatment in myocarditis. 
IFN treatment alters the profile of CD4+ T cells in the immune cell infiltrate 
during myocarditis.  BALB/c mice were challenged with 1x10
4 pfu of MCMV i.p. 
at 2 weeks post-DNA inoculation.  The infiltrating CD4+ T cells were visualised 
in murine heart section by immunohistochemical analysis using a CD4 (L3T4) 
antibody.  Histopathology of murine cardiac tissue demonstrating CD4+ T cells is 
shown for Blank, IFNA6, IFNA9 and IFNB-treated, MCMV-infected mice at (A) 
day 7 p.i. (x 20, original magnification) and (B) day 30 p.i. (x 10, original 
magnification).  (C) The number of CD4+ T cells per heart section was determined 
and is expressed as the average number of cells per heart section ± SEM (n=2-3). 
*Statistical significance (p≤0.05) compared with Blank treatment groups. Chapter Six 
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Figure 6.4.  The B cell response to IFN treatment during myocarditis.  IFN
treatment alters B cell numbers in the myocardium during myocarditis. BALB/c 
mice were challenged with 1x10
4  pfu of MCMV i.p. at 2 weeks post-DNA 
inoculation.  Infiltrating B cells were visualised in the myocardium by 
immunohistochemical staining with a CD45R/220 antibody. Histopathology of 
murine cardiac tissue demonstrating positive staining of B cells is shown for Blank, 
IFNA6, IFNA9 and IFNB-treated, MCMV-infected mice at (A) day 7 p.i. and (B) 
day 30 p.i. (x 20, original magnification).  The number of B cells per heart section 
was determined in the acute and chronic phase and is expressed as the average 
number of cells per heart section ± SEM (n=2-3). *Statistical significance (p≤0.05) 
compared with Blank treatment groups. 
C Chapter Six 
  160
acute phase with B cells comprising 5% total cell number in the Blank treatment group 
(Table 6.1).  Similar to the profiles observed with CD4+ T cell infiltration, B cell numbers 
increased during the chronic phase by 9-fold to comprise 23% total cell number in the Blank 
treatment group (Fig. 6.4C and Table 6.2).  IFNA9 and IFNB increased B cell numbers 
during the acute phase and this was statistically significant for IFNA9 (Fig. 6.4C).   
Interestingly, during the chronic phase of disease, IFN inoculation reduced B cell numbers 
with IFNB significantly reducing B cells.  Therefore, similar to CD4+ T cell phenotyping, an 
increase in infiltrating B cell numbers correlated with protection during the acute phase, 
while suppression of B cell infiltration was associated with reduced chronic myocarditis. 
 
6.2.4  IFNA6 Treatment Increases Infiltrating DCs in the Myocardium During 
Chronic Myocarditis 
Immunohistochemical analysis of the effect of IFN inoculation on the DC response to 
MCMV infection during the acute and chronic phases of myocarditis was evaluated as 
described in section 6.2.1 using a CD11c (Integrin αx chain) antibody.  CD11c was chosen as 
a marker for DCs since CD11c+ immature DCs in the blood respond to various chemokines 
expressed during inflammation and CD11c- DC precursors do not respond to these 
chemokines (reviewed in Caux et al., 2000).  Histology demonstrated a positively stained 
DC for IFNA6-treated mice at day 30 p.i. (Fig. 6.5B).  DCs were scarce in number during the 
acute phase of myocarditis with approximately 1 cell/ heart section detected following 
IFNA6 treatment at day 7 p.i. (Fig 6.5A).  During the chronic phase of disease, numbers 
increased slightly with a significant enhancement of DCs during IFNA6 treatment (Fig. 
6.5A).  Notably, DCs in the Blank treatment group comprised only 1.4% total cell numbers 
during the chronic phase (Table 6.2).  IFNA9 and IFNB had no effect on DC number in the 
myocardium (Fig. 6.5A).  Therefore, IFN treatment altered numbers of infiltrating DCs with 
IFNA6 having the most significant effect. Chapter Six 
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Figure 6.5.  Characterisation of the DC response to IFN treatment during myocarditis. 
IFNA6 treatment enhances DC numbers in the myocardium during chronic myocarditis. 
BALB/c mice were challenged with 1x10
4 pfu of MCMV i.p. at 2 weeks post-DNA 
inoculation. (A) The numbers of infiltrating DCs per heart section were determined by 
immunohistochemical staining at day 7 and 30 p.i. with a CD11c (Integrin αx chain) 
antibody and are expressed as the average number of cells per heart section ± SEM 
(n=2-3).  *Statistical significance (p≤0.05) compared with Blank treatment groups. (B) 
Histopathology of murine cardiac tissue (x 40, original magnification) demonstrating 
positive staining DCs is shown for IFNA6-treated, MCMV-infected mice at day 30 p.i. 
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6.2.5  Effect of IFN Treatment on the Neutrophil Response During Acute and 
Chronic Myocarditis 
Determination of the effect of IFN  inoculation on the neutrophil response to MCMV 
infection was performed by immunohistochemical staining using a Ly-6G (Gr-1) antibody 
during the acute and chronic phases of myocarditis as described in section 6.2.1.  Positively 
stained infiltrating neutrophils comprised 6% of the total number of infiltrating cells in the 
myocardium of Blank treated mice during the acute phase of disease (Fig. 6.6A and Table 
6.1).  IFN treatment reduced neutrophil numbers significantly with IFNA6 and IFNB (Fig. 
6.6A), while IFNA9 also reduced neutrophils compared to the Blank treatment group.  In the 
chronic phase, neutrophil numbers increased 4.2-fold in the Blank treatment group.   
Strikingly, IFNB treatment significantly reduced neutrophils in the myocardium at this stage 
compared to the Blank treatment group (Fig. 6.6A).  No other IFN treatment had any effect 
(Fig. 6.6A). 
 
6.2.6  IFNB Treatment Enhances Macrophage Infiltration During Acute and 
Chronic Myocarditis 
The macrophage response to MCMV infection following IFN inoculation was determined 
during the acute and chronic phases of myocarditis by immunohistochemical analysis using a 
Mac-3 monoclonal antibody.  Histopathology shows positively stained macrophages during 
the chronic phase of disease (Fig. 6.7B).  Numbers of positively stained infiltrating 
macrophages were low during both the acute and chronic stages of disease (Fig. 6.7A).  No 
macrophages were detected during the acute phase in the Blank treatment group, while 
during the chronic phase macrophages comprised 2.2% of the total cell number in this group 
(Table 6.2).  Interestingly, IFNB treatment marginally increased macrophage cell number in 
the acute phase of disease and increased numbers during the chronic phase compared to the 
Blank treatment group, however, not significantly.  Inoculation with IFNA6 and IFNA9 had 
no significant effect on macrophage infiltration (Fig. 6.7A). Chapter Six 
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Figure 6.6.  The neutrophil response to IFN treatment during myocarditis.  BALB/c 
mice were challenged with 1x10
4  pfu of MCMV i.p. at 2 weeks post-DNA 
inoculation. (A) The number of infiltrating neutrophils per heart section was 
determined by immunohistochemical staining at day 7 and 30 p.i. with a Ly-6G (Gr-1) 
antibody and is expressed as the average number of cells per heart section ± SEM 
(n=2-3).  *Statistical significance (p≤0.05) compared with Blank treatment groups. (B) 
Histopathology of murine cardiac tissue (x 40, original magnification) demonstrating 
neutrophils is shown for Blank-treated, MCMV-infected mice at day 7 p.i. Chapter Six 
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Figure 6.7.  Identification of macrophages following IFN treatment during 
myocarditis.  IFN-DNA treatment does not significantly affect infiltrating 
macrophages during myocarditis. BALB/c mice were challenged with 1x10
4 pfu of 
MCMV i.p. at 2 weeks post-DNA inoculation. (A) The number of infiltrating 
macrophages per heart section was determined by immunohistochemical staining at 
day 7 and day 30 p.i. with a Mac-3 monoclonal antibody and is expressed as the 
average number of cells per heart section ± SEM (n=2-3).  (B) Histopathology of 
murine cardiac tissue (x 20, original magnification) demonstrating macrophages is 
shown for IFNA9-treated, MCMV-infected mice at day 30 p.i. 
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Table 6.1.  The immune cell infiltrate during IFN treatment and acute MCMV-induced 
myocarditis. 
  Blank
a IFNA6
b  IFNA9
 b IFNB
 b 
CD8+
c  69%  100% ± 26.75%  94.27%  ± 28.47%  156.69% ± 10.57% 
CD4+  20.2%  150% ± 68.12%  241.30% ± 21.24%*  311.96% ± 34.49% 
B  5%  127.27% ± 85.71%  400% ± 16.44%*  304.55% ± 1.49% 
DC  0% -
d  -
d -
d 
Neutrophil  6%  4.88% ± 100%*  21.95% ± 100%  9.76% ± 50%* 
Macrophage  0% -
d -
d -
d 
aDNA (200µg) was injected bilaterally into regenerating TA muscles of adult mice 5 days 
after bupivacaine treatment. Fourteen days following DNA injection, mice were challenged 
with 1x10
4 pfu MCMV i.p. Heart sections were examined at day 7 p.i.  Data for Blank is 
given as a percentage of total cell number. 
bData for IFN treatment groups is expressed as a percentage of the Blank treatment group ± 
SEM for each cell type. 
cHeart sections were immunohistochemically stained using specific antibodies for a panel of 
immune cells. 
dBlank treatment group contains 0 cells/ heart, therefore percentage of Blank treatment group 
can not be determined for IFN treatment groups. 
Statistically significant differences between IFN  treatment groups and Blank vector are 
shown, * p≤0.05 (n=2-3). 
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Table 6.2.  The immune cell infiltrate during IFN treatment and chronic MCMV-induced 
myocarditis. 
  Blank
a IFNA6
b  IFNA9
 b IFNB
 b  
CD8+
c  34%  25% ± 81.08%  50% ± 35.14%  19.59% ± 55.17%* 
CD4+  26.4%  37.93% ± 15.91%  46.34% ± 30.23%  17.24% ± 40% 
B  23%  27.32% ± 42.86%  28.78% ± 25.42%  21.95% ± 6.67%* 
DC  1.4%  408.33% ± 6.12%*  58.33% ± 100%  8.33% ± 100% 
Neutrophil  13.2%  84.35% ± 31.96%  70.43% ± 23.46  7.83% ± 55.56%* 
Macrophage  2.2%  57.89% ± 100%  221.05% ± 28.57%  557.89% ± 26.42% 
aDNA (200µg) was injected bilaterally into regenerating TA muscles of adult mice 5 days 
after bupivacaine treatment. Fourteen days following DNA injection, mice were challenged 
with 1x10
4 pfu MCMV i.p. Heart sections were examined at day 30 p.i.  Data for Blank is 
given as a percentage of total cell number. 
bData for IFN treatment groups is expressed as a percentage of the Blank treatment group ± 
SEM for each cell type. 
cHeart sections were immunohistochemically stained using specific antibodies for a panel of 
immune cells. 
Statistically significant differences between IFN  treatment groups and Blank vector are 
shown, * p≤0.05 (n=2-3). 
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6.3  Discussion 
Data presented in this chapter supports an immune response driven mechanism for the 
pathogenesis of myocarditis in the CMV model and demonstrates immunomodulation of the 
cell infiltrate during myocarditis following type I IFN subtype inoculation.  Infectious virus 
is undetectable by plaque assay in the hearts of MCMV infected mice beyond day 10 p.i. 
(Lenzo et al., 2002; Fairweather et al., 2001), while transcripts of early viral genes can be 
detected by PCR through to day 100 p.i. (Lenzo et al., 2002).  Therefore, virus alone is not 
sufficient to cause the myocardial damage and necrosis observed during acute and chronic 
stage myocarditis.  Accumulating evidence indicates that the nature of the cellular 
inflammatory response following viral infection is directly associated with the level of 
virally induced myocarditis (Henke et al., 1995; Opavsky et al., 1999; Lenzo et al., 2002). 
 
There is a delicate balance between the beneficial and detrimental effects of the immune 
response which must be assessed for optimal efficacy against CMV induced disease.  In 
previous chapters the therapeutic efficacy of IFNA6, IFNA9 and IFNB, has been proven 
during both the acute and chronic stages of CMV-induced myocarditis.  These IFN subtypes 
reduce disease and skew the immune response towards a protective Th1-like cytokine and 
antibody response.  In this chapter, we determine whether this efficacy correlates with 
regulation of the immune cell infiltrate in the myocardium of susceptible MCMV-infected 
mice. 
 
The type I IFNs regulate many arms of the immune response, at the cellular level this 
includes T cells, B cells and DCs.  IFNα/β promote antigen processing and presentation 
through MHC class I molecules, activate T cells (Biron, 1999) and promote proliferation of 
memory CD8+ T cells (Tough et al., 1996) and their survival after activation (Marrack et al., 
1999).  In addition, they act on CD4+ T cells by promoting Th1 responses via regulation of 
expression of the IL-12 receptor (de Waal Malefyt, 1997).  In contrast, type I IFNs can also 
interfere with thymocyte development in vitro (Su, 1997) and impair T and B cell Chapter Six 
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development by inhibiting IL-7 induced growth (Lin et al., 1998).  Type I IFNs also promote 
B cell antibody responses and induce antibody isotype switching via DC stimulation in vivo 
(Le Bon et al., 2001) and enhance DC maturation and activation (Luft et al., 1998).  Given 
these immunomodulatory mechanisms, the therapeutic efficacy of individual type I IFNs 
(IFNA6,  A9 and B) were examined for potential in altering the profile of immune cell 
infiltrates in the myocardium following MCMV infection.  
 
The pivotal role of CD8+ T cells as cytotoxic lymphocytes is to mediate antiviral immunity.  
CD8+ T cells recognise antigen via MHC Class I presentation and mediate effector 
mechanisms including cytolysis (Bossi et al., 1999), cytokine secretion (Van Den Broek et 
al., 1995; Kagi et al., 1996) and chemokine production (Conlon et al., 1995; Price et al., 
1999).  Reduction of acute phase myocarditis via IFNA6, IFNA9 and IFNB treatment did not 
correlate with any reduction in CD8+ T cells in this study.  However, the composition of 
cells in the foci of inflammation was altered with IFNA6 and IFNA9 treatment reducing the 
percentage of CD8+ T cells in the foci.  In addition, reduction of infiltrating CD8+ T cells 
following IFN treatment, during the chronic phase appears to correlate with reduced chronic 
myocarditis.   
 
This study demonstrates that CD8+ T cells are the major infiltrating cell type in the 
myocardium during myocarditis and this is in agreement with previous studies (Lenzo et al., 
2002).  The findings that athymic nu/nu mice do not develop myocarditis following CMV 
infection (Lawson et al., 1989) and that myocarditis can be transferred following inoculation 
of autoimmune T cells from virally infected mice (Guthrie et al., 1984; Huber, 1997), in 
addition to studies in mice lacking CD8+ T cells (Henke et al., 1995) have contributed to 
evidence for a role for CD8+ T cells in myocarditis.  Our findings indicate it may be that 
CD8+ T cells are important early in disease for viral clearance, however, infiltrating CD8+ T 
cells during the chronic phase of myocarditis is detrimental.  Reduction of disease with type Chapter Six 
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I IFN treatment correlates with reduced chronic disease, therefore, type I IFNs may regulate 
the CD8+ T cell response during this stage. 
 
CD4+ T cells differentiate into Th1 and Th2 cells which play a central role in regulating the 
cell mediated immune response to infection (Abbas et al., 1996).  The Th1 and Th2 CD4+ 
subsets regulate the immune response by cytokine secretion, immunoglobulin isotype 
switching, affinity maturation of the antibody response, macrophage activation, and 
enhancement of NK cell and CTL activity (Martin et al., 1998).  CD4+ T cells recognise 
antigen presented in association with MHC class II molecules.  CD4+ T cells have been 
implicated in the pathogenesis of myocarditis (Lawson et al., 1989; Smith and Allen., 1991; 
Henke et al., 1995).  Data presented in this chapter demonstrates that CD4+ T cells are the 
second most predominant cell type during myocarditis.  Numbers of CD4+ T cells were 
significantly increased in the myocardium following IFNA9 treatment and also increased 
following IFNB treatment during the acute phase.  Furthermore, effective IFN treatment 
correlates with a decrease in CD4+ T cells late in disease.  Therefore, a persisting CD4+ T 
cell response may contribute to chronic inflammation. 
 
Previous studies characterising the T cell response during myocarditis have supported a role 
for CD4+ T cells (Rose et al., 1992; Lenzo et al., 2002).  A/J mice lacking CD4+ T cells 
(CD4 -/-) show a small but significant decrease in CB3 induced myocarditis (Opavsky et al., 
1999).  However, this group also demonstrated that the absence of both CD4+ and CD8+ T 
cells had a more beneficial effect on myocardial inflammation (Opavsky et al., 1999).   
Conflictingly, depletion of CD4+ T cells protects mice from early death whilst enhancing 
disease severity (Henke et al., 1995).  Thus it appears that in our model, increased CD4+ T 
cells during the acute phase is important both for viral clearance and stimulation of other 
arms of the immune response.  However, a reduction in CD4+ T cells with IFN treatment 
during the chronic phase corresponds with protection against myocarditis. 
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B lymphocytes are implicated in the development of myocarditis due to their critical role in 
the immune response as antibody producing cells.  The antibody response to CMV infection 
is also crucial to the development of myocarditis.  Autoantibodies produced against cardiac 
myosin cross-react with viral antigenic determinants and are thought to be important in the 
development of chronic disease (O’Donoghue et al., 1990; Lawson et al., 1992).  Findings 
presented here demonstrate a low B cell response during the acute phase of myocarditis, 
which was enhanced by IFNA9 treatment, corresponding with increased antibody titres and 
reduced disease (chapter 4).  During the chronic phase, effective IFN treatment reduced B 
cell infiltration in the myocardium.  Therefore, B cell infiltration may be a contributing 
factor during chronic myocarditis.  Previous studies have demonstrated that B cells can 
mediate myocarditis (Lawson et al., 1992; Paque and Miller, 1992).  Passive transfer of anti-
cardiac myosin antibodies from MCMV-infected mice induces inflammation and necrosis of 
the myocardium in uninfected recipients (Lawson et al., 1992).  Similarly, adoptive transfer 
of B cells or splenocytes pulsed in vitro with anti-idiotypic antibodies against anti-CB3 virus 
antibodies induced antibody production and myocarditis in recipient mice (Paque and Miller, 
1992).  In this chapter, the protective response mediated by IFN treatment corresponded with 
increased B cell numbers in the myocardium during the acute phase of disease and decreased 
B cell numbers during the chronic phase of myocarditis. 
 
DCs are the most effective APCs in the induction of immune responses (Huang et al., 1994).  
Despite the fact that DCs have previously been identified in the hearts of patients with 
myocarditis (Yokoyama et al., 2000), a study in our laboratory characterising the immune 
cell infiltrate during myocarditis found no evidence of DCs in the hearts of either susceptible 
BALB/c or resistant C57BL/6 mouse strains (Lenzo et al., 2002).  Similarly, data presented 
here demonstrates no DC infiltrate during the acute phase with Blank treatment.   
Surprisingly,  IFNA6 treatment significantly increased chronic stage DC numbers in the 
myocardium.  The finding that MCMV infection of DCs impairs cellular function (Andrews 
et al., 2001) may explain the low numbers of DCs in the myocardium during MCMV Chapter Six 
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infection.  IFNA6 treatment may overcome inhibition of DC function by reducing viral titres 
in the acute phase of disease, and allowing enhanced DC responses during the chronic phase.   
 
Neutrophils are a major reservoir of infectious CMV (Dankner et al., 1990; Gerna et al., 
1991; Grundy et al., 1998).  Neutrophils, phagocytic cells which migrate into tissues in 
response to specific stimuli, play an important role in virus dissemination during acute 
infection (Craigen et al., 1997).  In this study, low numbers of neutrophils detected in the 
myocardium during the acute phase were further suppressed by IFN treatment.  Interestingly, 
increased neutrophil numbers during the chronic phase of myocarditis were not observed 
with the IFNB treatment group.  Characterisation of infiltrating neutrophils during 
myocarditis revealed that although neutrophils are observed in the myocardium of 
susceptible BALB/c mice, resistant C57BL/6 mice did not mount a neutrophil response 
(Lenzo et al., 2002).  Similarly, a correlation between neutrophil activity and host tissue 
destruction has previously been observed (Burg and Pillinger, 2001). 
 
Macrophages have been identified as the major cell type infiltrating the heart during CB3-
induced myocarditis (Rose, 1992) and are thought to be a major source of viral dissemination 
(Sinzger et al., 1996).  Macrophages have an important role in presentation of antigen to T 
lymphocytes.  Low numbers of macrophages were observed in the myocardium of all 
treatment groups during both the acute and chronic phases of myocarditis with an increase 
during the chronic phase.  During the chronic phase, increased macrophage numbers were 
observed in the myocardium of mice in the IFNA9 and IFNB treatment groups.  Similarly, 
low numbers of macrophages have previously been demonstrated in the myocardium of 
susceptible BALB/c mice throughout both phases of disease following CMV infection 
(Lenzo et al., 2002).  Therefore, in this MCMV-induced model of myocarditis, increased 
macrophage numbers in the chronic phase correlated with reduced myocarditis. 
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The type I IFN subtypes, IFNA6, IFNA9 and IFNB, effectively modulate the immune 
response to MCMV infection resulting in reduced acute and chronic myocarditis.   
Furthermore, data presented here demonstrates that exogenous type I IFN expression 
modulates the phenotypic profile of the immune cell infiltrate both within the foci of 
inflammation and throughout the myocardium during acute and chronic MCMV-induced 
myocarditis.  The type of immune cells involved in myocardial inflammation may ultimately 
lead to either resolution or progression of disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter Six 
  173
6.4  Summary 
The type I IFN transgenes were examined for their effect on altering the profile of immune 
cells infiltrating the myocardium at both the acute and chronic stages of disease (day 7 p.i. 
and day 30 p.i.).  IFN transgene inoculation reduced myocarditis and altered cell phenotypes 
in the myocardium.  In the acute phase, IFNA6 significantly reduced neutrophil numbers 
whilst IFNA9 treatment significantly increased CD4+ T and B cells and slightly reduced 
neutrophils.  IFNB treatment slightly enhanced CD4+ T cells and significantly reduced 
neutrophils in the myocardium.  In addition, IFNA6 and IFNA9 treatment altered the 
distribution of CD8+ T cells in the heart, reducing the number of CD8+ T cells in the foci of 
inflammation.  During the chronic phase, IFNA6, A9 and B all reduced CD8+ T, CD4+ T and 
B cells.  IFNA6 significantly enhanced DCs, IFNA9 and B increased macrophage numbers 
and IFNB significantly reduced neutrophils.  IFNA6, A9 and B are all effective at reducing 
chronic myocarditis, however, this data indicates their differential effect on infiltrating 
immune cells potentially implicates different mechanisms of action. 
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7.1  Introduction 
The advent of gene transfer technology provided an avenue for the development of a new 
generation of vaccines.  The finding that intramuscular inoculation with plasmid DNA 
encoding antigenic proteins leads to protein expression in vivo (Wolff et al., 1990) and can 
initiate a strong and persistent cell-mediated and humoral immune response to the DNA-
encoded antigen (Tang et al., 1992; Donnelly et al., 1997) led to the development of DNA 
vaccines.  Initially DNA vaccines encoding viral and other pathogenic antigens were 
developed for a number of disease models.  This approach has proven effective in viral 
models such as Influenza A (Ulmer et al., 1993), HIV-1 (Wang et al., 1993), HBV (Davis et 
al., 1996) and HCV (Geissler et al., 1997).  In addition, DNA vaccines are effective in 
bacterial, parasitic, and allergic diseases (Tascon et al., 1996; Hoffman et al., 1995; 
Waisman et al., 1996). 
 
More recently, the potential of cytokines for immunotherapeutic gene transfer has been 
explored.  Effective cytokine DNA therapy has been developed for autoimmune diseases, 
infectious diseases and cancers.  More specifically, cytokines demonstrating effective DNA 
immunotherapy include: IFNα1, IFNβ and IL-6 in HSV-1 infection and disease induction 
(Noisakran et al., 1999; Carr and Cui, 2000; Carr and Campbell, 1999), IFNα in metastatic 
tumors (Horton et al., 1999), IL-10 in autoimmune diabetes (Nitta et al., 1998) and type I 
IFN in CMV infection and disease induction (Yeow et al., 1998; Cull et al., 2002a).  Recent 
advances in cytokine DNA immunotherapy include cytokine co-vaccination for superior 
efficacy in the treatment of disease.  Effective cytokine co-vaccination has been 
demonstrated with GM-CSF and HIV-1 (Kusakabe et al., 2000; Barouch et al., 2002) and, in 
our laboratory, type I IFN co-vaccination with MCMV gB has proven protective in CMV-
induced myocarditis (Cull et al., 2002b). 
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Several groups have demonstrated enhanced immune responses using synergistic cytokine 
combinations. Combinations of recombinant GM-CSF/IL-12 and TNFα/IL-12 act 
synergistically to enhance immune responses in a model of HIV-1 (Ahlers et al., 1997).  
Synergy following cytokine immunotherapy has also been reported.  Combined IL-4 and IL-
10 plasmid administration prevents the development of autoimmune diabetes in non-obese 
diabetic mice (Ko et al., 2001).  In addition, plasmid administrated IL-2 and IL-12 
demonstrated synergistic antitumour properties in a Lewis Lung carcinoma model (Tanaka et 
al., 2000).  Co-administration of more than one cytokine is believed to allow more effective 
‘steering’ of the immune response toward a protective outcome.  In this chapter, the potential 
for synergistic therapeutic efficacy by co-treatment of effective type I IFN subtypes will be 
evaluated in the MCMV model. 
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7.2 Results 
7.2.1  Type I IFN Co-administration Using Excess DNA Is Inhibitory In Vivo 
The effect of combining two individually efficacious type I IFN subtypes was examined for 
determination of their combined therapeutic efficacy in MCMV infection and disease in vivo.  
Combinations of Blank, IFNA6, IFNA9 and IFNB DNA were examined for their antiviral 
and therapeutic efficacy and their effect on cytokine production.  BALB/c mice were 
inoculated i.m. with 200µg of each DNA construct (total 400µg DNA) 14 days prior to 
challenge with 1x10
4 pfu MCMV i.p. 
 
Surprisingly, IFN DNA combination treatment did not significantly affect viral titre in the 
spleen or liver at day 3 p.i. (Fig. 7.1A and B).  Interestingly, IFNB/Blank treatment 
significantly increased MCMV titres in the liver at day 3 p.i. (Fig. 7.1B).  In addition, 
combination treatment did not affect salivary glands viral titres, although IFNA6/Blank 
treatment reduced salivary glands titres at day 7 p.i. as expected from previous studies using 
IFNA6 (Fig. 7.1C).  The 400µg combination of IFN subtype/Blank did not demonstrate the 
antiviral effect observed with 200µg IFN treatment, presented in chapter 4.  Previously, a 
significant reduction in MCMV titres was shown following IFNA6 treatment while 
inoculation with either IFNA9 or IFNB had no effect on MCMV replication (200µg DNA/ 
mouse).  
 
IFN combination treatment (400µg DNA/ mouse) had no effect on acute phase MCMV-
induced myocarditis with the exception of the IFNA9/B treatment combination (Fig. 7.2).  
Notably, no reduction in acute myocarditis was observed with IFNA6/Blank, IFNA9/Blank 
and IFNB/Blank (Fig. 7.2) despite the protective effect previously observed following DNA 
treatment with these subtypes at doses of 200µg/ mouse (chapter 4). 
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Figure 7.1.  Co-treatment with 400µg  IFN subtype DNA does not affect MCMV 
replication in vivo. Following bupivacaine treatment, BALB/c mice were treated with Blank
vector, or combinations of IFN-A6/A9, IFN-A6/B or IFN-A9/B vector DNA (total of 400µg) 
bilaterally in the TA muscle.  At 14 days post-inoculation, mice were challenged with 1x10
4
pfu MCMV i.p. Viral titres were determined in (A) spleen and (B) liver at day 3 p.i. and (C) 
salivary glands at day 7 p.i. Viral titres are expressed as mean pfu/g ± SEM (n=5).  *, 
Statistical significance to Blank vector group is shown (p≤0.05).  Chapter Seven 
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Figure 7.2. Co-treatment with 400µg IFN subtype DNA is not effective against acute 
phase myocarditis. Following bupivacaine treatment, BALB/c mice were treated with 
Blank vector, or combinations of IFN-A6/A9,  IFN-A6/B or IFN-A9/B DNA (total of 
400µg) bilaterally in the TA muscle.  At 14 days post-inoculation, mice were challenged 
with 1x10
4 pfu MCMV i.p.  Myocarditis was evaluated at day 7 p.i. and is expressed as 
the number of foci per heart section ± SEM (n=5). *Statistical significance to the Blank
vector treatment group is shown (p≤0.05).  Chapter Seven 
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Efficacious  IFN  subtype DNA inoculation was previously shown to correlate with the 
induction of a protective cytokine response (chapter 4).  Administration of combination IFN 
treatment (400µg/ mouse) had no effect on circulating cytokine titres (Fig. 7.3).  The 
exception to this was IFNA9/B, which significantly reduced IFNγ levels (Fig. 7.3A).   
However, no change in either IL-4 or IL-6 was observed following co-treatment of mice with 
IFN subtypes (Fig. 7.3B and C). 
 
Thus co-inoculation of effective type I IFNs with Blank vector (400µg/ mouse) resulted in 
abrogation of the therapeutic efficacy previously observed in this model (chapter 4).  It may 
be that excess doses of IFN DNA (400µg) render the IFN DNA treatment ineffective at 
reducing antiviral titres and myocarditis and altering cytokine profiles (with the exception of 
IFNA9/B, which reduced disease and reduced circulating IFNγ titres).  The potential of 
combination IFN inoculation will be further evaluated with reduced doses in this chapter 
(200µg/ mouse). 
 
7.2.2  Synergy of IFN Subtypes In Antiviral Therapy 
The potential for antiviral synergy between IFN subtypes was determined using reduced IFN 
DNA inoculations of 100µg DNA of each IFN subtype (200µg/ mouse).  Mice were given 
combinations of the type I IFN constructs (IFNA6/A9, IFNA6/B and IFNA9/B) or Blank 
vector.  As previously described, mice were challenged with 1x10
4 pfu MCMV 14 days 
following DNA inoculation and virus titres determined in target tissues by plaque assay (Fig. 
7.4). 
 
Co-administration of the type I IFNs demonstrated varying degrees of antiviral efficacy.  
Inoculation with IFNA6/A9 and IFNA6/B significantly reduced virus titres in the spleen at 
day 3 p.i. compared to Blank vector treated mice (Fig. 7.4A) and this was superior to  
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Figure 7.3. Combination IFN subtype therapy using 400µg DNA inhibits the induction of an 
effective cytokine response. Following bupivacaine treatment, BALB/c mice were injected 
bilaterally in the TA muscle with a total of 400µg of Blank, IFN-A6/A9, IFN-A6/B, or IFN-
A9/B vector DNA 14 days prior to infection with 1x10
4 pfu MCMV i.p.  Cytokine levels, in 
day 3 sera from MCMV infected mice, were determined by ELISA for (A) IFNγ, (B) IL-4 and 
(C) IL-6. Cytokine levels are presented as mean pg/mL ± SEM (n=5). *, Statistical 
significance to Blank vector treatment group (p≤0.05).  
0
10
20
30
40
50
60
70
Blank A6/Blank A9/Blank B/Blank A6/A9 A6/B A9/B
C 
0
10
20
30
40
50
60
70
80
90
Blank A6/Blank A9/Blank B/Blank A6/A9 A6/B A9/B
B
*
0
200
400
600
800
1000
1200
1400
Blank A6/Blank A9/Blank B/Blank A6/A9 A6/B A9/B
A
I
L
-
6
 
(
p
g
/
m
L
)
 
I
L
-
4
 
(
p
g
/
m
L
)
 
I
F
N
γ
 
(
p
g
/
m
L
)
 Chapter Seven 
  182
 
*
*
0
5000
10000
15000
20000
25000
30000
35000
40000
45000
50000
Blank IFNA6/A9 IFNA6/B IFNA9/B
A
M
C
M
V
 
T
i
t
r
e
 
(
p
f
u
/
g
)
 
*
*
0
50
100
150
200
250
300
350
400
450
Blank IFNA6/A9 IFNA6/B IFNA9/B
B
M
C
M
V
 
T
i
t
r
e
 
(
p
f
u
/
g
)
 
0
50000
100000
150000
200000
250000
300000
Blank IFNA6/A9 IFNA6/B IFNA9/B
C
M
C
M
V
 
T
i
t
r
e
 
(
p
f
u
/
g
)
 
Figure 7.4.  Co-treatment with effective IFN subtype DNA reduces MCMV titre in 
vivo.  Following bupivacaine treatment, BALB/c mice were inoculated with a total 
of 200µg of Blank vector, IFN-A6/A9, IFN-A6/B or IFN-A9/B DNA 14 days prior 
to infection with 1x10
4 pfu MCMV i.p.  Viral titres were determined by plaque 
assay in (A) spleen and (B) liver at day 3 p.i. and (C) salivary glands at day 7 p.i. 
Viral titres are expressed as mean pfu/g ± SEM (n=5). *, Statistical significance to 
Blank vector treatment groups is shown (p≤0.05).Chapter Seven 
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individual  IFN treatment alone (Fig. 4.1A and Fig. 5.1A).  However, the IFNA9/B 
combination treatment had no effect on virus titres in the spleen.   
 
In the liver, virus replication was reduced with all IFN subtype combinations examined.  A 
significant reduction was observed with IFNA6/B and IFNA9/B co-treatment.  This effect 
was superior to that observed in the liver with individual subtype treatment (Fig. 4.1B and 
Fig. 5.1B).  No effect on viral replication was detected with IFNA6/A9, IFNA6/B and 
IFNA9/B DNA at day 7 p.i. in the salivary gland.   
 
7.2.3  Co-administration of Type I IFN Subtypes in Acute and Chronic 
Myocarditis 
Combinations of subtypes previously shown to be effective in reducing MCMV-induced 
myocarditis (IFNA6, IFNA9 and IFNB) were examined for their synergistic properties at the 
reduced DNA dosage of 200µg/ mouse.  Mice DNA-treated and MCMV-infected, as 
described in the previous section (section 7.2.2), were examined for both the acute and 
chronic phase of myocarditis. 
 
Both IFNA6/A9 and IFNA9/B combinations significantly reduced acute myocarditis (Fig. 
7.5A), as shown by histological staining (Fig. 7.5B).  Furthermore, IFNA9 and IFNB were 
superior when used in combination compared to use as single DNA constructs (Fig. 4.3 and 
Fig. 5.2).  In chronic myocarditis, all IFN subtype combinations were effective (day 56 p.i.) 
and statistically significant compared to Blank (Fig. 7.6).  IFNB used in combination with 
IFNA6 was the most efficacious combination and was superior to individual IFNB subtype 
treatment (Fig. 4.6B and Fig. 5.3).  Therefore, type I IFN subtypes demonstrated a 
synergistic effect on MCMV-induced myocarditis during both the acute and chronic phases 
at a defined inoculum dose of 200µg DNA/ mouse. 
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Figure. 7.5.  Co-treatment of IFN subtype DNA is effective in reducing acute-phase 
myocarditis.  Following bupivacaine treatment, BALB/c mice were inoculated bilaterally 
in the TA muscle with 200µg of either Blank, IFN-A6/A9, IFN-A6/B or IFN-A9/B DNA 
(100µg each DNA construct) and 14 days later mice were infected with 1x10
4 pfu MCMV 
i.p.  Hearts were transected down the mid-line and H&E stained for evaluation of 
myocarditis at day 7 p.i. (A) Myocarditis is expressed as the average number of foci/heart 
section ± SEM (n=5). (B) Histopathology of the hearts demonstrating infiltrating immune 
cells, (original magnification x4). *, Statistical significance to Blank vector group is shown 
(p<0.05). 
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Figure 7.6.  Co-treatment with IFN subtype DNA reduces chronic-phase myocarditis. 
Following bupivacaine treatment, BALB/c mice were inoculated bilaterally in the TA 
muscle with 200µg of either Blank vector, IFN-A6/A9,  IFN-A6/B or IFN-A9/B DNA 
(100µg each DNA construct) and 14 days later mice were infected with 1x10
4 pfu MCMV 
i.p. Hearts were transected down the mid-line and H&E stained for evaluation of 
myocarditis at day 56 p.i.  (A) Myocarditis is expressed as the average number of 
inflammatory foci/heart section ± SEM (n=5).  (B) Histopathology of the hearts 
demonstrating infiltrating immune cells, (original magnification x4). *, Statistical 
significance to Blank vector group is shown (p<0.05). 
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7.2.4  Co-administration of Type I IFN Subtypes Influences Cytokine 
Expression 
It has been demonstrated that type I IFN expression alters the cytokine profile in vivo.  Here, 
we examine the effect of combinational IFN subtype treatment on the production of 
circulating cytokines.  Mice were treated as detailed previously (section 7.2.2) and sera taken 
at day 3 p.i. for quantitation of IFNγ, IL-4, IL-6, IL-10 and TNFα by ELISA. 
 
Co-treatment of IFNA6/B significantly reduced IFNγ levels (Fig. 7.7A) while IFNA6/A9 
significantly down-regulated IL-4 titre in the sera (Fig. 7.7B).  Both IFNA6/A9 and IFNA6/B 
significantly reduced the level of the proinflammatory cytokine, IL-6 (Fig. 7.7C).  Levels of 
IL-10 production were significantly reduced with IFNA6/A9 and IFNA9/B co-treatment (Fig. 
7.7D).  No significant differences in TNFα were observed (Fig. 7.7E) although levels were 
very low for IFNA6/A9 and IFNA9/B groups.  However, individual cytokine profiles 
following effective IFN DNA co-treatment did not correlate with cytokine profiles following 
effective individual IFN DNA treatment which induced a Th1-like cytokine response.  Taken 
together, the treatments with effective IFN DNA combinations did not preferentially dictate 
a Th1- or a Th2-like response. 
 
 
 
 
 
 
 
 
 
 Chapter Seven 
  187
 
 
 
 
 
 
 
 
A 
*
0
100
200
300
400
500
600
700
800
900
Blank IFNA6/A9 IFNA6/B IFNA9/B
I
F
N
γ
 
(
p
g
/
m
L
)
 
**
0
20
40
60
80
100
120
Blank IFNA6/A9 IFNA6/B IFNA9/B
C 
I
L
-
6
 
(
p
g
/
m
L
)
 
B 
*
0
5
10
15
20
25
30
35
40
45
Blank IFNA6/A9 IFNA6/B IFNA9/B
I
L
-
4
 
(
p
g
/
m
L
)
 Chapter Seven 
  188
 
 
 
 
 
 
*
*
0
500
1000
1500
2000
2500
3000
Blank IFNA6/A9 IFNA6/B IFNA9/B
D 
I
L
-
1
0
 
(
p
g
/
m
L
)
 
0
200
400
600
800
1000
1200
1400
1600
Blank IFNA6/A9 IFNA6/B IFNA9/B
E 
T
N
F
α
 
(
p
g
/
m
L
)
 
Figure 7.7.  Co-treatment of IFN DNA subtypes alters circulating cytokine levels. 
Following bupivacaine treatment, BALB/c mice were inoculated bilaterally in the 
TA muscle with 200µg of Blank vector, IFN-A6/A9, IFN-A6/B, or IFN-A9/B DNA 
14 days prior to infection with 1x10
4 pfu MCMV i.p.  Cytokine levels, in day 3 sera 
from MCMV infected mice, were determined by ELISA for (A) IFNγ, (B) IL-4, (C) 
IL-10, (D) IL-6 and (E) TNFα.  Data is presented as mean pg/mL ± SEM (n=5). *, 
Statistical significance to Blank treatment group (p≤0.05). Chapter Seven 
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7.3  Discussion 
The individual therapeutic efficacy of IFNA6, IFNA9 and IFNB DNA treatment has been 
demonstrated in chapter 4.  These IFN subtypes, used as single inoculation DNA treatments, 
effectively reduced MCMV-induced myocarditis with IFNA6 treatment also reducing acute-
phase viral replication.  The potential for enhanced therapeutic efficacy with combined type I 
IFN subtype plasmid administration was investigated here.  Co-administration of cytokine 
for immunotherapy has been effectively demonstrated in other murine models (Okada et al., 
1997; Ko et al., 2001; Tanaka et al., 2000).  Evidence suggests that specific combinations of 
cytokines can be used to steer the immune response toward a therapeutically effective 
outcome potentially regulating different arms of the immune response (Ahlers et al., 1997; 
Kusakabe  et al., 2000).  For example, GM-CSF/ IL-12 treatment enhances antigen 
presentation and CD4+ responses, while TNFα/ IL-12 treatment drives a Th1-like immune 
response in a murine model of HIV-1 infection (Ahlers et al., 1997). 
 
Similar to findings in chapter 5, dosage of DNA was found to be crucial for therapeutic 
outcome.  In this scenario, excess DNA, as compared to insufficient DNA, suppressed the 
efficacy of type I IFN treatment.  Dose-response curves from previous studies demonstrate 
optimal DNA doses at 100-200µg with decline in efficacy at higher concentrations 
(Moelling, 1997).  Effective gene immuno-therapy has previously been demonstrated with 
doses of 200µg/ mouse for IFNγR-Fc (Prud’homme and Chang, 1999) and IL-4/IgG1 
(Chang and Prud’homme, 1999) and type I IFNs (Yeow et al., 1998).  Similarly, data 
presented here demonstrates that type I IFN DNA inoculation is most effective at 200µg/ 
mouse both individually and as combination treatments. 
 
Synergy was observed upon co-administration of IFNA6, IFNA9 and IFNB subtypes at a 
final DNA dose of 200µg/ mouse.  Co-administration of IFN subtypes at this dosage 
improved antiviral activity by up to 95%.  Previously, only IFNA6 had been found to Chapter Seven 
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significantly reduce viral titres, however, treatment with IFNA6/A9 reduced splenic viral 
replication, and IFNA9/B reduced viral titres in the liver, while IFNA6/B reduced virus 
replication in both tissues.  As previously discussed, different NK cell responses regulate 
MCMV replication in the spleen and liver (Tay and Welsh, 1997), therefore, the specific 
combinations of type I IFNs may act differently to enhance or suppress cytolytic 
mechanisms in the spleen and/ or IFNγ and nitric oxide production in the liver. 
 
IFN subtypes effective in reducing acute phase myocarditis also synergistically reduced 
disease by up to 75%.  Interestingly, a reduction in acute-phase myocarditis was observed 
with  IFNA6/A9 and IFNA9/B treatment but not IFNA6/B treatment despite the severely 
reduced viral titres observed with the latter treatment.  In the chronic phase, all combinations 
investigated significantly reduced myocarditis.  Notably, IFNA6/B co-treatment was least 
effective in the acute phase of myocarditis yet proved the most efficacious combination in 
the chronic phase of disease.  Therefore, whilst viral load did not correlate with severity of 
acute stage myocarditis, it may be an important factor in the development of chronic disease.  
 
Data presented in chapter 4 implicated that induction of a Th1-like immune response was 
linked with reduced severity of MCMV pathogenesis following effective IFN subtype 
treatment.  Indeed, the type I IFNs have previously been reported to induce a Th1-like 
cytokine milieu by enhancing IL-15, IL-12 and IFNγ production (Zhang et al., 1998; 
Cousens  et al., 1999; Brinkmann et al., 1993).  Furthermore, protective roles in virus-
induced myocarditis have been established for Th1-like cytokines, whilst Th2-like responses 
and proinflammatory cytokines are thought to contribute to disease pathogenesis 
(Afanasyeva et al., 2001).  The co-administration of type I IFN subtypes in this chapter 
resulted in altered cytokine expression of IFNγ, IL-4, IL-6 and IL-10 during the acute phase 
of disease.  However, no distinct correlation between Th1 or Th2 responses and effective 
subtype co-treatment could be determined from the data presented in this thesis.  It may be Chapter Seven 
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that the cytokine concentration in individual target tissues, rather than in circulating sera 
would reveal more specific cytokine responses skewed by IFN subtype treatment.  In future 
studies, serum levels of type I IFN should be determined for comparison to treatment with 
individual subtypes.  In addition, microarray technology could be employed to determine 
whether type I IFNs, in combination, differentially augment known anti-viral pathways such 
as 2'5'OAS and PKR. 
 
The type I IFNs are established as an important link between the innate and adaptive immune 
response.  Indeed, emerging evidence indicates that the innate immune response is critical to 
the development and onset of autoimmune disease (Shi et al., 2001).  The exogenous 
expression of type I IFN transgenes during the early immune responses to MCMV infection 
may therefore be pivotal in the development of chronic myocarditis.  In this chapter, 
protection from disease was demonstrated despite the lack of a “protective”, predominantly 
Th1-like cytokine response following co-administration of type I IFN subtypes.   
Examination of the effect of type I IFN, individually and in combination, on NK cells, NKT 
cells or γδT cells which are also implicated in autoimmunity (Shi et al., 2001), may reveal 
alternate mechanisms of action. 
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7.4  Summary 
Type I IFN subtypes were assessed for synergy by co-administration in an 
immunotherapeutic regime utilising the MCMV model of infection and disease.  Treatment 
with 400µg DNA proved inhibitory to the protective antiviral and immunomodulatory 
effects previously demonstrated with individual IFNA6, IFNA9 and IFNB treatment (200µg 
DNA/ mouse).  However, synergistic immunotherapeutic effects were revealed following 
type I IFN subtype treatment with a total reduced dose of 200µg DNA/ mouse.  IFNA6/A9 
and IFNA6/B greatly reduced splenic viral titres while IFNA6/B and IFNA9/B reduced virus 
replication in the liver. In addition, IFNA6/A9 and IFNA9/B reduced acute viral myocarditis, 
whereas  IFNA6/B was the most efficacious treatment regime in autoimmune chronic 
myocarditis.  The cytokine profiles induced by combinational type I IFN treatment did not 
reveal any predominant Th1- or Th2-like immune response.  The synergistic properties of 
IFN demonstrated here further highlight the potential of type I IFN DNA immunotherapy 
using select subtypes. 
 
 
 
The findings presented in this chapter are presented in the following publication: 
 
Bartlett E.J., Cull V.S., Brekalo N.L., Lenzo J.C., and James C.M.  (2002)  Synergy of type I 
interferon-A6 and interferon-B naked DNA immunotherapy for cytomegalovirus infection.  
Immunology and Cell Biology.  80:425-435. 
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The type I IFNs comprise a family of cytokines, which are widely used as viral and disease 
therapeutics due to their diverse and potent biological properties.  The multigenic nature of 
the type I IFN family is an area for further research since the biological relevance and 
purpose of the individual subtypes remains unclear.  Thus, the therapeutic applications and 
the multigenic nature of the type I IFNs formed the focus for studies presented in this thesis.  
An extensive panel of DNA constructs designed for in vivo expression of type I IFN 
transgenes via i.m. delivery was prepared.  Evaluation of the antiviral and 
immunomodulatory efficacy of the type I IFN subtype transgenes in an MCMV model of 
infection and myocarditis demonstrated functional diversity within the type I IFN family. 
 
Murine IFNα1, α2, α4, α5, α6, α9 and β were chosen for investigation in this study.  Each 
subtype was specifically chosen for characteristics which indicated potentially unique 
features which may extend to biological function.  This included sequence homology and 
position on the chromosome, either within (α1, α4, α5 and α6) or outside (α2, α9 and β) a 
cluster of IFN genes (Kelley and Pitha, 1985).  Design and construction of the panel of DNA 
constructs and confirmation of in vitro and in vivo IFN protein expression was described in 
chapter 3.  Low-level expression of biologically active type I IFN proteins was demonstrated 
both locally and systemically for up to one month following i.m. inoculation of the IFN 
transgenes.  Furthermore, confirmation of the biological activity of these IFNs was 
demonstrated following induction of PKR and 2’5’OAS in J2E cells by IFN proteins from 
transiently transfected COS-7 cells.  Similarly, antiviral efficacy of the expressed IFN 
transgenes was demonstrated by reduction of EMCV-mediated cpe in the IFN bioassay.  The 
finding that the type I IFNs differentially reduced MCMV replication in vitro demonstrated 
potential for in vivo efficacy in the MCMV model (Table 8.1).  Previously, studies have 
demonstrated differential in vitro antiviral efficacy between IFN subtypes in models of 
EMCV (Foster et al., 1996), HSV-1 and HSV-2 (Harle et al., 2002a; Harle et al., 2002b).  In 
addition, in vivo studies have reported some differential antiviral activity within the type I  Chapter Eight 
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IFN family.  In particular, studies in our laboratory have demonstrated the superior antiviral 
efficacy of an IFNA1 transgene over IFNA4 and IFNA9 in reducing local MCMV replication 
in the inoculated muscle (Yeow et al., 1998).  However, studies presented in this thesis 
comprise the most extensive in vivo analysis of the type I IFNs to date with a panel of seven 
individual murine type I IFN subtypes for examination in the MCMV model. 
 
The functional diversity of the type I IFNs in vivo was demonstrated in chapter 4.  Studies 
revealed differential therapeutic efficacy between the subtypes with regard to antiviral and 
immunomodulatory properties (Table 8.1 and 8.2).  Specifically, IFNA6 was the most 
efficacious subtype examined.  Treatment with IFNA6 resulted in reduced viral replication in 
all target tissues, reduced acute and chronic phase myocarditis and induction of a Th1-like 
antibody and cytokine response.  However, IFNA6 was the least effective type I IFN subtype 
in reducing viral replication in vitro.  Similarly, IFNA1 and IFNA2 were most effective in 
vitro yet had no effect on MCMV replication in vivo with the exception that IFNA2 markedly 
reduced splenic viral titre at day 3, which was not significant.  This highlights the complexity 
of the in vivo mammalian system.  Additional IFN transgenes demonstrating efficacy in vivo 
included IFNA9 and IFNB which reduced acute and chronic myocarditis.  In these treatment 
groups no reduction in viral titres was observed, however, induction of a Th1-like immune 
response did correspond with reduced disease (Table 8.1 and 8.2).  Therefore, it was 
hypothesised that viral load is not indicative of disease and further, that it is regulation of the 
immune response to viral infection by exogenously expressed IFN that determines disease 
outcome.  Indeed, previous studies have demonstrated that the presence of infectious virus is 
not the determining factor in the development of myocarditis (Fairweather et al., 2000) and 
that the immune response to the virus infection directs disease pathogenesis (Lawson et al., 
1989; O’Donoghue et al., 1990; Lenzo et al., 2002). 
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Table 8.2.  Summary of the effect of type I IFN subtype DNA inoculation during chronic 
MCMV infection and myocarditis. 
  MCMV 
replication
b 
Myocarditis Anti-MCMV 
antibody 
Anti-myosin 
antibody 
Infiltrating 
Cells 
     IgG1 IgG2a IgG1 IgG2a   
IFNA2
a  +6.5x10
4%* +20.9%  +3.0% 0.0%  -41.1%  -3.3%  ND
c 
IFNA4  +745.7% -25.6%  +3.0%  0.0%  -21.4%  +12.9%  ND 
IFNA6  -85.0%  -71.3%*  0.0%  +3.3%  -39.3%*  -12.9%  -75.0% CD8+     
-62.0% CD4+   
-73.7% B 
+308.3% DC* 
IFNA9  ND  -69.0%*  ND  ND  ND  ND  -50% CD8+      
-53.7% CD4+   
-71.3% B 
+121.1% mac 
IFNB  +3.6x10
4%*  -10.1%        
(-31.1%*, 
day 56 p.i.) 
0.0% +3.3%  -10.8%  -6.5%  -80.4%  CD8+* 
-82.8% CD4+   
-78.0% B*       
-92.2% neut* 
+457.9% mac 
aDNA (200µg) was inoculated bilaterally into regenerating TA muscles of adult mice 5 days after 
bupivacaine treatment.  Fourteen days following DNA injection, mice were challenged with 1x10
4 pfu 
MCMV i.p.  Mice were examined for specific parameters at day 30 p.i., unless otherwise specified.   
bData is expressed as percentage reduction (-) or increase (+) in comparison to Blank treatment 
groups. 
cTreatment groups not examined for specific parameters are marked ND (Not done). 
Statistically significant differences between IFN treatment groups and Blank vector are shown, 
*p≤0.05. 
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Taken together, the results thus far offer great promise for improved clinical application of 
IFN with type I IFN subtype gene therapy.  Importantly, it has been demonstrated that 
inoculation of select type I IFN subtype transgenes 14 days prior to virus challenge 
effectively reduces MCMV replication and/ or MCMV-induced acute and chronic phase 
myocarditis while other subtypes are ineffective.  Therefore, type I IFN gene therapy may be 
advantageous over current therapeutic applications of IFN which employ either high doses of 
mixtures of natural IFNα/β subtypes, which have been associated with severe side effects, or 
treatment with recombinant subtypes, which can result in the production of neutralising 
antibody (Baron et al., 1991).  In addition, since IFN has a short half-life of 2h (Smyth et al., 
1987), it is difficult to maintain constant serum IFN levels following conventional IFN 
protein administration (Lai et al., 1995).  Considering that IFN transgene delivery results in 
low-level persistent expression for up to one month following inoculation, this may be 
advantageous over multiple protein administration.  Type I IFN gene therapy has potential 
clinical applications in the prophylactic treatment of patients receiving immunosuppressive 
therapy such as those awaiting organ transplantation.  Patients could be treated with monthly 
booster inoculations of select IFN DNA constructs to maintain levels of protein expression.  
Interestingly, despite the multigenic nature of the type I IFN family, little research has 
focused on the individual subtypes.  However, data presented in this thesis supports the 
proposal that administration of an effective type I IFN subtype of choice, with specific 
immunomodulatory properties, via naked DNA delivery may prove more efficacious than 
current IFN treatments.    
 
The advent of naked DNA transfer technology has provided an effective alternative approach 
to current IFN delivery.  However, most studies to date have focused on one or on a small 
number of IFN subtypes to determine the efficacy of IFN transgene therapy.  Specifically, 
IFNA1 treatment has proven effective in murine HSV-1 infection (Mester et al., 1995; 
Noisakran et al., 1999), MCMV infection (Yeow et al., 1998) and in murine primary and 
metastatic tumour models (Horton et al., 1999), while IFNB treatment has also proven Chapter Eight 
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effective in murine HSV-1 infection (Cui and Carr, 2000).  These studies provide evidence 
for the broader potential of IFN transgene therapy in additional viral models of disease and 
cancers.  Further research into the individual biological activities of the type I IFN subtypes 
may also reveal more efficacious IFN subtypes in these models.  
 
The importance of both timing and dose in DNA gene therapy was demonstrated in chapter 
5.  Previously, studies performed in our laboratory have demonstrated effective IFN 
transgene inoculation following bupivacaine treatment, with 200µg DNA 14 days prior to 
viral challenge (Lawson et al., 1997; Yeow et al., 1998).  The potential for effective 
inoculation with reduced doses was determined here.  Data demonstrated that doses of 50µg 
and 100µg are ineffective in the MCMV model.  In addition, excessive doses of IFN DNA 
(400µg) inhibit the efficacy obtained with 200µg IFN DNA, as demonstrated in chapter 7.  
The importance of dose and of optimising the DNA inoculation schedule has previously been 
demonstrated (Horton et al., 1999).  In the MCMV model, DNA treatments with IFN only 2 
days prior or 2 days post virus challenge were ineffective.  This is not entirely surprising 
considering that biologically active IFN from transgene expression is not detectable in the 
sera until day 14 following DNA inoculation.  The fact that IFNB treatment 2 days prior to 
virus challenge significantly enhanced acute-phase disease further highlights the importance 
of optimising the DNA inoculation regimen.  The endogenous IFN response to MCMV 
infection peaks at 6 and 48h following viral challenge (Allan and Shellam, 1985).  It is 
thought that interaction of IFNB with endogenously produced cytokines at this stage may 
contribute to induction of disease pathogenesis.  Timing of cytokine co-vaccination has been 
demonstrated to determine the nature of the subsequent adaptive immune response 
(Kusakabe et al., 2000). 
 
Further indication that the type I IFNs act differentially in vivo was presented in chapter 5.  
Data demonstrated that IFNA6 treatment, following establishment of the acute phase of Chapter Eight 
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MCMV infection and disease, suppressed the development of the chronic phase of 
myocarditis.  Interestingly, identical administration of IFNB had no effect on chronic 
disease.  This highlights the therapeutic potential of select IFN subtypes.  Furthermore, this 
study demonstrates the potential for IFN DNA treatment as an effective intervention therapy 
in the development of autoimmune myocarditis.  This is the first time that cytokine DNA 
treatment has effectively been used to treat the chronic phase of disease following the 
establishment of acute phase disease.  Further research in other models of chronic diseases 
currently treated with IFN (HCV, HIV, multiple sclerosis) would determine the broader 
application of this IFN subtype immunotherapy. 
 
The mechanisms leading to the development of myocarditis following viral infection are 
unclear, however, several hypotheses have been developed to explain disease pathogenesis.  
It is thought that during the acute phase, infectious virus present in the heart is detected by 
APCs such as macrophages and DCs which then cross-prime T cells, thus initiating a CD8+ 
cytolytic T cell response to virus-infected cells.  Alternatively, infectious virus present in the 
heart may directly injure myocytes leading to an inflammatory response.  This may result in 
the release of the self-antigen, cardiac myosin from myocytes, which may initiate an 
autoimmune response directed against cardiac myosin (Rose and Hill, 1996).  A model of 
autoimmune myocarditis, triggered by inoculation of cardiac myosin, supports this model 
(Neu et al., 1987).  The concept of molecular mimicry, whereby the immune system mounts 
a response towards a viral epitope which is similar to a self-antigen, can also be applied to 
MCMV-myocarditis.  Indeed, computer analyses of sequence homologies between cardiac 
myosin and MCMV have revealed a region of six out of nine aa in the large tegument protein 
M48 of MCMV and murine (BALB/c) cardiac myosin heavy chain (Lawson, 2000).  The 
common factor with all of these models is that viral infection is the trigger for disease, 
however, disease pathogenesis is determined by the immune response to viral infection.  
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A role for immune cells in the development of myocarditis has been well characterised 
(Lawson et al., 1989; Fairweather et al., 2000; Lenzo et al., 2002).  Indeed, data presented in 
chapter 5 demonstrated that adoptive transfer of T cells from MCMV-infected mice 
transferred myocarditis to uninfected recipient mice.  Furthermore, treatment with IFNB 
prior to T cell transfer resulted in reduced disease, while IFNA6 treatment had no effect on 
disease severity compared to controls.  IFNs have been shown to affect regulatory T cells, 
memory T cells, CD8+ T cells and induce apoptosis and proliferation of T cells.   
Mechanisms of action include inducing proliferation of memory T cells via IL-15 (Tough et 
al., 1999), and contributing to the persistence of immunological memory (Tough et al., 
1996).  However, dysregulated concentrations of IFN production in disease may cause 
inappropriate inhibition of T cell regulation (Akbar et al., 2000).  Evidence is accumulating 
to support CD8+ T cells as a source of tissue damage in other autoimmune diseases such as 
type I diabetes, rheumatoid arthritis, autoimmune thyroiditis and multiple sclerosis (Liblau et 
al., 2002).  In fact, intervention therapies targeting deletion or anergy of autoreactive T cells 
are emerging as novel areas of investigative research (Liblau et al., 2002).  Similarly, one 
mechanism for controlling the pathogenesis of MCMV-induced myocarditis may be via IFN 
regulation of the T cell response.  Data presented thus far demonstrates that the type I IFN 
subtypes exhibit differential effects on cytokine and antibody production.  Further 
differential regulation of the immune response to viral infection was demonstrated here with 
data indicating suppression of T cell responses following IFNB treatment. 
 
The results detailed thus far indicate immunomodulation by IFN as the main mechanism in 
suppressing the development of acute and chronic myocarditis following transgene 
inoculation.  Examination of the immune cell profiles throughout the myocardium during the 
acute and chronic phases of myocarditis, as described in chapter 6, revealed that effective 
IFN treatment (IFNA6,  IFNA9 and IFNB) corresponds with modulation of the cell 
phenotypes investigated.  Interestingly, although IFNA6, IFNA9 and IFNB effectively reduce Chapter Eight 
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both acute and chronic myocarditis (IFNA9 reducing disease at day 30 p.i. and IFNB 
reducing disease at day 56p.i.), these treatments induced distinct profiles of immune cell 
infiltrates in the myocardium, implying that each subtype may have an alternative 
mechanism of action (Table 8.1 and 8.2).  This is not unexpected considering that differential 
regulation of in vitro and in vivo MCMV replication, acute and chronic myocarditis, 
antibody isotype production, cytokine production, T cell-mediated myocarditis and post-
acute phase treatment of chronic myocarditis has also been demonstrated following IFN 
treatment.  However, immunohistochemical analysis demonstrated that all IFN treatment 
groups reduced neutrophils in the acute phase (Table 8.1) and reduced CD8+ T, CD4+ T and 
B cell numbers in the cardiac infiltrate in the chronic stage of myocarditis (Table 8.2).   
Indeed, a pivotal role for T and B cells in the development of myocarditis has been 
established (Lawson et al., 1989; O’Donoghue et al., 1990; Smith and Allen, 1991; Henke et 
al., 1995).  Interestingly, although IFN treatment did not affect the overall number of CD8+ 
T cells in the myocardium during the acute phase, IFNA6 and IFNA9 altered the composition 
of CD8+ T cells in the hearts by reducing the percentage of T cells in the foci of 
inflammation at this stage.  In addition, IFNA6 enhanced DCs in the chronic stage and 
IFNA9 enhanced CD4+ T and B cells in the acute phase and slightly enhanced macrophages 
in the chronic phase.  Similarly, IFNB treatment enhanced CD4+ T cells in the acute stage 
while suppressing neutrophils and enhancing macrophages in the chronic phase. Therefore, it 
is unclear as to whether it is the effect of type I IFN subtype expression on T and B cells or 
the differential effects of the subtypes observed on other cell types which contributes to 
reduced myocarditis.  It may be possible that it is a combination of both effects.  Indeed, 
further research is required to clarify whether the results observed are a direct or indirect 
effect of type I IFNs acting on these cell types.    
 
The immunomodulatory properties of the type I IFNs indicate that they are important links 
between the innate and adaptive immune responses.  Therefore, type I IFNs are essential in 
the initial events following viral infection and also act to determine the outcome of immune Chapter Eight 
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events downstream.  Interestingly, MCMV has been shown to be a poor inducer of type I 
IFN with low doses of IFN endogenously produced during infection (Biron, 2001).   
Normally, this low level of type I IFN expression leads to NK cell cytotoxicity, 
augmentation of IL-12 activity and promotion of CD4+ T cell responses (Biron, 1999).   
However, IFN transgene expression levels, via further cytokine networks, may act to inhibit 
IL-12 expression and hence IL-12 activation of NK cell production of IFNγ while inducing 
NK cell cytotoxicity and proliferation and promoting CD8+ T cell responses and T cell 
production of IFNγ.  The induction of IL-15 is also likely to occur which would boost NK 
cell and memory CD8+ T cell responses (Biron, 1999).  Further research may include 
investigation of the effect of type I IFN subtype expression of IL-8, IL-12 and IL-15 since 
these cytokines were not studied in this thesis. 
 
Data presented in chapter 7 further demonstrates the therapeutic potential of type I IFN gene 
therapy.  Examination of co-inoculation of effective type I IFN subtypes in the MCMV 
model revealed synergy between subtypes in antiviral activity and in reducing acute and 
chronic myocarditis. Surprisingly, combinations of subtypes most effective in the acute 
phase (IFNA6/A9 and IFNA9/B) were least effective in the chronic phase and, vice versa, 
subtype combinations most effective in the chronic phase (IFNA6/B) were not as effective in 
the acute phase.  However, the synergistic properties of the type I IFNs on co-administration 
may increase their therapeutic index in the treatment of a wide variety of diseases. 
Combination therapy using select subtypes is superior to individual transgene transfer.   
Therefore, assessment of the specific roles of type I IFN subtypes in the innate and adaptive 
immune responses is crucial to maximising the clinical applications of type I IFN DNA 
therapy. 
 
Co-evolution of CMV with its host has led to the development of various evasion tactics to 
circumvent immune control of virus replication.  These strategies include down-regulation of Chapter Eight 
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the MHC Class I and II molecules, synthesis of cytokine and chemokine homologues and 
disruption of the IFNα signal transduction pathway (Loenen et al., 2001).  Indeed, 
production of IL-8 following CMV infection can attenuate the activity of IFNα (Khabar et 
al., 1997).  These inhibitory effects are associated with down-regulation of 2’5’OAS (Khabar 
et al., 1997).  Therefore, type I IFN DNA therapy, via low level constitutive expression of 
biologically active IFN subtypes acts in an adjuvant-like manner during viral infection, 
allowing the host to overcome virus immune evasion strategies (Anderson and Matzinger, 
2000).  Exogenous IFN treatment during CMV infection would enhance MHC Class I 
expression, increase NK cell activity, induce DC maturation and skew towards a Th1-like 
response, thus restoring balance in the immune system. 
 
A mechanism by which IFN may direct some of its immunomodulatory efficacy during 
myocarditis is by upregulation of chemokines and chemokine receptors.  Chemokines are 
chemoattractant cytokines secreted by a variety of cells in response to exogenous stimuli 
such as viruses and LPS, and endogenous stimuli such as IL-1, TNF and IFN.  IFN can 
enhance the chemoattractive properties in certain cell types.  IFN-α2a has been shown to 
enhance DC stimulatory capacity towards CD8+ T cells correlating with increased 
production of IP-10/CXCL10 and MIG/CXCL9 chemokines (Padovan et al., 2002).  In 
addition, studies have revealed that the CXCR3 chemokine system is regulated by IFNα/β in 
CD8+ T cells and is critical for efficient cell activation (Ogasawara et al., 2002).  Therefore, 
further research in determining the effect of individual type I IFN subtypes on various 
chemokines may reveal alternative mechanisms of action between the subtypes.  
 
Interestingly, CMV infection can also alter cellular expression of chemokines, thus the virus 
itself may direct migration of specific leukocytes to sites of infection, thus playing a pivotal 
role in pathogenesis (Mahalingam and Karupiah, 1999).  Indeed, MCMV encodes CC 
chemokine homologues (m131/ 129) (Fleming et al., 1999) and chemokine receptor Chapter Eight 
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homologues (m33) (Soderberg-Naucler and Nelson, 1999) which play a role in promoting 
leukocyte migration to sites of infection and enhancing dissemination of infectious virus via 
cell migration.  Studies have also shown that HCMV infection of fibroblasts results in 
increased IL-8 production which ultimately enhances neutrophil transendothelial migration 
thus contributing to viral dissemination throughout the body (Craigen et al., 1997).  In 
addition, CMV induces transcripts of the CXCR1 receptor in fibroblasts (Khabar et al., 
1997).  Therefore, IFN transgene expression may act to overcome the effect of MCMV on 
the chemokine response and furthermore, it may be that the modulation of immune cell 
profiles observed in the myocardium following IFN treatment, may be due to modulation of 
chemokines and chemokine receptors in response to IFN therapy.   
 
In the current research climate, there is a shift towards the use of transgenic and knockout 
mouse models to study the biological functions of specific cytokines and protein molecules. 
Recently, an IFNβ
-/- mouse has been developed for the investigation of Vaccinia virus 
infection and tumour sensitivity (Deonarain et al., 2002).  These IFNβ
-/- mice show an 
enhanced T cell proliferative response in the activated lymph node and decreased TNFα 
release in splenic T lymphocytes.  In addition, a poorly defined interface between B and T 
cell zones is observed in the spleens along with a decrease in splenic macrophages, 
suggesting an indirect role for IFNβ in the development and support of organised primary B 
cell follicles in mice.  In addition, bone-marrow-derived B cells exhibit a potential defect in 
maturation and decreased levels of circulating Mac-1
+ and Gr-1
+ cells (Deonarain et al., 
2002).  These data highlight the diverse effects of IFNβ in both the innate and adaptive 
immune responses.  This technology may also provide an alternative avenue for the study of 
the type I IFN subtype DNA constructs. 
 
This thesis presents evidence for differential antiviral and immunomodulatory activities 
within the murine type I IFN family.  However, type I IFNs also exhibit potent Chapter Eight 
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antiproliferative and apoptotic functions and have been proven effective in the treatment of 
various malignancies such as hairy cell leukemia, basal cell carcinoma and kaposi’s sarcoma 
(Baron et al., 1991; Platanias and Golomb, 1992).  Studies performed in our laboratory have 
demonstrated that the type I IFNs differentially regulate proliferation, differentiation, 
viability and apoptosis in an in vitro J2E erythroid cell model (Cull et al., 2003).  In addition, 
the type I IFNs differentially activated STAT, MAPK and JNK signalling molecules in vitro.  
Furthermore, inoculation of the type I IFN transgenes resulted in differential regulation of 
the development of erythroleukemia in nu/nu mice with delayed onset observed following 
IFNA1, IFNA6 and IFNA9 treatment, with 40% and 60% survival observed in the latter two 
treatment groups (Cull et al., 2003).  Therefore, the biological activity of type I IFN 
transgene inoculation is not restricted to antiviral and immunomodulatory efficacy but also 
includes anti-leukemic effects. 
 
The potential for clinical efficacy of type I IFN subtype gene therapy has been demonstrated, 
however, further research into the potential limitations of this type of treatment is needed.  
Specific limitations in this model concern the application of research performed in the 
experimental murine model to the clinical human system.  Firstly, it has been demonstrated 
that IFNα6 is most efficacious in the murine system during MCMV infection and, although 
the human and murine IFN systems are highly homologous, murine type I IFNs do not 
directly correspond to their human counterpart.  In fact, MuIFNα6 is most homologous to 
HuIFNα1 (74.2%), HuIFNα2 (74.8%), HuIFNα8 (74.4%) and HuIFNα13 (74.8%) at the 
nucleotide level (Cull et al., 2002a).  Studies have also found that successful DNA transfer in 
mice is not always verified in man.  In fact, the larger the animal, the lower the efficacy of 
DNA vaccines (Mölling, 1997).  Therefore, extensive studies in the human IFN system are 
needed to gain the full clinical potential of type I IFN subtype gene therapy. 
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The safety of DNA plasmid inoculation needs to be addressed since public concerns over the 
use of genetically modified materials appear to be rising.  There is the possibility that the 
DNA plasmid may integrate into the host cell genome.  This can damage the cell genome, 
cause inactivation of tumour suppressor genes, or induce the expression of cellular 
oncogenes (Romano et al., 2000).  This is probably not sufficient to generate a neoplasia 
since cancer is a multistep process requiring a combination of genetic alterations and the 
expression of cellular and/ or exogenous oncogenic factors (Croce et al., 1999).  However, 
these issues must be addressed.  Another concern is that DNA transfer may trigger an 
autoimmune disease such as seen in systemic lupus erythematosus (McDonnell and Askari, 
1996).  However this is unlikely since studies have found that DNA plasmids neither initiate 
nor accelerate the development of systemic autoimmunity (Mor et al., 1997).  In addition, 
researchers must be aware in using cytokine gene transfer that the Centre for Biologics 
Evaluation and Research (CBER) guidelines caution that modulation of humoral and cellular 
immunity may result in immunosuppression, chronic inflammation, autoimmunity or other 
immunopathologies, however, as yet there are no reports of such adverse responses (Food 
and Drug Administration, CBER Office of Vaccine Research and Review, 1996).  Therefore, 
although IFN gene transfer has shown great promise for clinical application, caution must be 
applied in its use. 
 
Studies presented in this thesis demonstrate that the individual type I IFN subtypes 
differentially regulate the immune response to MCMV infection and that inoculation of 
select type I IFN subtype transgenes resulted in therapeutic efficacy in the MCMV model of 
infection and myocarditis.  Specifically, the type I IFNs were found to differentially regulate 
virus replication, development of acute and chronic disease, and the humoral and cellular 
immune response.  Effective type I IFN subtypes induced a Th1-like cytokine and antibody 
response correlating with reduced neutrophil infiltration during the acute phase and reduced 
CD8+, CD4+ and B cell numbers in the myocardium during the chronic phase.  Overall 
these findings highlight the importance of determining the biological activities of individual Chapter Eight 
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type I IFN subtypes.  It is proposed that improved clinical efficacy can be achieved in viral 
and disease models with the use of type I IFN subtypes specifically chosen for their 
immunomodulatory effects.  Thus a new generation of IFN therapies with improved 
therapeutic index and reduced side effects is achievable with the concept of type I IFN 
subtype gene therapy.  
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